Experimental determination of the optimal means of combining topotecan and (131 I) MIBG therapies for the treatment of neuroblastoma by McCluskey, Anthony Gerald
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
Experimental determination of the optimal 
means of combining topotecan and ['^^I]MIBG 
therapies for the treatment of neuroblastoma
Anthony Gerald McCluskey
A thesis submitted for the degree of Doctor of Philosophy to the 
Faculty of Medicine, University of Glasgow
Targeted Therapy Group 
Centre for Oncology & Applied Pharmacology 
Cancer Research UK Beatson Laboratories 
University of Glasgow
March 2005
ProQuest Number: 10391120
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10391120
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
gGLASGOW
u n iv e r s it y
LIBRARv:
Acknowledgements
There are many people whose help and guidance have been invaluable throughout 
the preparation of this thesis. First and foremost is my supervisor, Dr. Rob Mairs, who has 
provided more help and suggestions throughout the course of this work than I can 
remember. Likewise, Dr. Marie Boyd always lent a friendly ear, and provided a lot of 
assistance and encouragement.
I would also like to thank Dr. Sean Carlin, with whom I spent many scintillating 
hours wrestling with TaqMan RT-PCR, Dr. Shona Cunningham, who showed me the joy of 
clonogenic assays and ['^T]MIBG uptakes, Susan Ross and Anne Marie Clark for their work 
on tumour growth delay and CFU-A assays respectively, and Dr. Wilson Angerson, for his 
help with the statistical analyses in Chapter 7. Finally, I would like to thank all the staff 
(past and present) of the Targeted Therapy Group (Radiation Oncology as was). Cheers 
Guys!
Table of Contents
Declaration i
Acknowledgements ii
Table of Contents iii
List of Figures xiii
List of Tables xvii
Abbreviations xviii
Summary xxii
Chapter 1 Introduction: [ I]MIBG and topotecan: A rationale 
for combination therapy for neuroblastoma
1
1 . 1 Targeted radiotherapy as a treatment for cancer 2
1 . 1 . 1 Targeted therapy 2
1 . 1 . 2 Efficacy of targeted cancer therapy 4
1.1.3 Targeted radiotherapy 5
1.1.4 Radiological bystander effect 6
1 . 2 Neuroblastoma 8
1 .2 . 1 Incidence / Survival 8
1 .2 . 2 Molecular biology 8
1.2.3 Clinical features / Treatment regimes 9
1.2.4 Experimental treatment regimes 1 1
1.2.5 Combination therapy incorporating ['^^IJMIBG 14
1 .2 . 6 The potential of combination therapy incorporating 
[*^^I]MIBG and topoisomerase I inhibitors
17
1.3 Topoisomerase I and its inhibitors 18
1.3.1 Topoisomerase I 18
1.3.2 Inhibitors of topoisomerase I 2 0
1.3.3 Current status of topotecan used as a single agent 23
111
1.3.4 Topotecan in combination with other agents 25
1.3.5 Topotecan as a treatment for neuroblastoma 26
1.3.6 Interaction between topoisomerase I inhibition and 27
radiation induced DNA damage in vitro and in vivo
1.4 Aim of this study 28
Chapter 2 Development of a real-time RT-PCR assay for the 30
prediction of [ I]MIBG uptake
2.1 Introduction 31
2.1.1 MIBG and clinical diagnosis of neuroblastoma 31
2.1.2 TaqMan PCR 32
2.2 Materials and methods 36
2.2.1 Cells and culture conditions 36
2.2.2 Tumour samples 37
2.2.3 RNA extraction 37
2.2.4 Accumulation of [‘^ ‘IjMIBG in cell lines 38
2.2.5 Evaluation of scintigrams 39
2.2.6 Primers and probes 40
2.2.7 Standard curve generation and quantitation of test 42
samples
2.2.8 Real-time RT-PCR amplification 46
2.2.9 Statistical analysis 47
2.3 Results 47
2.3.1 Real-time PCR 47
2.3.2 ['^‘IJMIBG uptake compared with NAT gene expression 49
in cell lines
2.3.3 NAT gene expression in biopsy specimens 51
2.4 Summary or results 56
IV
Chapter 3 The effect of topotecan pre-treatment on intracellular 
uptake of [ "
58
3.1 Introduction 59
3.1.1 Effect of DNA-interacting agents on active uptake of 
['^T]MIBG
59
3.1.2 Topotecan and ['^^I]MIBG uptake 59
3.2 Materials & methods 60
3.2.1 Cell lines 60
3.2.2 The effect of topotecan on [’^ T]MIBG uptake 60
3.2.3 The effect of topotecan on expression of the 
noradrenaline transporter gene
61
3.2.4 RNA extractions 61
3.3 Results 62
3.3.1 The effect of topotecan on [^^TjMIBG uptake in NAT 
expressing cells
62
3.3.2 TaqMan RT-PCR analysis of NAT gene expression 65
3.4 Summary of results 67
Chapter 4 Cytotoxic effects of topotecan and I]M IBG in vitro 69
4.1 Introduction 70
4.2 Materials & methods 71
4.2.1 Topoisomerase I relaxation assays 71
4.2.2 Clonogenic assay 73
4.3 Results 76
4.3.1 Topoisomerase I assays 76
4.3.2 Clonogenic assays: The toxic effects of topotecan 79
4.3.3 Clonogenic assays: The toxic effects of f‘^ ’ijMIBG 81
4.4 Summary of results 83
Chapter 5 Analysis of the cytotoxic interaction between
topotecan and [ in vitro
I: The isobologram method
85
5.1
5.1.1
5.1.2
5.1.3
5.2
5.2.1
5.2.2 
5.3
5.3.1
5.3.2
5.3.3 
5.4
Introduction 8 6
Analysing the interaction between topotecan and 8 6
['"^I]MIBG
Isobologram analysis of the interaction between two 87
toxic agents
Scheduling of topotecan and [‘^ 'IJMIBG in combination 91 
treatment
Materials & methods 94
Clonogenic assays 94
Concentrations of TFT and [‘^ ‘I]MIBG 94
Results 95
Isobologram analysis of the interaction between 95
[‘^ ‘IJMIBG and topotecan
SK-N-BE(2c) 98
UVW/NAT 104
Summary of results 109
Chapter 6 Analysis of the cytotoxic interaction between 
topotecan and I]MIBG in vitro 
II: Median-effect / combination index analysis
111
6.1
6 . 1.1
6.1.2
Introduction 112
Analysing the interaction between topotecan and 112
[*"T]MIBG
Multiple drug effect analysis of the interaction between 113
two toxic agents
VI
6.2 Materials & methods 115
6.2.1 Clonogenic assays 115
6.2.2 Fixed ratios of TFT and [‘"‘I]MIBG 115
6.3 Results 116
6.3.1 Median-effect/combination-index analysis of the 116
interaction between ['^'l]MIBG and topotecan
6.3.2 SK-N-BE(2c) 121
6.3.3 UVW/NAT 123
6.4 Summary of results 125
Chapter 7 Analysis of the cytotoxic interaction between 127
topotecan and [ I]MIBG in vivo
7.1 Introduction 128
7.1.1 Anti-tumour effects of topotecan and ['^T]MIBG 128
7.1.2 Effect of TFT and [‘^ ^I]MIBG on marrow toxicity 128
7.2 Materials & methods 130
7.2.1 Experimental animals 130
7.2.2 Xenografts 130
7.2.3 SK-N-BE(2c) 131
7.2.4 UVW/NAT 131
7.2.5 Effect of topotecan pretreatment on the biodistribution of 131 
['^T]MIBG
7.2.6 Therapy experiments 132
7.2.7 Assessment of marrow toxicity 134
7.3 Results 135
7.3.1 Effect of topotecan on the biodistribution of ['^TjMIBG 135
7.3.2 In vivo effects of [^^TjMIBG and topotecan alone or 137
combined
7.3.3 SK-N-BE(2c) tumours 140
VII
7.3.4 UVW/NAT tumours 142
7.3.5 Assessment of marrow toxicity of ['^4]MIBG alone, and 143
combinations of topotecan and [^^TjMIBG
7.4 Summary of results 146
Chapter 8 The effects of topotecan and I]MIBG on cellular 147
mechanisms
8.1 Introduction 148
8.1.1 The effect of topotecan and [^^T]MIBG on cell cycle 148
distribution
8 .1.2 The effect of topotecan and [^^*I]MIBG on 149
topoisomerase I-induced unwinding
8.2 Materials & methods 149
8.2.1 Cell lines 149
8.2.2 Concentrations and incubation times of TFT and 150
[^'TlMIBG
8.2.3 Scheduled combinations of TFT and [^ ‘^IJMIBG 150
8.2.4 FACS analysis 151
8.2.5 Topoisomerase I relaxation assays 151
8.3 Results 152
8.3.1 Cell cycle distribution of SK-N-BE(2c) and UVW/NAT 152
cells
8.3.2 The effects on cell cycle distribution of topotecan and 154
[^^*I]MIBG as single agents
8.3.3 The effect of combinations of TFT and [ ’^ TjMIBG on 158
cell cycle distribution
8.3.4 The effect of TFT and [^^T]MIBG on topoisomerase I 160
activity
8.4 Summary of results 163
VI11
Chapter 9 The effects of topotecan and I]MIBG on DNA
damage and repair
165
9.1
9.1.1
9.1.2
9.2
9.2.1
9.2.2
9.2.3
9.2.4 
9.3
9.3.1
9.3.2
9.3.3
9.3.4
9.3.5
9.4
Introduction
The effect of topotecan on DNA damage 
Single cell gel electrophoresis (SCGE) assay 
Materials & methods 
Cell lines
Concentrations and incubation times of TFT and 
i^^TlMIBG
Scheduling of topotecan and [‘^ h]MIBG treatments
SCGE assay
Results
Analysis of DNA fragmentation 
Distribution of results 
Analysis of results
Comparison of DNA Fragmentation in treated cells at Oh 
and 24h -  Analysis of DNA damage repair 
DNA fragmentation in treated compared to untreated 
cells at Oh and 24h - Analysis of the duration of DNA 
damage
Summary of results
166
166
166
168
168
168
169
170
171 
171 
174 
181 
181
185
187
Chapter 10 Discussion I: The results of this study, and proposals 
for future work
188
10.1
10.1.1
Development of a real-time RT-PCR assay for prediction 
of the uptake of [‘^ T]MIBG by neuroblastoma tumours 
Clinical diagnosis of neuroblastoma
189
189
IX
10.1.2 Comparison of TaqMan RT-PCR to existing 190
methodologies
10.1.3 Limitations of T aqMan RT -PCR 190
10.1.4 Heterogeneity of uptake 191
10.1.5 Quality of biopsy material 191
10.1.6 Alternative internal sequences 191
10.1.7 Involvement of an alternative MIBG uptake pathway? 192
10.2 Future work arising from the development of a real-time 193
RT-PCR assay
10.2.1 Tumour heterogeneity and sensitivity of scintigraphy 193
and RT-PCR
10.2.2 The use of multicellular mosaic spheroids 193
10.3 The effect of topotecan pre-treatment on intracellular 195
uptake of f'^TjMIBG
10.3.1 TPT-induced enhancement of [’^ TJMIBG uptake m v/Yra 195
10.3.2 Drug-induced enhancement of [^^T]MIBG uptake m v/v(? 196
10.3.3 The effect of topotecan on the biodistribution of 196
['"T]MIBG
10.3.4 Assessment of marrow toxicity 197
10.4 The effect of topotecan on expression of the 198
noradrenaline transporter gene
10.5 The effects of combinations of topotecan and [^^^I]MIBG 200
in vitro and in vivo
10.5.1 Supra-additive cytotoxicity in SK-N-BE(2c) and 200
UVW/NAT cells in vitro
10.5.2 The effect on toxicity in vitro and in vivo of alternative 203
scheduling of topotecan and [^^^I]MIBG
10.5.3 Cytotoxicity and TPT-induced enhancement of 203
[‘^ T]MIBG uptake
10.6
10.6.1
10.6.2
10.7
10.7.1
10.7.2
The effects of topotecan and [‘^ TjMIBG on cellular 
mechanisms
The effect of scheduling of topotecan and [’^ T]MIBG on 
cell cycle distribution
The effect of scheduling of topotecan and [‘^ T]MIBG on
DNA damage and repair
Future work arising from the investigations of
combinations of topotecan and ['^‘l]MIBG
Multiple administration of TFT to enhance supra-
additivity of cell kill
Future work arising from investigations of the effects of 
topotecan and ['^’I]MIBG on cellular mechanisms
204
204
205
206
206
206
Chapter 11 Discussion II: The role of topoisomerase I in the 
response to DNA damage
208
1 1 . 1
11.2
11.3
11.4
11.5
Introduction 209
Factors which affect topoisomerase I activity: PARP-1 210
and p53
Topoisomerase I activity and DNA damage 210
Involvement of the camptothecins following DNA 213
damage
Future work which may resolve the role of the 215
camptothecins following DNA damage
Chapter 12 Discussion III: Further avenues of research arising 
from this study, and final conclusions
216
12.1 Possible enhancement of supra-additive cytotoxicity 
caused by combinations of topotecan and I]MIBG
217
XI
12.1.1 Potential of targeting cellular pathways to enhance 217
topotecan-induced toxicity
12.2 Improving on I’^ TjMIBG-derived regimens; Alternative 218
radiosensitising agents
12.2.1 Disulfiram (DS) 218
12.2.2 PJ34 218
12.3 Choice of radionuclide: Alternatives to *^ I^ as a 219
conjugate for MIBG
12.3.1 p"At]MABG 222
12.3.2 ['“ IjMIBG and ['"^IjMIBG 223
12.4 Radiation-induced biological bystander effects 224
(RIBBEs)
12.5 NAT gene therapy 226
12.5.1 Targeted radionuclide therapy for tumours with no 226
radiotargetable feature
12.5.2 Tumour specific gene expression: Telomerase promoter 227
elements
12.5.3 Radiation-inducible control elements 228
12.6 NAT gene therapy: Gene delivery 229
12.6.1 Viral vectors 229
12.6.2 Immunoliposomes 230
12.7 The use of multicellular mosaic spheroids to determine 232
transfection efficiencies
12.8 Conclusions 233
12.8.1 Development of a real-time RT-PCR assay for prediction 233
of the uptake of [*^T]MIBG
12.8.2 Cytotoxic interaction between topotecan and [^ ’^l]MIBG 234
References 235
XII
List of Figures
Figure 1 - 1 Radiological bystander effect 7
Figure 1-2 meta-iodobenzylguanidine 12
Figure 1-3 The noradrenaline transporter 13
Figure 1-4 The mechanism of topoisomerase I action 19
Figure 1-5 Camptothecin 21
Figure 1 - 6  Interaction of topoisomerase I with camptothecin 22
Figure 1-7 Topotecan 24
Figure 2-1 Summary of Taqman PCR amplification 33
Figure 2-2 Example of TaqMan PCR results 35
Figure 2-3 Calculation of initial number of molecules for generation 44
of a standard curve
Figure 2-4 Standard curve construction 45
Figure 2-5 Amplification plot and standard curve of the NAT 48
sequence
Figure 2-6 Distribution of NAT mRNA expression levels in 52
neuroblastoma biopsy samples 
Figure 3-1 The effect of topotecan on [‘^ T]MIBG uptake 63
Figure 3-2 Real-time RT-PCR analysis of NAT gene expression 6 6
Figure 4-1 Clonogenic assay of cell viability 75
Figure 4-2 Topoisomerase I activity in NAT expressing cell lines 77
Figure 4-3 The toxic effects of [’^ TjMIBG and TPT on 80
SK-N-BE(2c) cells
Figure 4-4 The toxic effects of ['^T]MIBG and TPT on 82
UVW/NAT cells
Figure 5-1 Toxic effects of two hypothetical drugs and in 89
combination
Figure 5-2 Isobologram analyses of the hypothetical relationship 90
between two agents
Xlll
Figure 5-3 Scheduling of TPT and [^^T]MIBG combinations 93
Figure 5-4 The effect of increasing TPT concentration on 96
['^T]MIBG treated SK-N-BE(2c) cells 
Figure 5-5 The effect of increasing [’^ T]MIBG concentration on 97
TPT treated SK-N-BE(2c) cells 
Figure 5-6 IC3 0  isobologram analyses of SK-N-BE(2c) cells treated 99
with different [^^'IjMIBG and topotecan schedules 
Figure 5-7 IC5 0  isobologram analyses of SK-N-BE(2c) cells treated 100
with different [^^^I]MIBG and topotecan schedules 
Figure 5-8 IC7 0  isobologram analyses of SK-N-BE(2c) cells treated 101
with different [‘^ T]MIBG and topotecan schedules 
Figure 5-9 The effect of increasing TPT concentration on 102
[/^‘I]MIBG treated UVW/NAT cells 
Figure 5-10 The effect of increasing [^^TJMIBG concentration on 103
TPT treated UVW/NAT cells 
Figure 5-11 IC3 0  isobologram analyses of UVW/NAT cells treated 106
with different [^^'ijMIBG and topotecan schedules 
Figure 5-12 ICgo isobologram analyses of UVW/NAT cells treated 107
with different [^^TjMIBG and topotecan schedules 
Figure 5-13 IC7 0  isobologram analyses of UVW/NAT cells treated 108
with different [^^^I]MIBG and topotecan schedules 
Figure 6-1 Equations used to study the interaction between two 114
agents by median-effect and combination index analysis 
Figure 6-2 Effect of f^^*I]MIBG and TPT alone and in combination 117
on clonogenic survival of SK-N-BE(2c) cells 
Figure 6-3 Median-effect plots for TPT and [^ ‘^l]MIBG treated 118
SK-N-BE(2c) cells
Figure 6-4 Effect of [’^ TjMIBG and TPT alone and in combination 119
on clonogenic survival of UVW/NAT cells
XIV
Figure 6-5 Median-effect plots for TPT and ['^‘IJMIBG treated
UVW/NAT cells
Figure 6 - 6  Combination Index (CI) versus cytotoxicity: Interaction
between TPT and [‘"*I]MIBG in SK-N-BE (2c) cells 
Figure 6-7 Combination Index (CI) versus cytotoxicity: Interaction
between TPT and ['"T]MIBG in UVW/NAT cells 
Figure 7-1 Haemopoiesis
Figure 7-2 The effect of topotecan pretreatment on [^^^IJMIBG
biodistribution
Figure 7-3 Effect of [^ ’^I]MIBG and TPT alone and in combination
on the growth of SK-N-BE(2c) tumours in nude mice 
Figure 7-4 Effect of ['^‘IJMIBG and TPT alone and in combination
on the growth of UVW/NAT tumours in nude mice 
Figure 8-1 The cell cycle distribution of SK-N-BE(2c) and
UVW/NAT cells
Figure 8-2 The effect of TPT and [‘^ TjMIBG administration on the
cell cycle distribution of SK-N-BE(2c) cells 
Figure 8-3 The effect of TPT and [^^TjMIBG administration on the
cell cycle distribution of UVW/NAT cells 
Figure 8-4 The effect of combinations of TPT and [‘^ 'I]MIBG on
the cell cycle distribution of SK-N-BE(2c) cells 
Figure 8-5 The effect of combinations of TPT and [‘^ ‘IJMIBG on
the cell cycle distribution of UVW/NAT cells 
Figure 9-1 Single cell gel electrophoresis assay (comet assay)
Figure 9-2 Total DNA fragmentation in SK-N-BE(2c) cells
Figure 9-3 Total DNA fragmentation in UVW/NAT cells
Figure 9-4 Distribution of results in SK-N-BE(2c) cells
Figure 9-5 Distribution of results in UVW/NAT cells
Figure 9-6 Statistical analysis of skewness
120
122
124
129
136
138
139 
153 
155 
157 
159 
161
167
172
173
175
176
177
XV
Figure 9-7 Repair of DNA fragmentation in SK-N-BE(2c) cells 183
Figure 9-8 Repair of DNA fragmentation in UVW/NAT cells 184
Figure 10-1 Multicellular mosaic spheroids 194
Figure 11-1 Hypothesised role of topoisomerase I in DNA repair 2 1 2
Figure 11-2 Hypothesised Interaction between [‘^ ‘IJMIBG and 214
topotecan
Figure 12-1 Relationship between particle range, radiological 2 2 1
bystander effect and linear energy transfer
Figure 12-2 Radiation-induced biological bystander effect (RIBBE) 225
XVI
List of Tables
Table 1-1 
Table 2-1
Table 2-2
Table 2-3
Table 3-1
Table 4-1 
Table 5-1
Table 7-1
Table 7-2
Table 7-3
Table 8-1
Table 9-1
Table 9-2
Table 9-3
Table 12-1 
Table 12-2
The International Neuroblastoma Staging System (INSS) 
NAT gene expression and MIBG uptake by 
neuroblastoma cell lines
Comparison of tumour uptake of ['^^I]MIBG with NAT 
mRNA expression in biopsy samples 
MIBG uptake by neuroblastoma tumours compared with 
NAT expression
Effect of topotecan pretreatment on f/^TjMIBG uptake: 
Comparison with other DNA interacting agents 
Topoisomerase I levels in NAT expressing cell lines 
Scheduled combinations of ionising radiation and Topo I 
inhibitors reported to cause synergistic cell killing 
Tumour cure and delayed tumour growth resulting from 
the administration of topotecan or [^ ’^I]MIBG alone or in 
combination
CFU-A colony formation and platelet production in
SK-N-BE(2c) tumours in nude mice
CFU-A colony formation and platelet production in
UVW/NAT tumours in nude mice
Effect of TPT and ['^^IJMIBG on topoisomerase I levels
in SK-N-BE(2c) and UVW/NAT cells
Analysis of skewness of tail moment data derived from
SK-N-BE(2c) cells treated with TPT and [’"‘I]MIBG
Analysis of skewness of tail moment data derived from
UVW/NAT cells treated with TPT and ['"TjMIBG
Significance of cellular DNA damage caused by TPT
and l^^'IJMIBG treatment
Alternatives to as a conjugate for MIBG
mABs or Fab fragments which may be coupled to CCLs
10
50
54
55
64
78
92
141
144
145 
162
179
180
186
220
231
xvii
Abbreviations
["^^AtJMABG
/^g
]à\
fim
jwM
ADEPT
ADP
AO
aii/AU
BER
bNAT
bp
BSA
CCL
cDNA
Cl
cm
CO,
cpm/lO^c
CPT
Q
D
( D )
(Dx)
dATP
DC
dCTP
dGTP
Dm
DMI
^^^lodine-labelled meta-iodobenzylguanidine
^“ Astatine-labelled meta-astatobenzylguanidine
Microgram
Microlitre
Micometre
Micromole
Antibody-directed enzyme prodrug therapy
Adenosine diphosphate
Antisense oligonuclide
Arbitrary units
Base excision repair
Bovine noradrenaline transporter
base pair
Bovine serum albumin 
Coated cationic liposome 
DNA complementary to mRNA 
Combination index 
Centimetre 
Carbon dioxide
Counts per minute per 10  ^cells 
Camptothecin 
Threshold cycle number 
Dose
Dose of drug causing x% effect in combination 
Dose of drug causing x% effect as single agent 
Deoxyadenosine-5 ’ -triphosphate 
Dendritic cells
Deoxycy tidine-5 ’ -triphosphate 
Deoxy guanosine-5 ’ -triphosphate 
ICgo dose
Desmethylimipramine
XVlll
DNA
dNTP
DS
DSB
dsDNA
dUTP
EDTA
fa
Fab
FACS
FAM
FCS
fu
g
GAPDH
GD,
Gy
h
HCl
HEPES
hNAT
HSV
hTERT
hTR
i.p.
ïCio
iQ o
IC 5 0
ICvo
ICgo
INSS
Kb
kBq
Deoxyribonucleic acid
2 deoxy nucleotide 5 tri-phophate
Disulfiram
Double-strand DNA break
Double stranded DNA
Deoxyuracil-5’-triphosphate
Ethylene-diamine-tetra-acetic acid
Fraction of cells affected by treatment
mAb fragment containing one antigen-binding site
Fluorescence-activated cell sorting
6 -carboxyfluorescein
Foetal calf serum
Fraction of cells unaffected by treatment
Force of terrestrial gravity
Glyceraldehyde-3-phosphate dehydrogenase
Disialoganglioside
Gray
Hours
Hydrochloric acid
4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid 
Human noradrenaline transporter 
Herpers simplex virus
Telomerase protein subunit 
Telomerase RNA subunit 
Intraperitioneal
Inhibitory concentration (10%)
Inhibitory concentration (30%)
Inhibitory concentration (50%)
Inhibitory concentration (70%)
Inhibitory concentration (90%)
International Neuroblastoma Staging System
Kilobase
Kilobequerel
x ix
kDa
Kl
LET
m
I
mAb
MBq
mCi
MDR
mg
Mg Cl,
MIBG
mins
ml
mM
mm
mRNA
n.c.a.
Na Cl
NAD+
NAT
Nb
ng
"C
PARP-1
PBS
PBSC
PCR
PMSF
RIBBE
Rn
RNAi
RPM
Kilodalton 
Potassium iodide 
Linear energy transfer
Coefficient of sigmoidicity of dose-effect curve 
litre
Monoclonal antibody
Megabequerel
millicurie
Multidrug resistance 
milligram
Magnesiun Chloride
Metaiodobenzy 1 guanidi ne
Minutes
Millilitre
millimole
milimetre
Messenger ribonucleic acid 
No-carrier added 
Sodium Chloride
Nicotinamide adenine dinucleotide
Noradrenaline transporter
Neuroblastoma
nanogram
Degrees centigrade
Poly(ADP-ribose)polymerase-1
Phosphate buffered saline
Peripheral blood stem cell
Polymerase chain reaction
Phenyl methyl sulfonyl fluoride
Radiation-induced biological bystander effect
Unbound fluorescent reporter
Ribonucleic acid interference
Revolutions per minute
XX
RSV Rous sarcoma virus
RT Reverse transcription
s.c. subcutaneous
SCGE Single cell gel electrophoresis
SCLC Small cell lung carcinoma
SES Standard error of skewness
SF Surviving fraction
SSB Single-strand DNA break
T 2 Time required for a doubling of tumour volume
Tio Time required for a ten-fold increase of tumour volume
TAB T ris-Acetate-EDT A
TAMRA 6 -carboxytetramethylrhodamine
Taq Thermus aquaticus
TBE Tris-Borate-EDTA
Tdp 1 Tyrosyl DNA phosphodiesterase
TOP 1 Gene encoding topoisomerase I
Topo I Nuclear enzyme topoisomerase I
TPT Topotecan
Tris (Hydroxymethyl)aminomethane
TSA Tumou specific antigen
V Volt
VDEPT Viral vector-directed enzyme prodrug therapy
XRCC-1 X-Ray Cross-Complementing group 1
XXI
Summary
Introduction: Neuroblastoma has a long-term survival rate of only 15%. While 
patients with early stage disease can usually be treated surgically, those with inoperable 
disease require intensive treatment. However, there has been no substantial 
improvement in the survival rates of patients with advanced disease. Targeted 
radiotherapy, using [’^ ^IJmeta-iodobenzylguanidine has induced
favourable remissions in some patients when used as a single agent However, the full 
potential of this therapy may only be realised when it is combined with other agents. 
One class of agents with the potential to improve therapy are the inhibitors
of topoisomerase I, which have previously shown synergy when used in combination 
with radiotherapy. Furthermore [^^^IJMIBG therapy could be improved by the rapid 
selection of patients who may derive benefit from this treatment.
Aims: The aims of this study were to develop a molecular assay for MIBG 
active uptake, and to determine the efficacy of [^^^I]MIBG in combination with the 
topoisomerase I inhibitor topotecan in vitro and in vivo.
Results: RT-PCR analysis of NAT expression by neuroblastoma biopsies was 
predictive of tumour uptake of MIBG. However RT-PCR negativity failed to correctly 
determine MIBG uptake capacity with a frequency of 45%.
The combined effects of topotecan and 1^^4]MIBG were assessed, in tumour 
cells expressing the noradrenaline transporter, using three treatment schedules: 
topotecan administered 24h before [i], after [ii] or simultaneously with [iii] [*^^I]MIBG. 
Pre-treatment with TPT enhanced the intracellular concentration of [^^^IJMIBG. 
However, analysis of TPT and ['^‘ijMIBG interactions in vitro and in vivo demonstrated 
that this was not the optimal order of administration for combination therapy. While 
supra-additive toxicity was observed in vitro by all combination schedules, schedule [i]
xxii
was less effective than schedules [iij and [iii]. This was reflected in failure to repair 
DNA damage.
With respect to delay of growth of NAT-expressing xenografts in nude mice, 
combinations of topotecan and [^^^I]MIBG were more effective than single agent 
treatments. Combination schedules [ii] and [iii] were superior to combination schedule 
[i]. Combination treatment caused negligible myelotoxicity according to platelet 
production, or stem cell clonogenic capacity.
Conclusions: Real-time PCR evaluation of primary neuroblastoma tumours has 
significant capability to reflect their capacity for the accumulation of MIBG, however 
PCR-based assessment of NAT gene expression cannot fully predict MIBG uptake. 
Inhibition of DNA repair and supra-additive toxicity to NAT expressing cells and 
xenografts were achieved using combinations of topotecan and [^^4]MIBG. 
Effectiveness was dependent on the order of administration of the two agents. If the 
synergy demonstrated in the model systems used in this study can be replicated in 
patients with neuroblastoma, there is potential for real therapeutic gain.
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Chapter 1
Introduction;
[131i]m ib G and topotecan: A rationale for 
combination therapy for neuroblastoma
1.1 Targeted radiotherapy as a treatment for cancer
I . L I  Targeted therapy
The diagnosis and treatment of cancer has a very long history. Hippocrates 
considered the disease incurable, while Cel sus and Galen both attempted surgical 
treatments. [1]. The 17th century clinicians Lusitanus and Sennert thought it was 
contagious [ 1 , 2 ].
In the last century, great advances have been made in the understanding and 
therapy of cancer, and it has long been recognised that surgery alone is insufficient in the 
treatment of many types of disease [3]. Also, while the use of external beam radiation and 
chemotherapy have shown some success, the inability of these treatment modalities to 
discriminate between tumour cells and normal tissue has severely limited their 
effectiveness [3].
In recent years, advances in our knowledge of the molecular biology of cancer and 
human genetics have led to the identification of a number of strategies with the potential to 
actively target cancer cells, either in a tumour mass or in metastatic disease. One strategy 
involves selective disruption of tumour-specific genes through antisense oligonucleotide 
(AO) [4], or manipulation of the endogenous RNA interference (RNAi) pathway [5, 6 ].
Another approach involves the use of gene therapy, where a “suicide” gene, or an 
anti-oncogene is introduced into tumour cells [7], via immunoliposomes [8 , 9], or tumour- 
targeting viral vectors [10]. Alternative gene therapy-derived strategies involve the 
introduction of a gene encoding a tumour specific antigen (TSA) into dendritic cells (DCs) 
to try to initiate an immune response [7, 11].
Other strategies currently under investigation involve the targeting of cytotoxic 
agents to malignant tissues. The efficacy of polyclonal or monoclonal antibodies, raised
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against tumour specific antigens has been investigated. Antibodies used in this way can 
act as directly targeting cytotoxic agents (through conjugation to radio-isotopes [3, 12], or 
cytotoxic drugs [13]), or as a method of targeting delivery vehicles such as liposomes [8 , 
9].
More experimental methodologies are currently under investigation, such as 
ADEPT (antibody-directed enzyme prodrug therapy) [14] and VDEPT (viral vector- 
directed enzyme prodrug therapy) [15]. These multistep targeting systems seek to localise 
the activity of cytotoxic drugs to tumour cells by converting a previously administered 
nontoxic prodrug to an active cytotoxic agent. The enzyme responsible for this conversion 
is targeted to tumour cells, either by conjugation to an antibody specific for a tumour 
antigen (ADEPT), or by introduction via a viral vector, followed by activation of a tumour 
specific promoter to drive expression of the gene for the enzyme (VDEPT). While both of 
these approaches could prove beneficial in the future, trials involving these techniques 
have so far been disappointing [3].
1.1.2 Ejficacy o f  targeted cancer therapy
Irrespective of the method of tumour targeting being utilised, it is important to 
ensure delivery of the treatment only to malignant sites, and not to normal tissues. Also, 
the targeting agent must be capable of maximal effectiveness at the site of the tumour mass 
[3J.
In many cases the efficacy of targeted cancer therapy has been hampered by 
inefficient delivery of the therapeutic agent, non-optimal penetration of anti-tumour effects 
throughout the tumour mass and, in the case of antibody-directed strategies, anti-mouse 
immunoglobulin immune responses, which have resulted in administered doses that are 
significantly lower than the amount needed for eradication of the malignant deposits [3, 4, 
12].
7.7.5 Targeted radiotherapy
After surgery, radiotherapy is the most commonly used form of cancer treatment, 
and it is estimated that 50% of all patients will require radiotherapy at some stage [16]. 
However, the main limitation in the use of radiotherapy is the potential damage to normal 
tissue, but, if the tumour is well defined, this can be circumvented by the use of eg. 
external beam conformai radiation, which can deliver a high dose to the tumour site, 
without extensively damaging nearby organs. Unfortunately, many tumours do not have 
well-defined margins, or are spread throughout the body, and cannot be treated in this 
fashion [17].
These problems can be overcome by targeted radiotherapy, where cytotoxic 
radionuclides are conjugated to tumour-seeking agents, leading to the selective irradiation 
of malignant areas while sparing normal tissues [18]. In theory, the use of monoclonal 
antibodies raised against tumour cellular structures should provide the specificity needed to 
target malignant sites. However, in practice, with the exception of antibody-directed 
therapy of lymphoma, this has been far from successful [3, 12].
An alternative to antibody-dependant methodologies is the use of small tumour- 
targeting molecules, which can be easily conjugated to radioisotopes. Due to their small 
size, these ligands do not evoke an immune response and have improved penetration [18].
1.1 A  Radiological bystander effect
An advantage of targeted radiation in the treatment of cancer is that the cytotoxic 
effects of radioisotopes are enhanced by the radiological bystander effect.
Heterogeneous uptake of the radioactive agent can result in only a fraction of 
tumour cells being successfully targeted. However, energy released by decay of the 
radioisotope emanates from the targeted portion of the tumour in three dimensions, causing 
damage to neighbouring cells that have not accumulated the radiolabelled drug [17]. 
Therefore, even if the success rate of transfer of the radiolabelled agent to tumour cells is 
less than 100%, underdosing of the tumour is circumvented (Figure 1-1).
Other targeting methodologies, such as ADEPT also employ bystander effects. 
However, these rely on the transport of activated cytotoxic drug through gap junctions, 
which often diminishes with tumour progression [19]. Toxicity due to radiation cross-fire 
does not rely on biological cellular functions, and energy emissions from a wide range of 
radio-nuclides have been evaluated, and their path lengths are well known. This raises the 
possibility of the utilisation of different radio-nuclides with different decay characteristics, 
to treat tumour masses of widely varying size [20].
The contribution of radioactive decay by particles emanating from targeted cells to 
kill of neighbouring, non-targeted cells is relatively well characterised [20]. Recently, it 
has been recognised that cellular processing of the radiation insult can translate the 
physical radiation insult into biological signals or toxins. This is known as the radiation- 
induced biological bystander effect (RIBBE). While investigations of RIBBE induced 
toxicity are outside the scope of this present study, these effects may have major 
implications on the course of future research, and this will be addressed in greater detail in 
Section 12.4.
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Figure 1-1: Radiological bystander effect
A Tumour cells are targeted by a radiolabelled agent
B Only a fraction of the tumour is successfully targeted. The majority remains 
unaffected
C Energy released by decay of the radioisotope emanates from the targeted 
portions of the tumour in three dimensions, causing damage to neighbouring cells 
that have not been successfully targeted.
1.2 Neuroblastoma
7.2.7 Incidence /  Survival
Neuroblastoma, an embryonal tumour of the sympathetic nervous system, is the 
most common extracranial solid tumour of childhood [21] and accounts for approximately 
8% of all pediadtric malignancy [22, 23]. 96% of cases occur before the age of 10 years
[24]. Neuroblastoma is responsible for approximately 15% of all childhood cancer deaths
[25] and has a long-term survival rate of only 15% [20].
7.2.2 Molecular biology
Neuroblastoma cells show large genetic abnormalities. Both gain of, and loss of 
genetic material is typically seen. Amplification of the N-myc oncogene (located on 
chromosome 2) is seen in 25-33% of neuroblastoma patients [21], and is one of the most 
important prognostic indicators [26, 27]. Gain of 17q is a very common genetic 
abnormality in primary neuroblastoma, and is found in over 50% of cases [25]. Deletion 
of the short arm of chromosome 1 is also a common feature of advanced disease [28, 29], 
and loss of heterozygosity (LOH) is seen in 19-36% of primary tumours [30-37]. 
Deletions of chromosome 11 are seen in 15-20% of neuroblastoma karyotypes [38], and 
evidence suggests that a neuroblastoma suppressor gene may be located on l l q  [25]. 
Other regions of the genome that show alterations, LOH and / or allelic abnormalities 
include 3p [39], 4p [40], 5q [41], 9p [42, 43], 14q [31, 33, 44, 45] and 18q [46]. Over­
expression of multidrug resistance genes (MDR) is also commonly seen [21, 25], and may 
be associated with over-expression of N-myc [47].
1 .23  Clinical features /  Treatment regimes
At presentation, approximately 33% of neuroblastoma patients have localized 
disease, while the remaining 67% of patients have métastasés 121]. However, 
neuroblastoma is an incredibly heterogeneous disease, and the likelihood of tumour 
progression varies widely depending on factors such as age of diagnosis and anatomic 
stage [25].
In general, children who are diagnosed before 1 year of age, and/or with localised 
disease can be cured by surgery, with little or no adjuvant therapy. Conversely, older 
children often show extensive métastasés at diagnosis, and clinical prognosis is poor [25]. 
Patients are staged using the recognised International Neuroblastoma Staging System 
(Table 1-1).
Patients with stage 1 and stage 2A disease have localised tumours, and can usually be 
treated surgically, without the need for radiotherapy and / or chemotherapy [21]. Patients 
with stage 2B and stage 3 disease display lymph node involvement, and can also be treated 
by surgery [23], in conjunction with adjuvant chemotherapy [21, 48]. The effectiveness of 
radiotherapy to these patients remains inconclusive [27, 49]. In the case of patients with 
inoperable stage 3 and stage 4 (with the exception of patients with stage 4S, who generally 
display spontaneous regression without intensive intervention [21, 50]), intensive 
treatments, or "megatherapies" are utilised, involving combinations of high-dose 
myeloablative chemotherapy with total body irradiation and stem cell rescue [21, 51].
However, despite the use of such aggressive therapies, there has been no substantial 
improvement in the survival rates of patients with advanced disease [52].
Table 1-1: The International Neuroblastoma Staging System (INSS)
Stage 1 :
Localized tumour* with complete gross excision, with or without microscopic residual 
disease; representative ipsilateral lymph nodes negative for tumour microscopically (nodes 
attached to and removed with the primary tumour may be positive).
Stage 2A:
Localized tumour with incomplete gross excision; representative ipsilateral nonadherent 
lymph nodes negative for tumour microscopically.
Stage 2B:
Localized tumour with or without complete gross excision, with ipsilateral nonadherent 
lymph nodes positive for tumour. Enlarged contralateral lymph nodes must be negative 
microscopically.
Stage 3:
Unresectable tumour infiltrating across the midline** with or without regional lymph node 
involvement; or localized unilateral tumour with contralateral regional lymph node 
involvement; or midline tumour with bilateral extension by infiltration (unresectable) or by 
lymph node involvement.
Stage 4:
Any primary tumour with dissemination to distant lymph nodes, bone, bone marrow, liver, 
skin and/or other organs (except as defined in Stage 4S).
Stage 4S :
Localized primary tumour (as defined for Stage 1,2A, or 2B), with dissemination limited 
to skin, liver, and/or bone marrow* * *
(limited to infants less tlian one year of age).
%
* Multifocal primary tumours (e.g., bilateral adrenal primaiy tumours) should be staged 
according to the greatest extent of disease, as defined above, and followed by a subscript 
“ M ” (e.g.,3M).
* * The midline is defined as the vertebral column, tumours originating on one side and 
“ crossing the midline” must infiltiate to or beyond the opposite side of the vertebral 
column.
* * * Marrow involvement in stage 4S should be minimal, i.e. less than 10% of total 
nucleated cells identified as malignant on bone marrow biopsy or on marrow aspirate. 
More extensive marrow involvement would be considered to be stage 4. The MIBG scan
(if done) should be negative in the marrow.
:
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1.2.4 Experimental treatment regimes
Attempts have been made to improve the outcome of patients with advanced 
neuroblastoma by utilising new techniques that can target the tumour directly. Pilot 
experiments have been carried out to evaluate the possibility of gene therapy using viral 
vectors for eg. prevention of angiogenesis [53]; generation of immune responses to 
neuroblastoma ceils [54]; and purging residual neuroblastoma cells before stem cell rescue 
[55]. Other lines of research are concentrating on targeted liposomes [56-58] and 
immunotherapy using monoclonal antibodies [59, 60].
To date, however, the most promising use of a novel treatment for neuroblastoma is 
non-immunological targeting using radioiodinated meta-iodobenzylguanidine ([^^^1]MIBG
- Figure 1-2).
85-90% of neuroblastoma tumour cells express the noradrenaline transporter (NAT
- Figure 1-3), a 12-spanning integral membrane protein responsible for the active 
intracellular accumulation of catecholamine neurotransmitters [61, 62]. 
Meta-iodobenzylguanidine (MIBG), a structural analogue of noradrenaline, is a derivative 
of the adrenergic neurone-blocking drugs bretylium and guanethidine, and is also 
selectively concentrated in neuroadrenergic tissue by this process [61, 62]. Tracer doses of 
radioiodinated MIBG have been used successfully for diagnostic scintigraphy of tumours 
derived from the neural crest [63], and it is expected that the ability of neural crest-derived 
tumours to accumulate and retain high concentrations of [^  ^ I]MIBG will lead to more 
extensive therapeutic application of this drug [64].
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Figure 1-2: [i3il] meta-iodobenzylguanidine ([i3iI]MIBG)
is a structural analogue of adrenergic neurone blockers bretylium and 
guanethidine. It is selectively concentrated in neuroadrenergic tissue by the 
noradrenaline transporter (NAT). [^^T]MIBG causes favourable remissions in 
neuroblastoma patients when used as a single agent.
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Figure 1-3: The noradrenaline transporter (NAT)
The noradrenaline transporter (NAT) is responsible for the active intracellular 
accumulation of catecholamine neurotransmitters in neuroadrenergic tissue by a 
process known as Uptake-1. It is expressed in 85-90% of neuroblastoma tumour 
cells.
The NAT protein consists of 617 amino acids and has 12 transmembrane domains. 
This conformation is similar to that of other membrane-associated proteins that are 
responsible for ion and solute transport. Note that the number of circles is not an 
accurate representation of the number of amino acid residues.
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1.2.5 Combination therapy incorporating [ ‘^^IJMIBG
Targeted therapy using has induced favourable remissions in some
patients when used as a single agent [65-70]. However long-term cure remains elusive, and 
the full potential of this therapy may only be realised when it is combined with other 
agents [71].
In Ghent University Hospital, Gent, Belgium and Emma Children’s Hospital, 
Amsterdam, The Netherlands, Potassium iodide (KI) was administered prior to ['^T]MIBG 
treatment, to prevent undesirable irradiation of the thyroid by free ^^ I^ (caused by 
breakdown of [^^^IJMIBG). One study found a large variation in radio-iodide uptake, both 
between different patients (absorbed thyroidal dose = 0.2-30.0 Gy) and, indeed, in 
individual patients at different timepoints (mean sd = 24.1 +/- 19.2 Gy per patient) [72]. 
Another study found that 52.4% of patients exhibited thyroid damage after a mean period 
of 1.4 years (0.1-5.8yrs). In 25 survivors, tested after a mean period of 3.5 years, the 
percentage displaying thyroid damage rose to 64%, suggesting that *^ I^ induced thyroid 
disfunction could be a major difficulty long-term [73].
At the Netherlands Cancer Institute, ['^T]MIBG has been given in conjunction with 
hyperbaric oxygen [74], to try to overcome radioresistance in poorly oxygenated tumour 
regions. Improved survival rates, compared with ['^T]MIBG alone, were observed. This 
has also been tested in Faculty Hospital Motol, Prague, with favourable results [75].
In another study carried out in Emma Children’s Hospital, Amsterdam, The 
Netherlands, [^^'l]MIBG was administered to newly diagnosed patients before either 
surgery or chemotherapy [76]. This also gave encouraging results. Preoperative 
[131i ]m i b G was found to be less toxic than chemotherapy, but equally effective.
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At the University of Michigan Medical Centre, Michigan, USA, in a pilot study 
patients were treated, following induction therapy, or after relapse, with a regimen which 
involved [^^^I]MIBG treatment, followed 14 days later by a combination of carboplatin, 
etoposide and melphalan for 4 days, and ending in stem cell rescue 3 days later. The 
combined therapy was well tolerated, with 25% (2/8) patients exhibiting partial responses 
100 days following transpantation and 37.5% (3/8) achieving complete response [77].
In the Gaslini Institute, Genova, Italy, patients with residual stage 4 neuroblastoma 
were treated with 4.1 - ll.lm C i/k g  [^^^I]MIBG 7-10 days before high-dose chemotherapy 
involving busulphan and melphalan followed by peripheral blood stem cell (PBSC) rescue. 
High gastrointestinal toxicity was seen in patients treated with ['^T]MIBG (76.5% or 
13/17) and in control patients subjected to PBSC without [^^^I]MIBG treatment (60% or 
9/15). 12% (2/17) of patients treated with [^^T]MIBG developed pneumonia, suggesting 
that refinement of this treatment may be required to avoid lung complications [78].
In Hacettepe University, Ankara, Turkey, [^^T]MIBG was administered in 
conjunction with a combined chemotherapy regimen of vincristine, VP16, iphosphamide, 
carboplatin, epirubicin and cyclophosphamide. 5/8 patients with refactory neuroblastoma 
responded to [^^^I]MIBG therapy, with 2/8 achieving complete responses and 3/8 
exhibiting partial responses. In total, 5 patients relapsed and died of progressive disease, 
suggesting that although survival was improved by the inclusion of [^^'l]MIBG into 
conventional therapy, overall prognosis was still poor [79].
At the Children’s Hospital, University of Tubingen, Germany, patients were treated 
with [^^T]MIBG, followed by a combination of melphalan carboplatin and etoposide. 
They were then subjected to stem cell rescue supplemented with immunotherapy using 
anti-GD 2  antibodies. 3/11 experienced complete responses, 1/11 exhibited a partial
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response, while 2/11 did not respond, and died. 19 months following treatment 9/11 were 
alive, with 8/11 showing no progression or relapse [80].
At Catholic University, Rome, Italy, [^^^I]MIBG was administered as a part of two 
separate treatment regimes. In the first regimen, [^^'l]MIBG was used along with cisplatin 
and cyclophosphamide. In the second regimen, VP16 and viscristine were added to the 
basic chemotherapy treatment. Favourable results have been reported for both of these 
regimens. [52]
In Middlesex Hospital, London, Britain, studies were undertaken to follow 
[131j]m i b G treatment with multiagent chemotherapy (with high dose carboplatin and 
melphalan), and haemopoetic stem cell rescue. Patients with newly presenting, advanced 
stage disease were treated firstly with [^^^I]MIBG and then with combinations of 
chemotherapy and radiotherapy five days later. Toxicity was assessed at an initial whole 
body dose of 1.5Gy, after which the [^^^I]MIBG component was increased until peripheral 
stem cell rescue was required [81]. The results of this study were encouraging. Combined 
treatment was generally well tolerated, and there was no early mortality.
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1.2.6 The potential o f  combination therapy incorporating f^ f jM lB G  and topoisomerase I  
inhibitors
As described in the last section, targeted therapy using [/^4]M1BG in combination 
with complementary therapies has produced favourable responses. However, to realise its 
full potential, the most effective way to use this tumour-targeting drug has yet to be 
defined.
[^^4]MIBG-induced toxicity is due to decay. Therefore, it is expected that the 
effectiveness of this drug will be improved if used in combination with agents which 
potentiate radiation-induced damage. One such class of agents, with the potential to 
improve on existing regimes based on [^^'l]MIBG therapy are inhibitors of the nuclear 
enzyme topoisomerase I (Topo I).
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1.3 Topoisomerase I and its inhibitors
1.3.1 Topoisomerase I
Topoisomerase I (Topo I) is a nuclear enzyme that relaxes supercoiled DNA and 
plays a crucial role in DNA replication and in transcription [82-84], It is a lOOkDa protein 
encoded by the single-copy TOPI gene, located on chromosome 20 [85-87]. The presence 
of up-regulated levels of Topo I in tumour cells compared to normal cells suggests a 
therapeutic advantage of utilising Topo I - targeting agents [85].
Topo I removes the topological tension in front of replication forks by inserting a 
nick on one of the DNA strands, allowing the other strand to pass through the cleavage 
site, before re-sealing the nick. During this process, an intermediatary state occurs by the 
formation of transient covalent bonds between the tyrosine-723 residue of the Topo I [82] 
and the 3 ’ terminus of the nicked strand (the so-called “cleavable complex”) [83, 84] 
(Figure 1-4).
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Figure 1-4: The mechanism of topoisomerase I action
Topoisomerase I (Topo I) is a nuclear enzyme that relaxes supercoiled DNA and plays a 
crucial role in DNA replication and in transcription. The mechanism of Topo I action is as 
follows:
A) Increasing tension and supercoiling of DNA occurs.
B) Topo I binds to one DNA strand and cuts it (cleavage reaction).
C) The intact strand of DNA passes through the neck, resulting in the relaxation of the 
torsional strain.
D) Topo I reseals the broken strand (religation step) and dissociates from the DNA 
molecule.
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1.3.2 Inhibitors o f topoisomerase I
Camptohecin (CPT - Figure 1-5), an alkaloid extract of the tree Camptotheca 
acuminata^ was first identified in 1966 as exhibiting antitumour activity in murine 
leukemia models [86], although it was not until 1988 that the mode of action was identified 
as Topo I inhibition [88]. The hypothesised cytotoxic mechanism of camptothecin is 
known as the fork collision model. Briefly, CPT binds to, and stabilises the normally 
transient cleavable complex, inhibiting the Topo I-induced religation step. During the next 
round of DNA replication, collision of the stabilised Topo I - DNA complex with the 
replication fork results in an irreversible double strand break, leading to cell cycle arrest 
and cell death [83, 85] (Figure 1-6).
Clinical trials of CPT were carried out in the 1970s. However these were 
terminated due to excessive and unpredictable toxicity [83, 85]. Instead, researchers 
attempted to synthesise derivatives of camptothecin which would exhibit lower toxicity 
and greater solubility in water. This led to the identification of a new class of 
campotohecin analogues, including the semi-synthetic derivative topotecan (TPT - Figure 
1-7).
Many studies have been carried out to ascertain the effectiveness of topotecan in 
the treatment of a variety of cancers.
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Figure 1-5: Camptothecin (CPT)
Camptothecin (CPT), is an alkaloid extract of the tree camptotheca acuminata. 
It is an inhibitor of topoisomerase I, Clinical trials of CPT were carried out in 
the 1970s. However these were terminated due to excessive and unpredictable 
toxicity.
In 1988 tire mode of action of CPT was identified as inhibition of 
Topoisomerase I [88].
21
/Topo I
Topo I
CPT
parent DNA 
daughter DNA
Figure 1-6: Interaction of topoisomerase I with camptothecin
Topoisomerase I interacts with the Topo I inhibitor camptothecin by the following 
mechanism:
A) Camptothecin binds to topo I and stabilises the normally transient cleavable complex, 
inhibiting the religation step.
B) Collision of the replication fork with the camptothecin-stabilized cleavable complex 
results in an irreversible double-strand break in the DNA.
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13.3  Current status o f  topotecan used as a single agent
Topotecan has shown effectiveness as a single agent in phase I/II trials for the 
treatment of head-and-neck cancer [89], small cell lung carcinoma (SCLC), [90] and 
ovarian cancer [91-93]. Pilot studies of topotecan's effectivness against breast cancer also 
produced favourable results [94]. However in phase II trials, it showed only modest 
activity [95].
Also, phase II trials of TPT activity on esophageal carcinoma produced 
disappointing results [96], and topotecan had no effect on the management of hormone- 
refactory prostate cancer [97].
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Figure 1-7: Topotecan (TPT)
Topotecan is a semi-synthetic derivative of camptothecin which has greater 
solubility. It inhibits the activity of Topo I in a similar fashion to CPT (see 
Figure 1-5).
Topotecan has been entered into a large number of clinical trials, to asceitain its 
effectiveness in the treatment of a wide range of cancers.
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1.3 A  Topotecan in combination with other agents
Combinations of topotecan and cyclophosphamide produced encouraging results in 
phase II trials for the treatment of rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma 
[98].
Topotecan has been used in phase I/II trials for the treatment of small cell lung 
carcinoma (SCLC), in combination with paclitaxel [99] gemcitabine [100, 101] cisplatin 
[101, 102] etoposide [103] cisplatin-etoposide [104], and doxorubicin [105]) and also in 
combination with irradiation for the treatment of SCLC métastasés [106]. Phase II trials 
have also studied topotecan in combination with gemcitabine in the treatment of non-small 
cell lung carcinoma, [107], with favourable results. There have also been encouraging 
results when TPT was studied as a treatment of ovarian cancer in phase I/II trials, in 
combination with paclitaxel [108], paclitaxel-cisplatin [109], carboplatin [110], 
gemcitabine [111] and doxorubicin [112]).
Other phase I/II trials have studied the effect of topotecan on leukemia [113-115], 
and favourable results were seen when topotecan was used in combination with etoposide 
and mitoxantrone [113]. Phase I/II trials of topotecan in combination with cisplatin and/or 
radiation have been carried out for the treatment of advanced cervical cancer [116], with 
encouraging results [117].
However, a phase II study of sequential topotecan and etoposide in non-Hodgkin's 
lymphoma produced only modest effects [118]. Similarly, combinations of topotecan and 
radiation for the treatment of glioblastoma [119-121] produced no significant improvement 
on radiation alone [119], and no substantial activity in relapsed gliomas was observed 
[122].
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1.3.5 Topotecan as a treatment for neuroblastoma
There have been tremendous advances in the treatment of childhood cancer during 
the past several decades with resultant improvement in survival of many children with 
cancer. However, this marked progress has not yet been realized for children with high-risk 
tumours such as neuroblastoma. Improvement of event-free and long-term survival of 
poor-prognosis paediatric tumours may depend on the identification of chemotherapeutic 
agents with novel mechanisms of action [123]. TPT has a distinctive mode of action, and 
its effectiveness is not compromised by tumour development of multi-drug resistance 
[124]. This characterisitic is particularly advantageous in therapy of neuroblastoma, which 
often involves multi-agent regimens.
Topotecan shows activity against neuroblastoma xenografts 1125], regardless of 
their level of expression of the multidrug resistance gene MDR 1 [124]. It has been used 
as a palliative agent [126], and has been entered into clinical trials for the treatment of 
neuroblastoma, where it has shown effectiveness as a single agent in phase I/II trials [126- 
130].
Encouraging results have been obtained from combinations of topotecan and other 
chemotherapeutic agents, for example topotecan given in combination with 
cyclophosphamide in phase I/II trials [98, 131, 132]. Favourable results were also 
obtained for topotecan given in combination with myeloablative doses of thiotepa and 
carboplatin [128], and topotecan in combination with vincristine and doxorubicin [134]. 
Topotecan combined with cyclophosphamide, and vincristine was also found to be a good 
preparative regimen for monoclonal antibody-based therapy of neuroblastoma [135].
These studies suggest that topotecan-based therapies could prove to be beneficial in 
the treatment of neuroblastoma. It is expected that the effectiveness of TPT against
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neuroblastoma could be greatly enhanced if this agent is given in combination with 
[^^^I]MIBG, due to the ability of TPT to potentiate radiation-induced toxicity.
1.3.6 Interaction between topoisomerase I  inhibition and radiation induced DNA damage 
in vitro and in vivo
In many previous studies, synergistic cell killing in vitro by ionising radiation and 
Topo I inhibitors has been reported in a wide range of tumour cell lines. Radiopotentiation 
has been observed in non-human cells such as murine leukemia (P388) [136], Chinese 
hamster ovary [136] Chinese hamster (V79) fibroblast [137] lines, and also from a wide 
range of human cell lines such as small-cell lung cancer (SBC3-CDDP) [138], 
glioblastoma (GBM) [139], HeLa [137], squamous carcinoma of the head and neck [133], 
breast cancer (MCF7) [85] and melanoma [141].
In vivo radiopotentiation by Topo I inhibitors has been seen in murine fibrosarcoma 
[140], and MCa-4 mammary carcinoma [142] and rhabdomyosarcoma [143].
However, no attempt has been made to investigate the potential of inhibitors of 
topoisomerase 1 to induce radiopotentiation in vitro and in vivo when combined with 
targeted radiotherapy.
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1.4 Aim of this study
Clinical diagnosis of neuroblastoma involves histological examination of biopsy 
specimens and evaluation of scintigrams obtained following the administration of a tracer 
dose of either or [^^^I]-labelled MIBG, and tumour uptake of MIBG at this stage also 
indicates suitability of the patient for a treatment regimen that includes [*^4]MIBG therapy. 
However, in many cases, radioiodinated MIBG is not immediately available, leading to 
possible delays of more than one week from the time of admission to gamma-camera 
scanning and reporting. A rapid and sensitive molecular assay for MIBG active uptake, 
which could be applied at initial biopsy, would be invaluable in selecting patients for 
therapeutic strategies which incorporate radiolabelled MIBG.
Experimental evidence has shown that the Camptothecins can act as 
radiosensitizers in vitro and in vivo when used in conjunction with ionising radiation 
delivered from an external source [85, 136-143]. However, to date, no attempt has been to 
demonstrate synergistic interactions between Topo I inhibitors and targeted radiotherapy.
The effectiveness of therapeutic applications of [^^*I]MIBG will be improved if this 
drug is used in combination with agents which potentiate radiation-induced damage. TPT- 
induced radiosensitisation has the potential to improve on existing regimes based on 
[i3ii]MiBG therapy for the treatment of neuroblastoma.
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The aims of this study were;
i) To evaluate the potential of reverse transcription and polymerase chain reaction
(RT-PCR) to accurately identify neuroblastoma patients who are most likely to benefit 
from [^^^I]MIBG therapy. mRNA extracted from neuroblastoma biopsy samples, was 
analysed for NAT gene expression, quantified by real-time PCR and referenced against the 
expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). The results of RT-PCR analyses were compared with scintigrams derived from 
the same patients.
ii) To investigate the efficacy of scheduled combinations of [^^^I]MIBG and TPT in
vitro and in vivo, to improve upon existing therapies for neuroblastoma. The interaction 
between the two drugs was investigated in vitro by two methods, namely isobologram and 
combination-index analyses. The interaction between [‘^ ^I]MIBG and TPT in vivo was 
investigated by delay of the growth of NAT-expressing tumour xenografts
iii) To assess the effect of TPT on [^^^I]MIBG-induced DNA damage and cellular
repair mechanisms using the single cell gel electrophoresis (SCGE), or comet assay.
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Chapter 2
Development of a real-time RT-PCR assay for the 
prediction of ['^hjMIBG uptake
30
2.1 Introduction
2.7.7 MIBG and clinical diagnosis o f neuroblastoma
85-90% of neuroblastoma tumours express the noradrenaline transporter (NAT), 
responsible for the active intracellular accumulation of catecholamines [61, 62]. MIBG is 
also selectively concentrated in neuroadrenergic tissue by this process, and previous 
studies have demonstrated that NAT gene expression correlates with [’^ ’l]MIBG uptake in 
vitro [62]. [^^^I]MIBG has been shown to be a useful agent for the diagnosis and treatment 
of neuroblastoma [144].
Clinical diagnosis of neuroblastoma involves histological examination of biopsy 
specimens and evaluation of scintigrams obtained following the administration of a tracer 
dose of either [^^^I]MIBG or [^^^I]MIBG. The ability of tumours to uptake [^^4]MIBG at 
this stage also indicates the suitability of the patient for a treatment regimen incorporating 
['^'I]MIBG therapy.
However, as radioiodinated MIBG is not available immediately to most hospitals, 
more than one week may elapse between the time of admission, to gamma-camera 
scanning and reporting. A rapid and sensitive molecular assay for the active uptake of 
[^^^I]MIBG, which could be applied at initial biopsy, would be invaluable in selecting 
patients for therapeutic strategies, which incorporate this radiopharmaceutical.
Whilst quantitative PCR is feasible using serial dilution of cDNA followed by 
analysis of PCR reaction end-points, this procedure has proven both time-consuming and 
poorly reproducible [145]. The recent development of fluorescent TaqMan methodology 
shows great promise and may supersede existing methods. Accordingly, a TaqMan RT- 
PCR based assay was developed to determine the suitability of neuroblastoma patients for 
therapy using radiolabelled MIBG.
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2.1.2 TaqMan PCR
Real-time, or TaqMan PCR is a system that enables quantitation of specific DNA 
sequences. The methodology employs a probe technology that exploits the 5'-3' nuclease 
activity of Amplitaq gold polymerase to allow the detection of PCR amplicon formation by 
the release of a fluorescent reporter during the amplification cycle [146] (Figure 2-1). This 
nuciease activity only occurs during polymerisation, therefore, probe that is not bound to 
target DNA remains uncleaved.
To facilitate TaqMan PCR analysis, it is necessary to design a primer / probe set, 
which hybridises specifically to the DNA sequence of interest. Three oligonucleotide 
sequences are utilised in TaqMan PCR. Two of these are forward and reverse primers, 
which are standard for PCR reactions. The third sequence, called the probe, is specific for 
a sequence which lies between the forward and reverse primers. A reporter dye such as 
FAM (6-carboxyfluorescein) is covalently liked to the 5' end, and a quencher, TAMRA (6- 
carboxytetramethylrhodamine) is covalently linked to the 3' end.
When the probe is intact, the proximity of the reporter to the quencher causes a 
suppression of reporter fluorescence by Forster-type energy transfer. During PCR, the 
probe anneals to its target sequence between the forward and reverse primers. The 5-3 ' 
nuclease activity of amplitaq gold polymerase cleaves the probe, leading to an increase in 
free reporter dye after each amplification cycle. Subsequently, the absence of the 
fluorescent suppression caused by the quencher causes an increase in reporter fluorescence 
levels. This is quantified, and provides a direct measurement of amplicon formation 
(Figure 2-1)
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Primer Probe
-------------------------  5 ’
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Reverse
Primer
B
c 5 ’3 ’5 ’ --------------------------- 5 ’--------------------------- 3 ’
5’
D 5 ’3 ’5 ’ 5 ’3 ’
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Figure 2-1: Summary of Taqman PCR amplification
A) Polymerisation: Forward and reverse primers anneal to specific sequences as in 
standard PCR. Probe binds to a specific sequence between the primers. Polymerisation 
commences.
B) Strand Displacement: Newly polymerised DNA reaches the probe, and begins to 
displace it from its target DNA as polymerisation continues.
C) Cleavage: 5-3' nuclease activity of amplitaq gold polymerase cleaves the probe leading 
to an increase in free reporter molecules.
D) Polymerisation completed: Separation of reporter dye from quencher dye leads to an 
increase in reporter fluorescence after each round of replication.
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Fluorescence emission by free reporter (Rn) is measured in real-time after every 
PCR cycle. At the completion of the last cycle of PCR, results are displayed as an 
amplification curve, where Rn (ARn) is plotted against cycle number (Figure 2-2). These 
results, which show a hypothetical TaqMan PCR reaction, allow the direct visualisation of 
product formation after each cycle. The threshold cycle (CJ value of product detection, 
used for quantitation, is derived from the exponential phase of the PCR reaction, rather 
than the plateau phase where increasing cycle number has no effect on product formation.
This results in greater accuracy and sensitivity over alternative methods of nucleic 
acid quantitation. These features should facilitate progress toward the clinical application 
of PCR-based assays. Moreover, an RT-PCR analysis of tumoural expression of NAT- 
specific transcripts can be completed in one half of a working day. Therefore this 
procedure has the potential to allow the prompt identification of patients who may benefit 
from targeted therapy.
Using real-time PCR, the goal was to establish the relationship between the level of 
NAT gene transcription by cell lines and their capacity for active uptake of [^^^I]MIBG, 
and to determine whether the detection of NAT cDNA sequences in neuroblastoma biopsy 
samples could predict the uptake by tumours of [^^^I]MIBG.
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Figure 2-2: Example of TaqMan PCR results
In this experiment, four hypothetical samples were subjected to PCR to test for presence 
of a specific sequence. Increasing fluorescence is measured after each cycle. The 
threshold line denotes where each sample enters the exponential phase of amplification, 
known as the C^ .
from these results, the following conclusions can be reached:
Sample 1: (red line) had the lowest C, (C, = 15), denoting the highest starting number 
of target molecules.
Sam ple 2: (blue line) had the next lowest C, (C, = 17.5).
Sample 3: (yellow line) had a higher C, (C, = 22.5) denoting a low starting number of 
target molecules.
Sam ple 4: (green line) did not enter the exponential phase, denoting negativity.
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2.2 Materials & methods
2.2.7 Cells and culture conditions.
Four human cell lines of neurogenic origin were cultured: SK-N-BE(2c), SHSY5Y, 
SK-N-MC [147] and IMR-32 [148]. In addition, three non-neural crest-derived cell lines 
were evaluated. These were the human breast adenocarcinoma line MCF-7 [149], the 
human gliob]astoma cell line UVW [150, 151] and UVW/NAT, a NAT expressing ceil line 
derived from UVW which was established in this laboratory [152] by transfection of UVW 
cells with a pREP9 episomal expression vector (Invitrogen) containing a copy of the 
bovine NAT (bNAT) cDNA. Utilisation of the bovine version of the NAT gene in the 
transfected cell line allowed differentiation between endogenous human NAT mRNA 
levels and transcription of the expression vector by TaqMan RT-PCR.
Cells were maintained in either MEM medium (lMR-32, SHSY5Y, SK-N-MC and 
UVW) or RPMI 1640 medium (SK~N-BE(2c) MCF-7, and UVW/NAT), containing 10% 
foetal calf serum (FCS) and glutamine (2mM) at 37°C in a 5% COj atmosphere. 
UVW/NAT media contained 500ng/ml Geneticin, which is toxic to cells not expressing the 
pREP9 vector. All media and supplements were purchased from Invitrogen (Paisley, UK).
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2.2 .2  Tumour samples.
Samples of 54 neuroblastoma tumours, frozen in liquid nitrogen immediately after 
excision, were obtained retrospectively from the Academical Medical Center, Amsterdam, 
Netherlands, the G. Gaslini Institute, Genova, Italy and from ten UK Children’s Cancer 
Study Group hospitals. Histological examination revealed that all samples contained 
greater than 20% neuroblastoma cellularity [153], Biopsy material was obtained from the 
primary tumour in each case.
2.2.3 RNA extraction
Total RNA was extracted from cell lines and patient biopsy material using the 
RNAzol method according to manufacturer’s instructions (Biogenesis, Poole, UK). The 
RNA samples were assessed for expression of NAT and the reference gene GAPDH by 
reverse transcription and real-time PCR. This study was approved by the Research Ethics 
Committees of the participating institutions.
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2.2.4 Accumulation o f in cell lines
Cells were seeded in six-well plates at 0.25 x 10  ^cells per well, and incubated at 
?>TC, in 5% CO 2  in RPMI 1640 medium containing 10% FCS. After 48h cells were 
washed once with PBS, and incubated in media containing 7kBq [^^^IjMIBG per well for 
2h, after which time uptake of [^^^I]MIBG is maximal [154]. After incubation, cells were 
washed twice in PBS, and the radioactivity was extracted with two 0.5ml aliquots of 10% 
trichloroacetic acid at 4°C.
Non-specific uptake was measured in the presence of 1.5//M desmethylimipramine 
(DMI), a tricyclic antidepressant which inhibits the re-uptake of neurotransmitters by 
adrenergic neurones. Activity was measured in a Cobra II auto-y counting system 
(Canberra Packard, Berkshire, UK). Specific uptake was calculated by subtracting values 
obtained from DMI inhibited extracts from total uptake, and expressed as counts per 
minute per 10  ^cells (cpm/lO^c).
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2 .2 .5  Evaluation o f scintigrams.
Evaluation of scintigrams was coordinated by Dr. Alan Sprigg (Department of 
Radiology, Sheffield Children’s Hospital). Radioiodinated-MIBG scintigrams were 
obtained from the referral centres, and the hard-copy images were appraised independently 
by two assessors. The activity pattern was compared with the known site of the primary 
tumour (as biopsied) and correlated with other cross sectional imaging as necessary (e.g. 
where liver uptake was superimposed on a primary upper abdominal tumour mass).
Review of the MIBG scintigrams and cross-sectional imaging was performed blind, 
without prior knowledge of the abundance of NAT-specific mRNA. Only samples from 
patients with evaluable MIBG scans were included in the study. The uptake of [’^ ^I]MIBG 
into the primary mass was recorded as negative or positive.
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2.2.6 Primers and probes
The primer and probe sequences chosen for liNAT and bNAT RT-PCR were 
species specific, in order to differentiate between endogenous transcripts, and those 
generated from pREP9 plasmid gene expression. Primer and probe sequences were 
designed from the published sequence for the human noradrenaline transporter (hNAT) 
(accession No. M65105) using the ABI prism PrimerExpress™ vl.O software. Both 
primers and probe were custom synthesised (MWG-Biotech, Milton Keynes, UK). The 
sense primer corresponded to bases 241-260 of the hNAT sequence (5’- 
CGCTTCCCCT ACCTCTGCT A -3 ’ ). The anti sense primer was complementary to bases 
372-391 of the hNAT sequence (5’-AGATTTTCCAAACGGTGGCA-3’). These primers 
generated a PCR product of 151 base pairs. The internal probe corresponded to bases 273- 
299 of the hNAT sequence (5’-CGGTGCCTTCTTGATCCCGTACACACT-3’). The 
probe was labelled with the fluorescent reporter dye 6-carboxyfluoroscein (FAM) at the 5 ’ 
end, and the quencher molecule 6-carboxytetramethylrhodamine (TAMRA) at the 3 ’ end.
Similarly, primer and probe sequences were designed from the published sequence 
for the bovine noradrenaline transporter (bNAT) (accession No. U09198), and custom 
synthesised as above (MWG-Biotech). The sense primer corresponded to bases 1583-1602 
of the bNAT sequence (5’-TCAGCAACGACATCCAGCAG-3’). The antisense primer 
was complementary to bases 1637-1657 of the bNAT sequence (5’- 
GGCT GACA A ACTT CC AG C AG A-3 ’ ). These primers generated a PCR product of 75 
base pairs. The internal probe corresponded to bases 1612-1635 of the bNAT sequence 
(5’-TTCAAGCCCGGCCTGTACTGGAGA-3’). This probe was also labelled with the 
fluorescent reporter dye FAM at the 5 ’ end, and the quencher molecule TAMRA at the 3 ’ 
end.
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The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
used as an internal standard for all real-time PCR reactions. GAPDH PCR was carried out 
using the specifically designed primers and probe kit, TaqMan GAPDH control reagents. 
This was obtained from Perkin-Elmer Applied Biosystems (Cheshire, UK), P/N 402869.
41
2 .2 .7  Standard curve generation and quantitation of test samples
A standard curve was constructed, which was used to produce an exact quantitation 
of starting number of copies of the target sequence. To construct the standard curve, firstly 
a PCR reaction was carried out using TaqMan-generated PCR primers, but using standard 
(ie. non-TaqMan) PCR reagents. The resulting PCR products were then purified. The 
PCR product was quantified spectrophotometrically at A^ go, and converted to number of 
molecules/;^l, using the equation in Figure 2-3 [155, 156]. TaqMan PCR of standards and 
unknown samples was then carried out, and the ABI 7700 sequence detection software 
determined the initial amounts of unknown samples by direct comparison of their C^  value 
with the C( values of known standards. An example of a standard curve is shown in Figure 
2-4.
hNAT-specific, and GAPDH-specific PCR products were obtained by reverse 
transcribing and PCR amplifying 1 g of total RNA obtained from the human 
neuroblastoma cell line SK-N-BE(2c) using the same primer pairs employed later in the 
quantitative real-time PCR. The resulting PCR products were then purified using an S-400 
spin column (Pharmacia Biotech, Uppsala, Sweden) and quality-assessed by agarose gel 
electrophoresis and ethidium bromide staining. The PCR product was quantified 
spectrophotometrically and then serially diluted in mouse genomic DNA (Clontech, CA, 
USA) to maintain a constant total DNA concentration. The standard curve used for 
quantitation of the real-time PCR reaction was constructed using 10^  to 10® copies of the 
SK-N-BE(2c) PCR products obtained from the reaction described above.
Similarly, bNAT specific PCR products were obtained by reverse transcribing and PCR 
amplifying 1 g of total RNA obtained from the transfected glioblastoma cell line line 
UVW/NAT. The resulting PCR product was purified and assessed as above, and a standard
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curve used for quantitation of the real-time PCR reaction was constructed using 10' to 10® 
copies of the bNAT sequence.
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No. of molecules ! j i \  =
r 260
13.2 X S
 ^ N A
X ---------
J 1012
Where:
A 260 = absorbance at 260nm, = size of DNA in kilobases
iVA = Avogadro’s number: 6.022 x 10^ ^
Figure 2-3: Calculation of initial number of molecules for generation 
of a standard curve
This calculation is used to determine the number of molecules in a sample of known DNA 
concentration. It is based on the determination of concentration of double stranded DNA 
[155], which establishes the molarity (in pmol/pl) of a DNA sample from its absorbance at 
260nm.
1 mole contains 6.022 x 1Q2^  molecules (Avogadro’s number [156]), allowing calculation 
of tlie initial number of molecules in a DNA sample.
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Figure 2-4: Standard curve construction
8 standards of known initial copy number (10‘ to 10^  copies of target DNA) were 
subjected to TaqMan PCR.
ABI 7700 sequence detection software plotted the value for each standard against 
starting quantity, and automatically plots unknown test reactions onto this line.
It is therefore possible to determine the starting quantity of your test sample by comparing 
its C, to the C( values of the standards.
In this example, the samples previously shown in Figure 2-2 are plotted along with the 
standards. The results are as follows:
Sample 1 (C, = 15): I x 10  ^copies of target 
Sample 2 (Cj = 17.5): 4 x 1 0 ^  copies of target 
Sample 3 (C, = 22.5): 3x10"^ copies of target
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2.2.8 Real-time RT-PCR amplification.
Real-time RT-PCR was carried out using the commercially available TaqMan Gold 
RNA PCR kit (Perkin-Elmer Applied Biosystems, Warrington UK; P/N N808-0232).
Briefly, of total RNA was reverse transcribed in a 50/d reaction volume, 
containing 5.5 mM MgCl^, 5pi\ lOx TaqMan RT buffer, 2mM dNTP mix (SOOuM each 
nucleotide), 20 units of RNA se Inhibitor, 2.5pM  oligo d(T)i6 and 62.5 units of MultiScribe 
Reverse Transcriptase. 2.5/d of the resulting solution, containing cDNA template, was 
added to an amplification reaction mixture of total volume 25/fl consisting of 5.5 mM 
MgCI^, 2.5/d lOx TaqMan buffer, 200 M dATP, dCTP, dGTP and 400 M dUTP, 0.625 
units of AmpliTaq Gold, 0.25 units of AmpErase uracil N-glycosylase (UNG) and 100 nM 
each of both primers and probe.
The thermal cycling conditions consisted of an initial incubation for 2min at 50'"C, 
followed by 10 min at 95°C. Thermal cycling was then carried out at 95°C for 15 sec, 
followed by 60°C for 1 min, for 40 cycles.
Each assay included a standard curve (10* to 10  ^ copies) and a no-template control, 
along with the unknown cDNA templates obtained from the reverse-transcription step. 
PCR reactions were performed using an ABI prism 7700 Sequence Detection System 
(Perkin-Elmer Applied Biosystems, Foster City, USA), which measured the fluorescent 
signal generated by the PCR reaction.
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2 .2 .9  Statistical analysis.
The relationship between expression of the noradrenaline transporter and specific 
uptake of [*^*I]MIBG by NAT expressing cells was determined by linear regression. The 
relationship between tumour uptake of MIBG and NAT gene expression was examined by 
Fisher’s exact test (two-sided) using GraphPad Prism software, version 3.0, 1999 (CA).
2.3 Results
2.3.1 Real-time PCR.
A range of quantities of NAT- and GAPDH-specific PCR products were amplified 
using the real-time PCR method to establish corresponding C^  values (Figure 2-5A). These 
were plotted against the initial quantity of substrate to produce standard curves (Figure 2- 
5B). This exemplifies the high sensitivity and accuracy of amplification over a large 
concentration range (r = 0.985).
RNA obtained from cell lines and patient biopsy material was reverse transcribed 
and PCR-amplified using the real-time methodology. Samples were assayed three times in 
duplicate for both NAT and GAPDH expression.
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Figure 2-5: Amplification plot and standard curve of the NAT sequence
Standards were obtained by PCR amplification of cDNA from the cell line SK-N-BE(2c). 
The NAT-specific PCR product was then quantified spectrophotometrically, serially diluted 
and amplified using the real-time PCR method.
A: The plots, from left to right, correspond to 10^  to 10' NAT sequence copies.
B: The values obtained were plotted against the initial quantity of substrate to produce a 
standard curve.
A similar procedure was used to quantify the reference GAPDH sequence.
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2.3.2 uptake compared with N AT gene expression in cell lines.
Three out of four neuroblastoma cell lines, demonstrated active uptake of 
[^^T]MIBG. In non-neural crest-derived cell lines, [^^T]MIBG uptake was observed only in 
UVW/NAT, which was transfected with a plasmid containing bNAT. Real-time RT-PCR, 
with specificity for NAT and GAPDH sequences, indicated transcription of the NAT gene 
only in those cell lines which actively accumulated [^^^I]MIBG (Table 2-1). The 
coefficients of variation of the Q  values of the NAT-positive cell lines, obtained from three 
separate determinations in duplicate, were 2.9% (SK-N-BE(2c)), 2.5% (SHSY5Y), 2.0% 
(IMR-32) and 3.0% (UVW/NAT). These indices of reproducibility are superior to those 
previously obtained by means of conventional RT-PCR methodology 162]. The level of 
expression of the hNAT gene by the panel of five neuroblastoma cell lines correlated 
significantly (p < 0.05) with the capacity for active uptake of [^^^IJMIBG.
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Cell line Active MIBG uptake 
(cpm X 10  ^per 10^  cells)
NAT copies per 
10 GAPDH copies
SK-N-BE(2c) 112 ± 11 3.550 ± 0.103 !:
SHSY5Y 46 ± 5 1.117 ± 0.028=::
IMR-32 8 ±  2 0.402 ± 0.008*
SK-N-MC 0 0
MCF-7 0 0
u v w 0 0
UVW/NAT 132 ± 13 35.34 ± 1.07 ^
Table 2-1: NAT gene expression and MIBG uptake by 
neuroblastoma cell lines
Using the RNA obtained from seven human tumour cell lines, NAT and GAPDH 
expression were assessed by reverse transcription and real-time PCR amplification. 
The results are means ± s.d. of three separate determinations in duplicate. Active 
uptake of [^^TjMIBG was determined by subtraction of non-specific uptake 
(assessed in the presence of desmethylimipramine) from total [^^T]MIBG uptake.
* Expression of the human noradrenaline transporter (hNAT)
Expression of the bovine noradrenaline transporter (bNAT)
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2.3.3 NAT gene expression in biopsy specimens.
The real-time PCR procedure revealed a wide range of NAT gene expression levels 
in neuroblastoma biopsy samples (Figure 2-6). Most tumours (63%) expressed fewer than 
2 NAT copies per 10 reference gene (GAPDH) transcripts. A minority (37%) of the 
tumours exhibited higher NAT transcription. The highest expression of the cohort (two 
tumours, or 3.7%) was greater than 9 NAT transcripts per 10 GAPDH transcripts.
[^^TJMIBG uptake by neuroblastoma tumours was compared with NAT gene 
expression in biopsies. NAT and GAPDH copy numbers of neuroblastoma biopsy samples 
were obtained in the same manner as described for cell lines. RNA isolates from biopsy 
specimens were assayed three times in duplicate. Table 2-2 illustrates the disease stage 
and MIBG scintigraphic and RT-PCR results from the specimens collected from patients. 
Of the 54 patients’ samples with evaluable MIBG scans, 48 (89%) accumulated MIBG into 
the primary tumour. 43/54 (80%) tumour samples were positive for NAT mRNA.
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Figure 2-6: Distribution of NAT mRNA expression levels in
neuroblastoma biopsy samples
The real-time PCR procedure revealed a wide range of NAT gene expression levels 
in neuroblastoma biopsy samples. Most tumours (63%) expressed fewer than 2 
NAT copies per 10 reference gene (GAPDH) transcripts.
A minority (37%) of the tumours showed higher NAT transcription levels. The 
highest expression observed (two tumours) was greater than 9 NAT transcripts per 
10 GAPDH transcripts.
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Of the 11/54 (20%) tumour specimens in which NAT-specific sequences were 
undetectable, 6/54 (11%) were derived from tumours which did not accumulate MIBG 
whereas 5/54 (9%) originated from MIBG scan-positive primary tumours. Samples 
derived from tumours which failed to accumulate MIBG did not display NAT gene 
expression (Table 2-3).
There was a significant association between tumour MIBG uptake, evaluated by 
scintigraphy, and PCR-determined NAT expression (P < 0.0001, Fisher’s exact test). The 
prognostic value of a NAT-specific, positive PCR test was 1 (100%). However the 
predictive merit of a negative test was only 0.55 (55 %).
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Patient
No. Stage Scan RT-PCR
Patient
No. Stage Scan RT-PCR
1 4 + + 28 2 + 4
2 4s + + 29 2 + 4
3 2 + - 30 4 + 4
4 2 + + 31 4 - -
5 4 + + 32 4 + -
6 4 - - 33 3 + 4
7 4s + - 34 1 + 4
8 4 + 4" 35 4 4 4
9 3 + + 36 2 + 4
10 4 + + 37 1 - -
11 4 + + 38 1 + 4
12 2 + + 39 3 + 4
13 4 + + 40 4 + 4
14 2 + + 41 4 + 4
15 4 + + 42 4 + 4
16 4 + + 43 3 + 4
17 2 + 44 2 - -
18 3 - - 45 4 + 4
19 4s + + 46 3 + 4
20 4 + + 47 4 + 4
21 4 + + 48 4 + -
22 4s + + 49 3 - -
23 2 + + 50 4 + 4
24 4 + + 51 3 + 4
25 3 + - 52 3 4 4
26 4s + + 53 4 4 4
27 4 + + 54 1 4 4
Table 2-2: Comparison of tumour uptake of I]MIBG with NAT 
mRNA expression in biopsy samples
[!^:i]MIBG uptake and NAT mRNA levels were determined by gamma camera scanning 
of the patients and Taqman RT-PCR of biopsy-derived RNA respectively. Tumours were 
classified according to the International Neuroblastoma Staging System (Table 1-1).
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MIBG scan + ve MIBG scan -  ve Total
PCR + ve 43 0 43
PCR -  ve 5 6 11
Total 48 6 54
Fisher’s exact test, 2 sided,
Sensitivity
Specificity
Positive predictive value 
Negative predictive value
p  <  0.0001
= 90%
= 100%
= 100%
= 55%
Table 2-3: MIBG uptake by neuroblastoma tumours compared with 
NAT expression
The accumulation of MIBG by tumour was determined by gamma camera scanning 
after the administration to patients of [^^^IJMIBG. NAT expression in neuroblastoma 
biopsy specimens was assessed by real-time RT-PCR analysis.
There was a significant association between tumour MIBG uptake, evaluated by 
scintigraphy, and RT-PCR-determined NAT expression {p < 0.0001, Fisher’s exact 
test).
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2.4 Summary of results
The assay, based on real-time PCR analysis, showed substantial power to predict 
MIBG uptake capacity and has the potential to select patients for f/^^I]MIBG therapy. The 
real-time PCR technique allowed the simultaneous evaluation of a large number of 
individual samples as well as internal controls. This assay involves the use of industry- 
standardised reagents and requires less manipulation of sample than traditional PCR 
techniques, resulting in increased reliability and accuracy.
Of the 54 patients’ samples with evaluable MIBG scans, 48 (89%) showed MIBG 
uptake into the primary tumour, while 43 (80%) of the tumour samples were positive for 
the expression of NAT mRNA. This is equivalent to 90% concordance with respect to 
positive outcome of the two tests. All 6 tumours (11%) that failed to accumulate MIBG 
had undetectable NAT mRNA expression. However, biopsies from 5 patients (10.4%) 
with positive MIBG scans did not express detectable NAT mRNA.
Therefore, while a positive PCR test always predicted tumour uptake of MIBG, a 
negative PCR test failed to correctly determine MIBG uptake capacity with a frequency of 
45%. This may be due to heterogeneous uptake of radioidinated MIBG in different areas 
of a tumour mass, leading to a negative PCR result from biopsy material obtained from a 
NAT-negative area, and a positive MIBG scan from a NAT-positive area of the same 
tumour mass. It is also possible that the quality of biopsy material used for analysis was 
not optimal.
Furthermore, the possible presence of alternatively spliced NAT gene transcripts, 
mutant forms of the NAT protein, or alternative MIBG uptake pathways, which could be 
undetectable by the PCR primers employed in this study, cannot be discounted.
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Finally, in this study the house-keeping gene GAPDH was used as a reference to 
assess NAT gene expression. However, to predict tumour cell concentration of MIBG 
more accurately, it may be necessary to use alternative internal standards with specificity 
for neuroblastoma cells. The limitations of TaqMan PCR, and other avenues of research 
arising from this study will be further discussed in Chapter 10.
These results indicate that NAT-specific, real-time PCR evaluation of primary 
neuroblastoma tumours has significant capability to reflect their capacity for the 
accumulation of MIBG. However, PCR-based assessment of NAT gene expression cannot 
be regarded as fully predictive of MIBG uptake. The results of this study were recently 
published in Clinical cancer research [153].
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Chapter 3
The effect of topotecan pre-treatment on intracellular
uptake of ['^TjMIBG
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3.1 Introduction
3.L I  Ejfect o f DNA-interacting agents on active uptake o f
It has previously been reported that a wide range of DNA-interacting agents cause 
an increase in the ability of neuroblastoma cells to actively accumulate radiolabelled 
MIBG [154, 157-159]. This suggests that the efficacy of [^^^IJMIBG-induced cytotoxicity 
can be improved by the prior administration of an agent which enhances cellular uptake of 
the radiopharmaceutical, and clinical evaluation of therapy involving drugs which increase 
accumulation of the [^^^I]MIBG are currently underway [71].
3.1.2 Topotecan and [^^f]MIBG uptake
To date, no attempt has been made to investigate the potential of inhibitors of 
topoisomerase I to induce radiopotentiation in vitro and in vivo when combined with 
targeted radiotherapy. However, it is necessary to determine this potential effect of TFT, 
because of its possible influence on the optimal scheduling of the two agents.
The effect on NAT expressing cells of TPT pre-treatment was examined in two 
ways. Firstly, TPT treated cells were tested for their ability to accumulate [’^ T]MIBG 
(functional assay). Secondly, RNA was extracted from TPT treated cells, and expression 
of the noradrenaline transporter (NAT) gene was evaluated by real time RT-PCR as 
previously described (Chapter 2).
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3.2 Materials & methods
3.2.1 Cell Lines
Three NAT expressing cell lines were examined for the effect of TPT pre-treatment 
on their accumulation of [^^TjMIBG. These were the neuroblastoma cell lines SK-N- 
BE(2c) and SHSY5Y [62, 160], and the glioblastoma-derived UVW/NAT line [152] which 
had previously demonstrated uptake of ['^T]MIBG and NAT gene expression (Chapter 2).
3.2.2 The ejfect o f  topotecan on uptake
The ability of TPT to affect [^^T]MIBG uptake was studied using the protocol 
previously described (Section 2.2.4). Briefly, cells were seeded in six-well plates at 0.25 x 
10  ^ cells per well, and incubated for 48h at 37°C, in 5% CO^, TPT was added at the 
appropriate concentration and the plates were incubated for a further 24h. The 
concentration of TPT assessed for each cell line corresponded to the dose of the drug 
which was required for 50% clonogenic cell kill, which will be discussed in greater detail 
in Chapter 4. For SK-N-BE(2c) treatments, TPT dose was 2ng/ml. For UVW/NAT cells, 
TPT concentration was 4.2ng/ml. For SHSY5Y cells TPT dose was 0.67ng/ml.
To assess the extent, and longevity of TPT-induced enhancement of f^^I]MIBG 
uptake, cells were either assayed immediately following 24h TPT incubation, or left in 
fresh media, and tested at 24h intervals for 72h. Specific [^^4]MIBG uptake was measured 
as previously described (Section 2.2.4) and expressed as counts per minute per 10  ^cells 
(cpm /10%). Results were analysed for enhancement of [^^T]MIBG accumulation in treated 
cells compared to untreated controls by Student’s t-test (Excel 2001, ©Microsoft 
Corporation).
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3.2.3 The ejfect of topotecan on expression o f the noradrenaline transporter gene
The effect of TPT exposure on expression of the noradrenaline transporter gene 
was investigated by real time RT-PCR [153 ] (see Chapter 2). Cells were treated with TPT 
for 24h, and then either subjected to RNA extraction immediately following removal of the 
drug, or incubated in drug-free media. Further RNA extractions were carried out at 24h 
intervals up to 72h after removal of TPT.
3.2.4 RNA extractions
Total RNA was extracted from SK-N-BE(2c) cells using the RNeasy method 
(Qiagen, UK). Img of total RNA was reverse transcribed, and the resulting cDNA was 
analysed for NAT-specific sequence by real-time PCR, using an ABI Prism™ 7700 
sequence detector. PCR conditions were as previously described in Chapter 2 (Section 
2.2.8), as were hNAT, bNAT and GAPDH primer and probe sequences (Section 2.2.6).
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3.3 Results
3.3.1 The effect o f topotecan on uptake in NAT expressing cells
SK-N-BE(2c), UVW/NAT and SHSY5Y cells assayed immediately following TPT 
treatment exhibited a small, but insignificant enhancement of ['^^I]MIBG uptake compared 
to untreated controls. Cells assayed following a 24h incubation in fresh media consistently 
exhibited an significant increase in [^^^I]MIBG incorporatation {p < 0.05), approximately 
2-2,5 times that of untreated controls. Cells assayed 24h after this (ie. 48h after removal of 
the drug) retained an increased ability to uptake [^^T]MIBG {p < 0.05), but at a reduced 
level compared with the 24h time point. 72h after removal of TPT [^^^I]MIBG uptake 
capacity had returned to the level of untreated cells. See Figure 3-1.
Previous studies have reported that a wide range of DNA-interacting drugs cause 
an increase in uptake of radio-labelled MIBG by neuroblastoma cells. The enhancement 
factor of TPT pretreatment was similar to that caused by, IFN-y + retinoic acid [66], IFN-y 
+ IFN -a [157], cisplatin [154, 158], adriamycin [158] and y-rays [159] (Table 3-1). This 
suggests that a common mechanism may be involved.
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Figure 3-1: The effect of topotecan on uptake
This figure shows the effect of TPT pretreatment on the ability of SK-N-BE(2c), 
UVW/NAT and SHSY5Y cells to accumulate [ ’^ ‘^IlMIBG.
Cells were treated with TPT for 24h, and then either assayed immediately, or left in fresh 
media, and tested at 24h intervals for 72h. Results were analysed by Student’s t-test 
Results showing significant enhancement of uptake (p < 0.05) compared to untreated 
controls (C) are highlighted (*).
Cells assayed immediately following TPT treatment showed a small, but insignificant 
increase in jMIBG uptake compared to untreated controls (C). However, significantly 
enhanced uptake was observed after 24h incubation in fresh media; cells consistently 
exhibited an enhanced ability to incorporate |'^*I|MIBG, approximately 2-2.5 times that of 
untreated controls.
Cells assayed 24h after this (ie. 48h following removal of TPT) retained a significantly 
increased ability to uptake I'^'IjMIBG. Cells tested 72h after removal of TPT exhibited 
no increase in ['^'IjMIBG uptake. This pattern was observed in all cell lines tested.
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Treatment psillMIBO Uptake Enhancement Factor
5 Gy y-rays 1.8
IFN-y + retinoic acid 3.0
IFN-y + IFN-a 2.5
Cisplatin 2.8
Adriamycin 3.0
Topotecan 2-2.5
Table 3-1: Effect of topotecan pretreatment on [^^H]MIBG 
uptake: Comparison with other DNA interacting agents
Previous studies have shown that a wide range of agents which interact with 
DNA cause an enhancement in the ability of neuroblastoma cell lines to 
actively uptake radio-labelled MIBG in vitro.
The enhancement factor of topotecan pretieatment seen in [^^TjMIBG uptake 
studies (Figure 3-1) is similar to that which is caused by these other agents. 
This suggests that a common mechanism may be involved.
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3.3.2 TaqMan RT-PCR analysis of NAT gene expression
Previous studies have reported that increased [^^^I]MIBG uptake correlated with an 
increase in NAT gene expression [154, 157, 158|.
The results of real time RT-PCR of RNA derived from untreated SK-N-BE(2c) and 
SHSY5Y cells revealed expression of the human NAT (hNAT) gene (2.81 ± 1.59 and 1.02 
± 0.32 hNAT copies per 10 GAPDH copies respectively). SK-N-BE(2c) and SHSY5Y are 
human neuroblastoma cell lines, and therefore displayed no expression of the bovine NAT 
(bNAT) gene.
The UVW/NAT cell line is a human glioblastoma line that has been tranfected with 
an expression vector incorporating the bNAT gene under the control of a strong viral 
(RSV) promoter [152]. Real time RT-PCR revealed high expression of the bNAT gene 
(38.3 ± 5.9 bNAT copies per 10 GAPDH copies). However, UVW/NAT cells displayed 
negligible expression of the hNAT gene.
Following TPT incubation, SK-N-BE(2c) UVW/NAT and SHSY5Y cells were 
assayed by RT-PCR at Oh, 24h, 48h and 72h after removal of the drug. While similarly 
treated cells consistently exhibited an increase in [^^'l]MIBG uptake, this did not correlate 
with an increase of NAT gene product. SK-N-BE(2c) and SHSY5Y cells displayed little, 
or no stimulation of expression of the hNAT gene, compared to untreated controls at any 
of the time points (Oh, 24h, 48h) which gave rise to increased accumulation of ['^^I]MIBG. 
Likewise, UVW/NAT cells displayed no stimulation of bNAT or hNAT gene expression at 
any of the time points assessed (Figure 3-2).
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Figure 3-2: Real-time RT-PCR analysis 
of NAT gene expression
TPT treated SK-N-BE(2c) and UVW/NAT cells 
were assayed by RT-PCR at Oh, 24h, 48h and 72h 
after removal of TPT.
□ hNAT
0 bNAT
There was no increase in hNAT or bNAT gene 
expression in SK-N-BE(2c) or UVW/NAT cells, 
compared to untreated controls (C), at any of the time 
points assessed.
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3.4 Summary of results
Significant enhancement of [^^^I]MÏBG uptake, approximately 2-2.5 times the level 
in untreated controls, was observed in two neuroblastoma cell lines; SK-N-BE(2c) and 
SHSY5Y. This effect was optimal 24h after removal of the drug. At time points later than 
24h, there was a lower, but still significant accumulation of the radiopharmaceutical, and 
uptake capacity returned to the levels observed in untreated cells 72h after removal of TPT.
Interestingly, increased uptake of [^  ^ IjMIBG was also observed in vitro in TPT 
pretreated UVW/NAT cells, which contain an expression vector incorporating the bNAT 
gene under the control of a viral (RSV) promoter.
However, while previous studies have found an upregulation of mRNA signal (by 
Northern blotting or semi-quantitative RT-PCR) following administration of DNA 
interacting agents (Table 3-1), in this study, pre-treatment with TPT did not induce 
significant upregulation of hNAT gene expression in SK-N-BE(2c) or SPISY5Y cells. 
Likewise, TPT pre-treatmentment did not induce increased hNAT or bNAT gene 
expression in UVW/NAT cells, as measured by real time RT-PCR. It is possible that 
alternatively spliced forms of NAT mRNA, which allow production of functional NAT 
protein, but are undetectable by the PCR primers employed in this study, could be 
responsible for enhanced [^^TjMIBG uptake.
It may be necessary to design a new primer / probe set, which hybridises to another 
region of the NAT cDNA sequence. If NAT protein levels are entirely due to transcription 
of a single version of NAT mRNA, then identical results should be obtained by analysis of 
the copy numbers of different regions of the NAT mRNA sequence. However, any 
differences in the starting copy numbers detected by primers which anneal to different
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regions of the published NAT cDNA sequence would suggest the presence of alternative 
versions of NAT mRNA.
Alternatively, expression of the NAT gene product may be partially controlled at 
the post-transcriptional or post-translational stages, by an as yet undiscovered pathway. 
This could lead to some alteration in the cellular concentration of functional NAT protein, 
without affecting gene transcription. Development of assay for NAT protein concentration 
(eg. Western blot) would help to resolve this issue.
These points will be discussed further in Chapter 10.
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Chapter 4
Cytotoxic effects of topotecan and 
[i^TjMIBG in vitro
69
4.1 Introduction
The toxic effects of [^^^I]MIBG are due to its potential to generate DNA damage by 
radioactive decay of ^^ 1^. Combining [^^T]MIBG with an agent which enhances radiation- 
induced DNA breaks, will improve the effectiveness of [^^^I]MIBG as a therapeutic agent 
for the treatment of neuroblastoma [71].
Many previous studies have reported synergistic cell killing in vitro by ionising 
radiation and Topo I inhibitors in non-human cell lines [136, 137] and in human cancer- 
derived cell lines [85, 137-141]. In vivo radiopotentiation by Topo I inhibitors has also 
been observed [140, 142, 143]. This effect is associated with the creation of double-strand 
breaks [136, 139, 151]. However, to date, no attempt has been made to investigate the 
potential of inhibitors of topoisomerase I to induce radiopotentiation in vitro and in vivo 
when combined with targeted radiotherapy.
In order to assess the toxic effects of combinations of [^^^I]M1BG and TPT, it was 
first necessary to understand how each agent affects the clonogenic potential of treated 
cells. Therefore, initial experiments were carried out to characterise the toxic effects of 
[^^T]MIBG and TPT as single agents.
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4.2 Materials & methods
4.2.1 Topoisomerase I  relaxation assays
Topoisomerase I levels were determined using the Topoisomerase 1 Assay Kit 
(Topogen Inc, Columbus, Ohio, USA), which allows determination of Topo 1 activity 
through measurement of the amount of relaxation of a supercoiled DNA template.
Nuclear extracts were collected, using a protocol recommended by the 
manufacturers, from the neuroblastoma cell lines SK-N-BE(2c) and SHSY5Y [147], and 
the transfected glioblastoma line UVW/NAT [152].
Briefly, cells were centrifuged (800 x g for 5mins at 4°C) and the pellets washed 
once in TEMP buffer (lOmM Tris-HCl, ImM  EDTA, 4mM MgCl^, 0.5mM PMSF). Cells 
were then centrifuged (800 x g for 5mins at 4^ ’C), resuspended in TEMP buffer and 
homogenised. Nuclei were pelleted (1,500 x g for lOmins at 4°C), washed in TEMP, 
recentrifuged (1,500 x g for lOmins at 4°C) and resuspended in 4  pellet volumes of TEP 
buffer (lOmMTris-HCl, ImM  EDTA, 0.5mM PMSF). An equal volume of IM  Na Cl was 
added to the extracts, followed by centrifugation (15,000 x g for Imins at 4*=C). 
Topoisomerase I was contained in the resulting supernatant.
Topoisomerase I activity in each cell line was determined by serial two-fold 
dilutions of nuclear extracts. These solutions were incubated with 0.25/^g of supercoiled 
pHOT-1 plasmid for 15mins at 37°C, in 1 x assay buffer (lOmM Tris-HCl pH7.9, ImM  
EDTA, 0.15M NaCl, 0.1% BSA, O.lmM Spermidine and 5% Glycerol). The reaction was 
stopped using stop/loading dye (1% sarkosyl, 0.025% bromophenol blue, 5% glycerol) and 
loaded onto an agarose gel (2% agarose in 4 x TAE buffer: 0.16M Tris-Acetate, 0.004 M 
EDTA, pH 8.3), electrophoresed for 16 hours at 1.4 V/cm, then stained with ethidium 
bromide (0.5/^g/ml) for one hour. Gels were visualised using the GeneGenius bioimaging
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system, incorporating GeneSnap v6.03 software (SynGene Division, Synoptics Group, 
Cambridge UK). Band intensities were quantified densitometrically, using ImageJ vl.34i 
software (National Institutes of Health, USA).
Results were plotted as a percentage of a relaxed plasmid control and expressed in 
arbritary units (AU), where lAU is described as the amount of topoisomerase I needed to 
unwind 0.25/^g supercoiled (form 1) pHOT 1 plasmid in 15 mins at 37°C.
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4 2 .2  Clonogenic assay
The clonogenic assay [154] was used to assess the capacity of each cytotoxic agent 
to affect the ability of cultured cells to form viable colonies of daughter cells (Figure 4-1). 
This assay is based on the principal that, while clonogenic cells are capable of unlimited 
proliferation, viable, but damaged cells will only undergo a limited number of cell 
divisions and are incapable of forming colonies.
The neuroblastoma cell lines SK-N-BE(2c) and SHSY5Y [147], and the transfected 
glioblastoma line UVW/NAT were assessed for their ability to form colonies. While SK- 
N-BE(2c) and UVW/NAT cells readily formed clonogens, the results of initial experiments 
on SHSY5Y were disappointing Therefore, subsequent in vitro assessments of the toxic 
effects of TPT and [^^T]MIBG were conducted using SK-N-BE(2c) and UVW/NAT, but 
not SHSY5Y cells.
Monolayers of cells were cultured in 25cm^ flasks (Nunclon Plastics, Denmark) at 
2.5 X 10  ^ cells per flask in RPMI 1640 medium containing 10% FCS. After two days, 
medium was removed and replaced with fresh medium containing the appropriate 
concentration of test drug. After experimental therapy, medium was removed, the cells 
were washed twice in phosphate buffered saline (PBS), and allowed to grow in fresh 
medium for a further 24 hours. The cells were detached by addition of 1 x trypsin 
(Invitrogen, Paisley, UK) counted and seeded, in triplicate, in 25cm^ flasks at 1 x 10  ^ cells 
per flask, for each test concentration. Flasks were incubated at 37°C in 5% CO 2  for 14 
days. Colonies were fixed in 100% methanol, stained with Giemsa's stain solution (BDH 
Laboratory Supplies) and counted.
Results were expressed as a percentage of the initial concentration of cells plated, 
known as the plating efficiency. The cytotoxic potency of the drug was determined by
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comparing the number of colonies formed by treated cells to the number of colonies 
formed by untreated controls (the surviving fraction, or SF).
TFT incubation time was 24h, which has previously been shown to result in 
maximal supra-additive cell killing in cells treated with TFT and external beam irradiation 
[139]. TFT concentrations ranged from Ong/ml to 50ng/ml
The incubation time for [^^'IJMIBG was 2h, after which uptake is maximal [154]. 
Concentrations of [^^T]MIBG ranged from OMBq/ml to lOMBq/ml.
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Figure 4-1: Cionogenic assay of cell viability
This test is used to assess the capacity of a cytotoxic agent to affect the ability of 
cultured cells to form viable colonies of daughter cells. The experimental procedure is 
as follows;
A) Plated cells are dosed with cytotoxic agent.
B) Cells are trypsinised, placed in single cell suspension, and counted.
C) Single cells are plated in flasks and grown at 37°C in 5% CO2  for at least 6  
doubling times, to allow colony formation. A colony contains ^ 50 cells).
D) Cionogenic cells will grow into colonies. Damaged cells may still be viable for 
several cell divisions. However, they are unable to form colonies.
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4.3 Results
4 3 .1  Topoisomerase I assays
The results of Topo I unwinding assays are shown in Figure 4-2, and the resultant 
Topo I levels for SK-N-BE(2c), UVW/NAT and SHSY5Y cells are shown in Table 4-1.
UVW/NAT had the highest level of Topo I activity, with 100% unwinding in 
undiluted extract and 10% unwinding at 1:8 dilution. This gave a Topo I level of 
1.99AU//rl. This was almost double the activity exhibited by SK-N-BE(2c) cells, which 
exhibited 100% unwinding in undiluted extract and 10% at approximately 1:3.5 dilution, 
corresponding to a Topo I level of 1.01AU//d. SHSY5Y had the lowest levels of Topo I 
activity, with 100% unwinding in undiluted extract and 10% unwinding at 1:2, 
corresponding to a Topo I level of 0.34AU//^1.
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Figure 4-2: Topoisomerase I activity in NAT expressing cell lines
Endogenous topoisomerase I levels were elucidated by Topo I relaxation assay. Topo I 
was extracted from each cell line, and serial 2-fold dilutions were incubated with 0.25ug 
supercoiled (form 1) pHOT 1 plasmid for 15min at 37°C.
After electrophoresis, band intensities were quantified using densitometric analyses and 
plotted as a percentage of a relaxed plasmid control. Data values are means and standard 
deviations of two determinations. Each assay was carried out three times.
UVW/NAT: Highest level of Topo I - 100% unwinding in undiluted extract, falling to
1 0 % unwinding at 1 : 8  dilution.
SK-N-BE(2c): Intermediate level of Topo I - 100% unwinding in undiluted extract 
falling to 10% at approx. 1:3.5 dilution.
SHSY5Y: Lowest level of Topo I - 100% unwinding in undiluted extract falling to 10%
unwinding at 1 :2 .
Topo I levels were expressed in arbritrary units (U), where lU is described as the amount 
of topoisomerase I needed to unwind 0.25ug supercoiled pHOT 1 plasmid in 15 mins at 
37°C. These values are shown in Table 4-1.
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Cell Line Topoisomerase I level 
(Units/ul)
SK-N-BE(2c) 1.01
UVW/NAT 1.99
SHSY5Y 0.34
Table 4-1: Topoisomerase I levels in NAT expressing cell lines
This table shows the endogenous Topo I levels in each cell line, found by Topo I 
relaxation assay (Figure 4-2).
UVW/NAT had the highest level of Topo I activity, almost double the activity 
exhibited by SK-N-BE(2c). SHSY5Y had the lowest levels of Topo I activity.
1 Unit = the amount of topoisomerase I needed to unwind 0.25ug 
supercoiled (form 1) plasmid in 15 mins at 37°C
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43.2-1  SK-N-BE{2c)
Cell survival fell sharply in the l-5ng/ml TFT dose range, from 90% survival (IC,o) 
at a concentration of Ing/ml, to 10% survival (IC%) at 5ng/ml. Thereafter a plateau, with 
respect to cionogenic survival, was observed. That is, concentrations of TPT greater than 
5ng/ml did not result in greater toxicity than that achieved by 5ng/ml. This observation is 
in agreement, with previously reported effects of TPT [139] and of other Topo I inhibitors 
[137, 162]. The concentration of topotecan which caused 50% reduction in colony number 
(IC 5 0 ) in SK-N-BE(2c) cells was 2ng/ml (Figure 4-3A).
43 .2-2  UVW/NAT
Cell survival fell sharply, in the l - 8 ng/ml TPT dose range. 90% survival (IC^o) was 
observed at a concentration of Ing/ml, falling to 5% survival ( I C 9 5 )  at 8 ng/ml. Again, a 
plateau effect was observed. The concentration of topotecan which caused 50% reduction 
in colony number (IC 5 0 ) in UVW/NAT cells was 4,2ng/ml (Figure 4-4A).
4.3.2 Cionogenic assays: The toxic ejfects o f topotecan \
The toxic effects of TPT as a single agent were determined for each cell line:
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Figure 4-3: The toxic effects of and TPT on SK-N-BE(2c)
cells
The toxicity of (A) TPT and (B) | as single agents to SK-N-BE(2c) cells was
studied by cionogenic assay. The effects of each agent were determined by comparing 
the ability of treated cells to form colonies compared to untreated controls.
A) TPT:
Cell survival fell sharply in the I-5ng/ml TPT dose range, from 90% survival (IC,o) at a 
concentration of Ing/ml, to 5% survival (IC9 0 ) at 5ng/ml. Thereafter a plateau effect was 
observed, with no added toxicity seen. This effect tallies with previously reported effects 
of TPT and of other Topo I inhibitors. The concentration of topotecan which caused 
50% reduction in colony number (IC5 0 ) was 2ng/ml.
B) I'^'IIMIBG :
Cell survival fell from 70% survival (IC3 0 ) at IMBq,to 10% survival (IC9 0 ) at 8 MBq. The 
concentration of [*^'I1MIBG which caused 50% reduction in colony number (IC5 0 ) was 
4MBq/ml.
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4 .3 3  Cionogenic assays: The toxic ejfects o f [^^f]MIBG
The toxic effects of as a single agent were determined for each cell line.
4 3 .3 -J  SK-N-BE(2c):
Cell survival fell from 70% survival (IC 3 0 ) at IMBq, to 10% survival (ICç%) at 
8 MBq. The concentration of [^ ‘^IJMIBG which caused 50% reduction in colony number 
(IC 5 0 ) was 4MBq/ml (Figure 4-3B).
43 .3 -2  UVW/NAT:
In the case of UVW/NAT, survival fell from 70% survival (IC^J at IMBq, to 10% 
survival (ICgo) at lOMBq. The concentration of [^^^I]MIBG which caused 50% reduction in 
colony number (IC 5 0 ) was 4.1 MBq/ml (Figure 4-4B).
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Figure 4-4: The toxic effects of [^^ I^]MIBG and TPT on UVW/NAT 
cells
The toxicity of (A) TPT and (B) ['^'IlMIBG as single agents to UVW/NAT cells was 
studied by cionogenic assay. The effects of each agent were determined by comparing 
the ability of treated cells to form colonies compared to untreated controls.
A) TPT:
As with SK-N-BE(2c), cell survival fell sharply, this time in the l- 8 ng/ml TPT dose 
range. 90% survival (IC,o) was seen at a concentration of Ing/ml,falling to 5% survival 
(IC9 5 ) at 8 ng/ml. Again, a plateau effect was observed, with no added toxicity seen. The 
concentration of topotecan which caused 50% reduction in colony number (IC5 0 ) in 
UVW/NAT cells was 4.2ng/ml.
B) [‘3"|MIBG:
In the case of UVW/NAT, survival fell from 70% survival (IC3 0 ) at IMBq,to 10% 
survival (ICgg)at lOMBq. The concentration of I’^'IJMIBG which caused 50% reduction 
in colony number (IC5 0 ) was 4.1 MBq/ml.
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4.4 Summary of results
Both SK-N-BE(2c) and UVW/NAT cells were sensitive to [’^ T]MIBG, and similar 
doses of the radiopharmaceutical produced 50% reduction in cionogenic survival 
(4MBq/ml for SK-N-BE(2c), 4.1 MBq/ml for UVW/NAT).
SK-N-BE(2c) cells were highly sensitive to low doses of TPT (90% survival at 
Ing/ml; 10% survival at 5ng/ml (Figure 4-3)). Thereafter a plateau, with respect to 
cionogenic survival, was observed (ie. concentrations of TPT greater than 5ng/ml did not 
result in greater levels of toxicity). UVW/NAT were not as sensitive to low doses of the 
drug (90% survival at Ing/ml; 45% survival at 5ng/ml (Figure 4-4)), however a greater 
proportion of UVW/NAT were susceptible to treatment (ie. the plateau observed in 
UVW/NAT cells corresponded to approximately 2% cionogenic survival, compared to 
=10% in SK-N-BE(2c) cells).
This plateau is in agreement, with previously reported effects of TPT [139] and of 
other Topo I inhibitors [137, 162], and is attributed to the S-phase specificity of topotecan- 
induced toxicity. In any population of cells, different sub-populations will be at different 
stages of the cell cycle. Cells in G  ^ during treatment will be unaffected by topotecan 
exposure. The results of this study suggest that a higher proportion of SK-N-BE(2c) cells 
were in Gj, and were resistant to TPT, while a lower percentage of UVW/NAT cells were 
in Gj, and consequently a higher subpopulation was affected by topotecan treatment. The 
cell cycle distribution of SK-N-BE(2c) and UVW/NAT cells will be assessed in Chapter 8, 
and the results of this chapter will be further discussed in Chapter 10.
Characterisation of the toxic effects of ['^'l]MIBG and TPT as single agents as 
described in this chapter was necessary to allow subsequent assessment of the toxic effects 
of combinations of these two agents. Two different methods were used to assess the
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interactions between TPT and Chapter 5 describes the results of isoboiogram
analyses of TPT / [^^TjMIBG combinations. In this method, variable doses of each agent 
are administered, and the resultant level of toxicity is compared to a hypothetical 
combination which should theoretically produce an purely additive level of cionogenic cell 
kill.
Chapter 6 describes how the relative toxicities of TPT and [^^TjMIBG used as 
single agents to each cell line described in this chapter, were used to determine the 
concentrations of these drugs which were administered to SK-N-BE(2c) and UVW/NAT 
cells, to investigate the interactions between TPT and [^^^IJMIBG by median-effect 
analysis. In this method, a range of concentrations of each drug in a fixed ratio is assessed, 
so that the proportional contribution of each drug is similar at all treatment intensities for 
each cell line.
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Chapter 5
Analysis of the cytotoxic interaction between 
topotecan and ['^hjMIBG in vitro 
I: The isoboiogram method
85
5.1 Introduction
5.1.1 Analysing the interaction between topotecan and I]MIBG
Whenever the efficacy of combining different cytotoxic agents is investigated, the 
most important question which must be answered is whether the combination of the agents 
results in cell kill which is greater or less than would be expected by the action of each 
treatment modality individually. If the combination has an effect that is greater than the 
individual treatments, then this combination can be said to be “supra-additive”, or more 
effective than each agent alone. Conversely, combinations that are less effective than each 
agent alone can be said to be “infra-additive”, and convey no therapeutic benefit [163].
However, the choice of methodology used to assess the nature and intensity of 
agent interaction has historically proven to be controversial, and many competing models 
have been reported [156]. Examination of scientific literature suggests that the two most 
commonly reported models of drug interacton analysis are the isoboiogram method of 
Steel and Peckham [163-165], and the median-effect / combination-index method of Chou 
and Talalay [163, 166-167].
Therefore, in analysing the in vitro interaction between topotecan and [^^T]MIBG, 
both of these methodologies were utilised. This chapter describes the results of 
isoboiogram analyses of TPT / [^^T]MIBG combinations, while Chapter 6 describes the 
results of median-effect / combination-index analyses of TPT / [^^^I]MIBG interactions.
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5.1.2 Isoboiogram analysis o f the interaction between two toxic agents
The isoboiogram method [164, 165] is used to examine the interaction between two 
drugs, regardless of the mechanism of action of the individual agents. Cells are treated 
with combinations of the two drugs in various concentrations, and two dose-response 
curves are generated from the results. An example of this, using hypothetical data, is 
shown in Figure 5-1. The first plot (Figure 5-lA ) shows the effect of increasing the 
concentration of Drug A on cells treated with a specific dose of Drug B; the second plot 
(Figure 5-lB ) shows the effect of increasing Drug B concentration on cells treated with a 
specific dose of Drug A. From these curves, the doses of Drug A and Drug B which, as 
single agents, cause a certain level of toxicity are determined (eg. the IC 5 0  dose: the dose 
which inhibits 50% colony formation). Likewise, the combinations of Drug A and Drug B 
which cause 50% effect are determined. These are known as the isoeffect points.
A graph is drawn, with the IC 5 0  value for Drug A alone plotted on the horizontal 
axis, and the ICgo result for Drug B alone plotted on the vertical axis. A line is drawn 
connecting these two points. This line denotes the alignment of values of each agent, 
which would, in theory, give rise to an additive effect. The isoeffect points for 
combinations of Drug A and Drug B are then plotted on this graph (Figure 5-IC).
The different possible outcomes of isoboiogram analyses are shown in Figure 5-2. 
When the experimental isoeffect points lie directly on the line, the two agents are 
interacting in a purely additive way. For example, in Figure 5-1, ICgo <^ ose for Drug A is 
4mg/ml, and for Drug B the ICgo dose is 4mg/ml. An isoeffect point is generated by a 
combination of 2mg/ml Drug A + 2mg/ml Drug B. This plots directly onto the 
hypothetical line of additivity, suggesting that in this hypothetical example, the drugs are 
combining in a purely additive way (Figure 5-IC; Figure 5-2A).
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However, if the isoeffect points plot below the hypothetical line of additivity, a 
supra-additive, or synergistic effect is indicated. For example, in the hypothetical example 
the ICgo doses are 4mg/ml for Drug A alone, and 4mg/ml for Drug B alone. If these agents 
had combined in a supra-additive fashion, then the combination required to produce 50% 
cell kill would have been < 2mg/ml of Drug A + < 2mg/ml of Drug B (Figure 5-2B).
If the isoeffect points plot above the hypothetical line of additivity, an infra­
additive, or antagonistic effect is indicated. In the hypothetical example, the ICgo doses are 
4mg/ml for Drug A alone, and 4mg/ml for Drug B alone. If these agents had combined in 
an infra-additive fashion, then the combination required to produce 50% cell kill would 
have been > 2mg/ml of Drug A + > 2mg/ml of Drug B (Figure 5-2C).
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Figure 5-1: Toxic effects of two hypothetical 
drugs alone and in combination
Both of the survival curves represent the same data plotted in 
two ways:
(A) The effect of increasing the concentration of Drug A on 
cells treated with a specific dose of Drug B.
(B) The effect of increasing the concentration of Drug B on 
cells treated with a specific dose of Drug A.
(C) IC5 0  isoboiogram constructed from the isoeffect points 
generated from (A) & (B) above (ie. the combinations of 
Drug A and Drug B which cause 50% effect when 
combined). These are found where each survival curve 
crosses the dotted line.
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All of these isoeffect points plot directly onto the line of 
additivity. This suggests that in this example, the 
hypothetical drugs are combining in a purely additive way. 
See Figure 5-2.
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Figure 5-2: Isoboiogram analyses of the hypothetical relationship 
between two agents
The above figures provide examples of the different outcomes of isoboiogram analyses. The 
IC5 0  value for Drug A is plotted on the horizontal axis, and the IC5 0  result for Drug B is 
plotted on the vertical axis. A line is drawn connecting these two points, denoting the 
alignment of values of each agent, which, in theory, give rise to an additive effect. For 
combinations of Drug A and Drug B, the isoeffect points (being the concentrations, which 
cause 50% reduction in colony number when combined), are then plotted on this graph.
(A) The results obtained when Drug A and Drug B combine in a purely additive way. In 
this case, the isoeffect points all lie on the line.
(B) The results obtained when Drug A and Drug B combine in a synergistic way. In this 
case, the isoeffect points all lie below the line.
(C) The results obtained when Drug A and Drug B combine in an antagonistic way. In this 
case, the isoeffect points all lie above the line.
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5.] .3 Scheduling o f topotecan and [^  ^f]M IBG  in combination treatment
Synergistic cell killing in vitro and in vivo by ionising radiation and Topo I 
inhibitors have been widely reported. However, there is no consensus with respect to the 
optimum order of delivery of these therapeutic agents. While some studies state that 
radiosensitisation is observed when Topo I inhibitors are administered prior to irradiation 
[85, 140], others claim that radiopotentiation is only achieved when exposure to ionising 
radiation precedes, or is concurrent with administration of Topo I inhibitors [136, 141] 
(Table 5-1).
To date, no attempt has been made to investigate combinations of topotecan and 
[131j]m i b G. Therefore, it was not known if a synergistic interaction would occur. 
Likewise, it was unclear whether possible synergistic effects resulting from a combination 
of these drugs would be affected by the order of delivery, and possibly the greatest 
cytotoxicity would occur only when one agent was administered prior to exposure to the 
second.
Three treatment modalities were investigated. In schedule [i] topotecan was 
administered 24 hours before [^^^I]MIBG treatment. In schedule [iij topotecan was 
administered 24 hours after [^^^I]MIBG treatment. In schedule [iii] topotecan and 
[^^^I]MIBG were administered simultaneously. See Figure 5-3.
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In vitro: Non-human cell lines Treatment schedule examined IRefl
Murine leukemia (P388) (Hi), (iv), (v) [136]
Chinese hamster ovary (CHO) (iii), (iv), (v) [136]
Chinese hamster fibroblast (V79) (iii) [137]
In vitro: Human cancer cell lines
Breast cancer (MCF7) (i), (iii), (v) [85]
Cervical cancer (HeLa) (iii) [137]
Small-cell lung cancer (SBC3-CDDP) ( ii), ( iii) [138]
Glioblastoma (GBM) (ii), (iii),(iv) [139]
Squamous carcinoma of the head (i) [140]
and neck (SCC-25)
Melanoma (U 1-Mel) (ii), (iii), (iv) [141]
In vivo models
[140]Murine fibrosarcoma (i), (Hi) [142]Murine mammary carcinoma (ii), (iii) [143]Human rhabdomyosarcoma
Table 5-1: Scheduled combinations of ionising radiation and Topo I 
inhibitors reported to cause synergistic cell killing
Synergistic cell killing by ionising radiation and Topo I inhibitors have been widely 
reported, as shown above. However, there is no consensus on the order of delivery:
(i) Synergy observed when Topo I inhibitors were administered prior to irradiation;
(ii) Synergy observed when Topo I inhibitors were administered following irradiation;
(iii) Synergy observed when Topo I inhibitors and radiation were administered 
concurrently;
(iv) Administration of Topo 1 inhibitors prior to irradiation did not induce synergy;
(v) Administration of Topo I inhibitors following irradiation did not induce synergy.
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Figure 5-3: Scheduling of TPT and combinations
Three different scheduled combinations of topotecan and [^^T]MIBG were tested 
Schedule li1: Topotecan administered 24 hours before [^^^I]MIBG treatment 
Schedule liil: Topotecan administered 24 hours after [^^T]MIBG treatment 
Schedule liiil: Topotecan and [/^T]MIBG administered simultaneously
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5.2 Materials & methods
5.2.7 Cionogenic assays
Monolayers of SK-N-BE(2c) and UVW/NAT of cells were cultured in 25cm^ 
flasks (Nunclon Plastics, Denmark), at 2.5 x 10  ^ cells per flask. After two days, medium 
was removed and replaced with fresh medium containing a dose of TPT and/or 
[^^^I]MIBG. Following treatments, the cytotoxic effects of each combination schedule 
were assessed by cionogenic assay, as previously described in Chapter 4. For each 
schedule, every treatment group was assessed three times, in triplicate.
5.2.2 Concentrations o f  TPT and [ '^ fjM lB G
For SK-N-BE(2c) cells, TPT concentration ranged from 0-2ng/ml, and [^^^I]MIBG 
concentration ranged from 0~4MBq/ml. For UVW/NAT cells, TPT concentration ranged 
from 0“5ng/ml, and [^^^IJMIBG concentration ranged from 0-5MBq/ml.
These concentrations were based on the relative effectiveness of each agent to each 
cell line, as described in Chapter 4. Again, the incubation time for [^^^JMIBG was 2h, and 
incubation time for TPT was 24h.
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5.3 Results
5.3.1 Isoboiogram analysis o f the interaction between [^^fjMIBG and topotecan
The results of cionogenic assays of toxicity to combined treatments were plotted as 
dose-response curves. These results were presented in two ways for each data set. In the 
first, data was plotted as the effect of increasing TPT concentration on colony formation in 
cells treated with [^^^IJMIBG (SK-N-BE(2c): Figure 5-4; UVW/NAT: Figure 5-9). In the 
second, the data was plotted as the effect of increasing [‘^ 'IJMIBG concentration on TPT 
treated cells (SK-N-BE(2c): Figure 5-5; UVW/NAT : Figure 5-10).
From these dose-response curves, IC3 0 , IC5 0  and IC 7 0  isoeffect points were 
generated. These were TPT/MIBG combinations which produced a certain level of colony 
inhibition (ie. 30%, 50% and 70% of the maximum effect). From these data, the 
interaction between TPT and [^^^I]MIBG was evaluated at each toxicity level using the 
isoboiogram method.
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Figure 5-4: The effect of increasing TPT 
concentration on I]MIBG treated SK-N-BE(2c) cells
In this figure, survival data are plotted against TFT concentration for a 
range of doses of | IMIBG. Figure 5-5 shows the same data, 
plotted as the effect of increasing I'^'IJMIBG concentration on TPT 
treated cells.
The concentration of TPT which gives an IC3 0  (ie. the dose which 
causes 30% effect) when combined with each concentration of 
I |MIBG occurs at the point where the appropriate MIBG line 
crosses the dotted line. These isoeffect points were used along with 
the isoeffect points from Figure 5-5 to generate the isobolograms 
shown in Figure 5-6. Isoeffect points were derived in a similar 
fashion for the IC5 0  and the IC7 0  doses. These were used to generate 
the isoboiogram analyses in Figures 5-7 and 5-8 respectively.
conc
(MBq/ml)
Survival curves A, B and C were generated by the administration of
combination schedules |i |, |ii| and [iii| respectively.
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Figure 5-5: The effect of increasing [^^ I^]MIBG 
concentration on TPT treated SK-N-BE(2c) cells
In this figure, survival data are plotted against | '^U]MIBG 
concentration for a range of doses of topotecan. Figure 5-4 shows the 
same data, plotted as the effect of increasing TPT concentration on 
[‘^ UjMIBG treated cells.
As with Figure 5-4, the concentration of ['^‘I|MIBG which gives an 
IC3 0  (ie. the dose which causes 30% effect) when combined with each 
concentration of TPT occurs at the point where the appropriate TPT 
line crosses the dotted line. These isoeffect points were used along 
with the isoeffect points from Figure 5-4 to generate the isoboiogram 
analyses in Figure 5-6. Isoeffect points were derived in a similar 
fashion for the IC5 0  and the IC7 0  doses. These were used to generate 
the isoboiogram analyses in Figures 5-7 and 5-8 respectively.
Again, survival curves A, B and C were generated by the administration
of combination schedules [i|, [ii| and |iii| respectively.
TPT conc
(n g/ml)
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5.3.2 SK--N-BE(2c)
Isoeffect points generated at the IC 3 0  and the IC 5 0  by all three combination 
schedules examined plotted below the hypothetical line of additivity (Figures 5-6 & 5-7). 
This suggested that all of the scheduled combinations of TPT and l^^^IjMIBG produced 
supra-additive effects at these levels of toxicity. However, at the ICgo, cells treated by 
combination schedules [i] and [iii] displayed some isoeffect points which plotted above the 
hypothetical line of additivity. These were generated by combinations of a relatively low 
dose of [^^^IjMIBG and a relatively high dose of TPT, suggesting that combinations 
involving relatively high dose of [^^^IjMIBG and a relatively low dose of TPT may be 
more effective.
At the IC7 0  (Figure 5-8), the majority of isoeffect points generated by administration 
of TPT and [^^^IjMIBG plotted above the hypothetical line of additivity. This was 
observed in cells treated with all three scheduled combinations. This suggests that 
combinations of TPT and [^^^IJMIBG were not as effective at this level of toxicity, 
although as with the results obtained by isoboiogram analyses at the ICgo, combinations 
involving relatively high doses of [^^'IJMIBG and relatively low doses of TPT appeared to 
be more effective.
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Figure 5-6: IC3Q Isobologram analyses of SK-N-BE(2c) cells treated 
with different and topotecan schedules
The interaction between TPT and was analysed at the IC3 0  toxicity level by
isobologram analysis. These diagrams were generated using the isoeffect points generated 
by Figures 5-4 and 5-5. The doses of each agent (D) are expressed as a fraction of the 
IC3 0  dose (D30).
Isobolograms A, B and C show the effect of administration of combination schedules [i|, 
|ii| and [iii| respectively.
This data suggested that administration of TPT and[ '^'I|MIBG, in any scheduled 
combination, produced a supra-additive effect in SK-N-BE(2c) cells.
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Figure 5-7: ICgg Isobologram analyses of SK-N-BE(2c) cells treated 
with different I]MIBG and topotecan schedules
The interaction between TPT and |*'^'I|MIBG was also analysed at the IC5 0  toxicity level by 
isobologram analysis. These diagrams were generated using the isoeffect points generated 
by Figures 5-4 and 5-5. The doses of each agent (D) are expressed as a fraction of the 
IC5 0  dose (D50).
Again, isobolograms A, B and C show the effect of administration of combination 
schedules |i|, |ii| and |iii| respectively.
This data suggested that administering TPT and[^^*I|MIBG, in any scheduled combination, 
produced a supra-additive effect in SK-N-BE(2c) cells, although combinations involving a 
relatively low dose of ['^^IJMIBG and a relatively high dose of TPT were less effective.
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Figure 5-8: IC^q Isobologram analyses of SK-N-BE(2c) cells treated 
with different [*^^I]MIBG and topotecan schedules
The interaction between TPT and ['^'IIMIBG was also analysed at the IC7 0  toxicity level by 
isobologram analysis. These diagrams were generated using the isoeffect points generated 
by Figures 5-4 and 5-5. The doses of each agent (D) are expressed as a fraction of the 
IC7 0  dose (D70).
Again, isobolograms A, B and C show the effect of administration of combination 
schedules |i|, |ii| and |iii| respectively.
This data suggested that, at this toxicity level, administration of TPT and| ' '^I jMIBG, in any 
scheduled combination, produced a predominantly infra-additive effect in SK-N-BE(2c) 
cells. As with the results obtained by isobologram analyses at the IC^ g, combinations 
involving relatively high doses of |'^T|MIBG and relatively low doses of TPT appeared to 
be more effective.
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Figure 5-9: The effect of increasing TPT 
concentration on [^^^I]MIBG treated UVW/NAT cells
These survival curves show the combined effects of TPT and 
1 JMIBG on UVW/NAT cells. In this figure, survival data are 
plotted against topotecan concentration for a range of doses of 
[ IMIBG. Figure 5-10 shows the same data, plotted as the effect 
of increasing |'^'I|MIBG concentration on TPT treated cells.
Again, the concentration of TPT which gives an IC3 0  (ie. the dose 
which causes 30% effect) when combined with each concentration of 
1 *^*I1MIBG occurs at the point where the appropriate MIBG line 
crosses the dotted line. These are the isoeffect points used along with 
the isoeffect points from Figure 5-10 to generate the isobolograms 
shown in Figure 5-11. Isoeffect points were derived in a similar 
fashion for the IC5 0  and the IC7 0  doses. These were used to generate 
the isobologram analyses in Figures 5-12 and 5-13 respectively.
Again, survival curves A, B and C were generated by the
administration of combination schedules |i |,  |ii| and [iii| respectively.
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Figure 5-10: The effect of increasing 
concentration on TPT treated UVW/NAT cells
These survival curves show the combined effects of topotecan and 
I |MIBG on UVW/NAT cells. In this figure, survival data are 
plotted against [‘^ TlMIBG concentration for a range of doses of 
topotecan. Figure 5-9 shows the same data, plotted as the effect of 
increasing TPT concentration on | ‘^ T)MIBG treated cells.
Again,the concentration of |'^T|MIBG which gives an IC3 0  (ie. the 
dose which causes 30% effect) when combined with each 
concentration of TPT occurs at the point where the appropriate TPT 
line crosses the dotted line. These isoeffect points were used along 
with the isoeffect points from Figure 5-9 to generate the isobologram 
analyses in Figure 5-11. Isoeffect points were derived in a similar 
fashion for the IC5 0  and the IC7 0  doses. These were used to generate 
the isobologram analyses in Figures 5-12 and 5-13 respectively.
Again, survival curves A, B and C were generated by the
administration of combination schedules |i |,  |ii| and [iiij respectively.
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5.3.3 UVW/NAT
At the IC3 0  dose, administration of TPT before, or simultaneously with 
(schedules [i] & [iii]) produced isoeffect points which plotted above the hypothetical line 
of additivity (Figure 5-1 lA , 5 -llC ). Administration of TPT after [*^4]MIBG (schedule
[ii]) produced isoeffect points which plotted below the hypothetical line of additivity 
(Figure 5 -llB ). This suggested that supra-additive effects at the IC 3 0  level of toxicity by 
combinations TPT and [^^^I]MIBG were only achieved by combination schedule [iij at this 
toxicity level.
At the ICgo dose, administration of TPT before [^^^I]MIBG (schedule [i]) produced 
isoeffect points which plotted above the hypothetical line of additivity (Figure 5-12A). 
This suggested that, as with the results at IC3 0 , administering TPT before [‘^ ^I]MIBG 
produced an antagonistic effect. Again, as with the results at IC3 0 , administration of TPT 
after [^^^I]MIBG (schedule [ii]) produced isoeffect points which plotted below the 
hypothetical line of additivity (Figure 5-12B). However, unlike the results observed at 
IC 3 0 , isoeffect points generated at the ICgo by administration of TPT and [^^^I]MIBG 
simultaneously (schedule [iii]) plotted below the hypothetical line of additivity (Figure 5- 
12C). As with the results observed in UVW/NAT cells treated with schedule [ii], this 
suggested that administering TPT and [^^^]MIBG simultaneously also produces a supra- 
additive effect.
As with the results obtained at the ICgo dose, at the IC 7 0  toxicity level, the majority 
of isoeffect points generated by administration of TPT either after, or simultaneously with 
[^^^I]MIBG (schedules [ii] & [iii]) plotted below the line of additivity (Figures 5-13B & 5- 
13C), suggesting supra-additive interactions. However, some isoffect points, generated by 
combinations of a relatively low dose of TPT and a relatively higher dose of [^^^I]MIBG
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plotted above the hypothetical line of additivity. Also, unlike the results obtained at the 
IC 3 0  and IC 5 0  levels of toxicity, at the IC 7 0 , administration of TPT before 
(schedule [i]) generated some isoeffect points which plotted below the hypothetical line of 
additivity. This response was obtained by combinations of a relatively low dose of 
[^^^I]MIBG and a relatively high dose of TPT (Figure 5-13A).
However, as with the effects of combination schedules [ii] and [iii], isoffect points 
generated by combinations of a relatively low dose of TPT and a relatively higher dose of 
[‘^ ^I]MIBG plotted above the hypothetical line of additivity. This suggests that 
combinations involving relatively high doses of [^  ^ 1]MIBG and relatively low doses of 
TPT may be less effective than administration of combinations involving relatively high 
doses of TPT and relatively low doses of [^^^I]M1BG, which resulted in supra-additivity at 
the IC 7 0  toxicity level in cells treated by all three combination schedules, although schedule 
[i] was not as effective as schedules [ii] or [iii].
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Figure 5-11: Isobologram analyses of UVW/NAT cells treated
with different I]MIBG and topotecan schedules
The interaction between TPT and |* ’^I|MIBG was analysed at the IC3 0  toxicity level by 
isobologram analysis. These diagrams were generated using the isoeffect points generated 
by Figures 5-9 and 5-10. The doses of each agent (D) are expressed as a fraction of the 
IC3 0  dose (D30).
Again, isobolograms A, B and C show the effect of administration of combination 
schedules [i|, (ii| and |iii| respectively.
This data suggested that combination schedule |ii| was inducing supra-additive responses 
at this toxicity level. However, schedules |i| and [iii] were not as effective,as isoeffect 
points plotted above the theoretical line of additivity, suggesting infra-additive responses.
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Figure 5-12: ICg^  Isobologram analyses of UVW/NAT cells treated 
with different [^^^I]MIBG and topotecan schedules
The interaction between TPT and ['^'I|MIBG was also analysed at the ICgo toxicity level by 
isobologram analysis. These diagrams were generated using the isoeffect points generated 
by Figures 5-9 and 5-10. The doses of each agent (D) are expressed as a fraction of the 
ICgo dose (D50).
Again, isobolograms A, B and C show the effect of administration of combination 
schedules |i|, |ii| and |iii] respectively.
This data suggested that combination schedules [iii and [iii] induced supra-additive 
responses at this toxicity level. However, schedules |i] was notas effective, as isoeffect 
points plotted above the theoretical line of additivity, suggesting an infra-additive response.
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Figure 5-13: Isobologram analyses of UVW/NAT cells treated
with different I]MIBG and topotecan schedules
The interaction between TPT and [*^*I|MIBG was also analysed at the IC7 0  toxicity level by 
isobologram analysis. These diagrams were generated using the isoeffect points generated 
by Figures 5-9 and 5-10. The doses of each agent (D) are expressed as a fraction of the 
IC7 0  dose (D70).
Again, isobolograms A, B and C show the effect of administration of combination 
schedules |i|, |ii| and |iii| respectively.
Combinations involving relatively low doses of ^^BlMIBG and relatively high doses of 
TPT resulted in supra-additivity at the IC7 0  toxicity level in cells treated by all three 
combination schedules.
However, isoffect points generated by combinations of a relatively low dose of TPT and a 
relatively high dose of ['^TjMIBG plotted above the hypothetical line of additivity, 
suggesting that combinations involving relatively high doses of [‘^ ‘IJMIBG and relatively 
low doses of TPT may be less effective.
Schedule [i| was notas effective as schedules |ii| or |iii|.
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5.4 Summary of results
In SK-N-BE(2c) cells, while isoeffect points generated at the IC3 0  by all three 
combination schedules examined plotted below the hypothetical line of additivity (Figures 
5-6 & 5-7), at the IC 5 0 , cells treated by combination schedules [i] and [iii] displayed some 
isoeffect points which plotted above the hypothetical line of additivity. These were 
generated by combinations of a relatively low dose of [^^^I]MIBG and a relatively high 
dose of TPT, suggesting that combinations involving relatively high dose of [^^^I]MIBG 
and a relatively low dose of TPT may be more effective. Combinations of TPT and 
[131i]mibG were not as effective at the IC 7 0  level of toxicity, and most of the isoeffect 
points generated by the three scheduled combinations plotted above the line of additivity. 
Again, relatively high doses of [^^^I]MIBG and relatively low doses of TPT were more 
effective.
In UVW/NAT cells, at the IC 3 0  level of toxicity, administration of schedule [ii] 
produced isoeffect points which plotted below the theoretical line of additivity, suggesting 
a supra-additive interaction. Combination schedules [i] and [iii] were less effective at this 
toxicity level. At the ICgg toxicity level, supra-additive interactions were obtained 
following administration of combination schedules [ii] and [iii], but not following 
administration of combination schedule [i]. All three combination schedules produced 
supra-additive responses at the IC 7 0  level of toxicity. Again, combination schedule [i] was 
less effective than the other two schedules. However, unlike SK-N-BE(2c) cells, 
combinations involving relatively high doses of ['^^I]MIBG and relatively low doses of 
TPT were not as effective against UVW/NAT cells than combinations involving relatively 
low doses of [^^^I]MIBG and relatively high doses of TPT.
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These results indicate that supra-additive levels of killing may be achieved in NAT 
expressing cells treated with a combination of TPT and [^^TjMIBG, suggesting that 
combined therapies involving these two agents for the treatment of neuroblastoma could 
improve upon existing modalities.
In this study, the cytotoxic interaction between topotecan and ['^^IjMIBG was 
assessed by isobologram analysis. However, the choice of methodology used to assess the 
nature and intensity of agent interaction has historically proven to be controversial, and 
many competing models have been used to assess the nature and intensity of agent 
interactions [156]. While the isobologram method has been utilised by many previous 
studies, this technique is not universally applied. Indeed, several different versions of 
isobologram analyses have been reported [164, 165, 168, 169].
For this reason, the cytotoxic interaction between TPT and [^^4jMIBG was further 
assessed using another model of drug interacton analysis, in order to confirm the results of 
isobologram analyses described in this chapter. This second model is the median-effect / 
combination-index method, and is described in Chapter 6 .
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Chapter 6
Analysis of the cytotoxic interaction between 
topotecan and [^ '^I]MIBG in vitro 
II: Median-effect / combination index analysis
I I I
6.1 Introduction
6.1.1 Analysing the interaction between topotecan and
As previously discussed in Chapter 5, many competing models have been used to 
assess the nature and intensity of agent interactions. While the isobologram method 
described in the previous chapter has been utilised by many previous studies, this 
technique is not universally applied.
Therefore, in order to accurately assess the interaction between TPT and 
[^^^I]MIBG, another commonly reported model of multiple drug interaction, the median- 
effect / combination-index method of Chou and Talalay [163, 166, 167] was also used to 
examine the in vitro effects of these agents. Unlike isobologram analysis, where a range of 
concenti'ations of drug A are combined with each dose of drug B (and vice versa), in this 
model the agents are combined using a fixed dose ratio of drug A to drug B based on the 
effectiveness of each drug as single agents, so that the proportional contribution of the 
effect of each drug in the mixtures should be the same at all treatment intensities.
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6.7.2 Multiple drug effect analysis o f the interaction between two toxic agents
The multiple drug effect analysis of Chou and Talalay [166, 167] is based on the 
median-effect principle. Dose-effect curves were constructed using the equations 
described in Figure 6-1. In equations (1) and (2), D  is the dose, Dm  is the ICgo d o se ,/a  is 
the fraction of cell affected, fu  is the unaffected fraction and m is the coefficient of the 
sigmoidicity of the dose-effect curve. The logarithmic form of equation (2) converts the 
equation into the form of “y=mx+c”, where the value m becomes the slope of the line, and 
the log ICgo value becomes the x-intercept.
Therefore, from the plot of log {D) against log ifa/fu), the x-intercept (log ICgo) 
slope m  were calculated for each drug and for combinations by the method of least squares. 
These parameters were then used to calculate doses of the component agents and 
combinations required to produce various cytotoxicity levels according to the non- 
logarithmic form of equation (2 ).
For each level of toxicity, the combination index (Cl) was calculated according to 
equation (3), where (Z))i and (Djg are the doses of each agent which sterilise x% of 
clonogens when used in combination, and (79x), and (Dx)^ are the doses of each drug 
which sterilise x% of clonogens when used as single agents.
If the agents have similar, or dependent modes of action, then a  = 0 and the Cl 
value is equivalent to the sum of the first two terms. If the agents have independent modes 
of action, then ct ~ 1 and the Cl value is equivalent to the sum of all three terms. If the 
manner of the interaction between the agents is uncertain, then the formula is solved in 
both ways.
Cl < 1, Cl = 1 and Cl > 1 indicate synergism, additivity and antagonism 
respectively.
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Equation (1): fd fu  = (DIDm)"^
Equation (2): D  = D m [ fa / fu Ÿ ^ ^
Equation (3): CI = ( D \ / ( D x \  + { D y { D x \  + a { D \ { D y { D x \ { D x \
Figure 6-1: Equations used to study the interaction between two 
agents by median-effect and combination index analysis
The cytotoxic interaction between two agents can be further evaluated using multiple 
drug effect analysis, based on the median-effect principle of Chou & Talalay, which 
allows the analysis of drug effect using the median-effect equation (equation ( 1 )), which 
can be rearranged to give equation (2 ).
In equations (1) & (2),D  is the dose. Dm is the dose required for 50% effect (ie. the 
IC 5 Q dose),/a is the fraction of cell a f f e c te d , is  the unaffected fraction and m is a 
coefficient of the sigmoidicity of the dose-effect curve.
In equation (3), (D)^ and (D)^ are the doses of each agent which inhibit x% of cell 
growth when used in combination, and (Dx)j and ( p x \  are the doses of each drug 
which inhibit x% of colonies when used as single agents. If the agents have similar, or 
dependent modes of action, then a  = 0 (ie the Cl value = the sum of the first two terms). 
If the agents have independent modes of action (eg independent modes of action) then a  
= 1 (ie the Cl value = the sum of all three terms).
Cl < 1, Cl = 1 and Cl > 1 indicate synergism, additivity and antagonism respectively.
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6.2 Materials & methods
6.2.1 Clonogenic assays
As with isobologram analyses of drug interactions (Chapter 5), three scheduled 
combinations of TPT and [^^^I]MIBG were investigated. In schedule [i] topotecan was 
administered 24 hours before [^^^I]MIBG treatment. In schedule [ii] topotecan was 
administered 24 hours after [^^^I]MIBG treatment. In schedule [iii] topotecan and
[131I]M1BG were administered simultaneously (Figure 5-3).
Monolayers of SK-N-BE(2c) and UVW/NAT of cells were cultured in 25cm^ 
flasks (Nunclon Plastics, Denmark) at 2.5 x 1 0  ^ cells per flask. After two days, medium 
was removed and replaced with fresh medium containing a dose of TPT and/or 
['3^I]MIBG. Following treatments, the cytotoxic effects were assessed in triplicate by 
clonogenic assay, as previously described (Section 4.2.2). Every treatment group was 
assessed three times.
6.2.2 Fixed ratios o f  TPT and [^^fjM IBG
For combination treatments the fixed ratio of TPT (ng/ml) to [^ ^^ i j m IBG (MBq/ml) 
employed was 1:2 (i.e 1 ng/ml:2MBq/ml) for SK-N-BE (2c) cells.
For analyses of drug interactions in UVW/NAT cells the fixed ratio of 
TPT:[^31j]MIBG employed was 1:1. These ratios were determined from the relative 
toxicities to each cell line of the drugs used as single agents, described in Chapter 4. This 
meant that the proportional contribution of each drug was the same at all treatment 
intensities for each cell line.
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6.3 Results
6.3.1 Median-effect/combination-index analysis o f  the interaction between y f jM I B G  and 
topotecan
The effects of TPT and on SK-N-BE(2c) as single agents or in
combination are shown in Figure 6-2. From the survival curves from Figure 6-2, median- 
effect plots were constructed, to enable the calculation of various levels of toxicity. These 
are shown in Figure 6-3.
Similarly, the effects of TPT and [^^rijMIBG on UVW/NAT cells as single agents 
or in combination are shown in Figure 6-4. Median-effect plots were constructed from this 
data, and these are shown in Figure 6-5.
Cl values were determined using equation (3) from Figure 6-1. The formula was 
solved in two different ways, as the manner of the interaction between the agents was 
uncertain. TPT has an effect which is independent of [‘^ ^IJMIBG activity (S-phase specific 
toxicity [83, 85]) and an effect which is dependent on [‘3^I]MIBG activity (due to Topo Fs 
involvement in the response to [^^^ijMIBG-initiated DNA damage [170-175]).
In Figure 6 - 6  (SK-N-BE(2c)), and in Figure 6-7 (UVW/NAT) the data (Cl values) 
corresponding to the modes of action of the two agents which are dependent or distinct, are 
presented graphically as (a) solid lines, or (b) dashed lines, respectively. These modes of 
action therefore represent the extreme values that can be generated by the interaction 
between these agents, and the “true” Cl value is likely to lie somewhere in between. Data 
corresponding to similar modes of action are presented in bold type. Data corresponding 
to distinct modes of action are presented in italics. Cl < 1, Cl = 1 and Cl > 1 indicated 
synergism, additivity and antagonism respectively.
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Figure 6-2: Effect of and TPT alone
and in combination on clonogenic survival of 
SK-N-BE(2c) cells
A) The effects of TPT and l'^ ’UMIBG on SK-N-BE(2c) 
cells as single agents. These survival curves were plotted 
using the same data shown in Figure 4-3.
B) The effects of TPT and [‘^ ‘IlMIBG on SK-N-BE(2c) 
cells in combination. Based on data from (A), SK-N-BE(2c) 
cells were dosed with TPT and | ’^ ’I|M IBG in a fixed 1:2 
ratio (TPTiMIBG.
lau = 0.333..ng/ml of TPT + 0.666...MBq/ml of 
I'^iIlMIBG .
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Figure 6-3: Median-effect plots for TPT and 
treated SK-N-BE(2c) cells
The cytotoxic interaction between TPT and was
further assessed using the median-effect principle.
The dose response curves from Figure 6-2 were replotted 
using the logarithmic form of equation ( 1 ): \og\fa/fu \ = mlogD 
- mlogDm. This converts the relationship between effect (fa/Ju) 
and dose (D) into a linear form (ie. y = mx -+- c).
From the resulting median-effect lines, x-intercept (log IC^ g) 
and slope m were calculated for each agent alone (A) and for 
each agent in combination (B).
These parameters were used to calculate D, the doses of 
component agents (and combinations) required to produce 
various levels of toxicity, using equation (2): D =
Dm\falfuŸ''^.
The resultant toxicity data were used to calculate the Cl values 
shown in Figure 6 -6 .
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Figure 6-4: Effect of and TPT alone
and in combination on clonogenic survival of 
UVW/NAT cells
A) The effects of TPT and on UVW/NAT cells 
as single agents. These survival curves were plotted using 
the same data shown in Figure 4-4.
B) The effects of TPT and on SK-N-BE(2c) 
cells in combination. Based on data from (A), UVW/NAT 
cells were dosed with TPT and |'^T |M IBG  in a fixed 1:1 
ratio (TPTiMIBG).
lau = 0.5ng/m lofTPT-k 0.5MBq/ml of |'^ 'I|M IB G  .
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Figure 6-5: Median-effect plots for TPT and 
[13ii]MIBG treated UVW/NAT cells
As with SK-N-BE(2c) cells, the cytotoxic interaction between 
TPT and |'^'I|MIBG was further assessed using the median- 
effect principle.
Again, the dose response curves from Figure 6-4 were 
replotted using the logarithmic form of equation ( 1 )
\og\fa/fu\ = mlogD - mlogDm, and from the resulting 
median-effect lines, x-intercept (log IC^,) and slope m were 
calculated for each agent alone (A) and for each agent in 
combination (B).
These parameters were used to calculate D, the doses of 
component agents (and combinations) required to produce 
various levels of toxicity, using equation (2): D = 
Dm\falfuŸ''^).
The resultant toxicity data were used to calculate the Cl 
values shown in Figure 6-7.
f  TPT only  
I  I] MIBG on ly
X Schedule [i]
X Schedule [ii]
+  Schedule [iii]
120
6.3.2 SK-N-BE(2c)
The results of combination analyses of different scheduled combinations of TPT 
and [^^TJMIBG are shown in Figure 6 - 6 . The data (Cl values) corresponding to the modes 
of action of the two agents which are dependent or distinct, are presented below in bold 
type and italics respectively. Supra-additive kill of SK-N-BE(2c) cells after treatment with 
all combination schedules resulted in Cl values < 1 at the IC^o, and IC3 0 . (eg. at ICgg: 
schedule [ij = 0.501 ± 0.117 / 0.566 ± 0.147; schedule [ii] = 0.282 ± 0.037 / 0.302 ± 
0.043; schedule [iii] = 0.260 ± 0.018 / 0.277 ± 0.020),
However, after combination therapy involving levels of cytotoxicity greater than 
IC 5 0 , the combined treatments were less effective than the individual drugs and Cl values > 
1 were obtained at the IC 7 0  and IC%.
At the IC 5 0 , in the case of schedule [i], the Cl value calculated assuming a 
dependent interaction was slightly less than 1 (0.922 ± 0.027) whereas the Cl value which 
was calculated, assuming independent modes of action of the two agents, was slightly 
greater than 1 {1.134 ± 0.039). In contrast, the effects of combination schedules [ii] and 
[iii] were synergistic at the IC 5 0  regardless of the method of derivation of Cl (schedule [ii] 
= 0.562 ± 0.015 / 0.641 ± 0.019\ schedule [iii] = 0.507 ± 0.043 / 0.572 ± 0.054).
Likewise, at every level of toxicity analysed, administration of TPT before 
[131I]MIBG (schedule [i]) was not as effective as administration of TPT either after, or 
simultaneously with [^^^IJMIBG (schedules [ii] and [iii] respectively).
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Figure 6-6: Combination-index (Cl) v e r s u s  cytotoxicity: 
Interaction between TPT and [i^^IJMIBG in SK-N-BE(2c) cells
The data (Cl values) corresponding to modes of action of the two agents which are similar, 
are presented as bold text, and graphically as solid lines. The Cl values corresponding to 
modes of action of the two agents which are distinct, are presented as italics, and graphically 
as dashed lines.
Cl < 1,CI = 1 and Cl > 1 indicated synergism, additivity and antagonism respectively.
Supra-additive levels of kill were achieved at low toxicity levels. This was observed in each 
scheduled combination of the two agents. However, at each level of toxicity analysed, 
administration of TPT before exposure to ['^U|MIBG was not as effective as administration 
of TPT either after, or simultaneously with ['^‘IjMIBG; eg. at IC^ o-
Schedule |i| = 0.922 ± 0.027 (1.134 ± 0.039);
Schedule |ii| = 0.562 ± 0.015 (0.641 ± 0.019);
Schedule |iii| = 0.507 ± 0.043 (0.572 ± 0.054).
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6.3.3 UVW/NAT
The results of combination analyses of different scheduled combinations of TPT 
and [^^4]MIBG are shown in Figure 6-7. The data (Cl values) corresponding to the modes 
of action of the two agents which are dependent or distinct, are presented below in bold 
type and italics respectively. Unlike SK-N-BE(2c) cells, administration of all combination 
schedules resulted in Cl values > 1 at the IC^ Q. At the IC3 0  however, while cells treated by 
schedule [i] and schedule [iii] continued to exhibit infra-additive interactions (schedule [i] 
= 1.564 ± 0.140 / 2.176 ± 0.250; schedule [iii] = 1.204 ± 0.076 / 1.565 ± 0.121), in the 
case of schedule [ii], the Cl value calculated assuming a dependent interaction was slightly 
less than 1 (0.973 ± 0.022) whereas the Cl value which was calculated, assuming 
independent modes of action of the two agents, was slightly greater than 1 (1.208 ± 0.033).
At the IC 5 0  level of toxicity, treatment by schedule [ii] and schedule [iii] resulted in 
Cl values < 1 (schedule [ii] = 0.662 ± 0.043 / 0.772 ± 0.057; schedule [iii] = 0.856 ± 0.094 
/  1.041 ± 0.135). Treatment by schedule [i] continued to result in an infra-additive 
interaction Cl = 1.021 ± 0.128 / 1.284 ± 0.193).
UVW/NAT cells exposed to combinations of TPT and [^^^I]MIBG at levels of 
colony inhibition > IC 5 0  exhibited supra-additive sterilisation of clonogens with all three 
schedules of administration (eg. at IC^q: schedule [i] = 0.672 ± 0.108 / 0.785 ± 0.144; 
schedule [ii] = 0.455 ± 0.057 / 0.507 ± 0.070; schedule [iii] = 0.615 ± 0.097 / 0.710 ± 
0.126).
As in the case of SK-N-BE(2c) cells, at every level of toxicity analysed, treatment 
with TPT before exposure to [^^^I]MIBG (schedule [i]) was less effective than 
administration of TPT either after, or simultaneously with [^^T]MIBG (schedules [ii] and
[iii] respectively).
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Figure 6-7: Combination-index (Cl) v e r s u s  cytotoxicity: 
Interaction between TPT and [^^*I]MIBG in UVW/NAT cells
Again, the data (Cl values) corresponding to modes of action of the two agents which are 
similar, are presented as bold text, and graphically as solid lines. The Cl values 
corresponding to modes of action of the two agents which are distinct, are presented as 
italics, and graphically as dashed lines.
Cl < 1,CI = 1 and Cl > 1 indicated synergism, additivity and antagonism respectively.
Supra-additive levels of kill were achieved by combinations of TPT and |'^‘I|MIBG at high 
toxicity levels. This was observed in each scheduled combination of the two agents. 
However, as with SK-N-BE, at each level of toxicity analysed, administration of TPT before 
exposure to |'^'I|MIBG was not as effective as administration of TPT either after, or 
simultaneously with |'^'I|MIBG; eg. at IC^ g:
Schedule |ij = 1.021 ± 0.128 (1.284 ± 0.193 );
Schedule |iil = 0.662 ± 0.043 (0.772 ± 0.057);
Schedule |iii| = 0.856 ± 0.094 (1.041 ± 0.135).
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6.4 Summary of results
In SK-N-BE(2c) cells, administration of combinations of TPT and [^^'IJMIBG at 
low levels of toxicity (ie. < IC5 0 ) resulted in supra-additive levels of clonogenic 
sterilisation. However, following the administration of doses which resulted in higher 
levels of cytotoxicity (ie. > I C 5 0 ) ,  the combined treatments were less effective than the 
individual drugs and Cl values > 1 were obtained at the IC 7 0  and ICgq. At every level of 
toxicity analysed, administration of TPT before [^^^IjMIBG (schedule [i]) was less 
effective than administration of TPT either after, or simultaneously with [^^^IjMIBG 
(schedules [ii] and [iii] respectively).
UVW/NAT cells were more resistant than SK-N-BE(2c) cells to combination 
therapy, and Cl values < 1 were obtained following doses of TPT and [^^^I]MIBG which 
resulted in low levels of toxicity (ie. < IC^J. UVW/NAT cells were more sensitive to 
higher doses of TPT/MIBG combinations, and all three schedules induced supra-additive 
responses at high levels of toxicity (ie. > IC 7 0 ). However, as was observed in SK-N- 
BE(2c) cells, administration of combination schedule [i] was less effective than 
combination schedules [ii] or [iii], and at the IC 5 0  level of toxicity, while administration of 
schedules [ii] and [iii] resulted in supra-additive responses, treatment by schedule [i] 
resulted in an infra-additive interaction.
The results of combination-index analyses described in this chapter were in 
agreement with the results of isobologram analyses previously reported in Chapter 5, 
which found that supra-additive levels of killing were achieved in NAT expressing cells 
treated with combinations of TPT and [^  ^ l]MIBG. Furthermore, combination-index 
analyses suggested that schedule [i] was less effective than schedules [ii] and [iii] at every 
toxicity level evaluated.
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The isobologram method described in Chapter 5 involved the administration of 
variable doses of each agent. The use of fixed TPTiMIBG ratios in median-effect / 
combination-index analysis meant that this model did not provide as much information on 
the specific interactions between, for example, combinations involving low doses of TPT 
and high doses of [^^^I]MIBG. However, while different versions of isobologram analyses 
have been reported [164, 165, 168, 169], the same mathematical equations are applied in 
all examples of combination-index analyses [163, 166, 167]. Furthermore, median-effect / 
combination-index analysis is less laborious than isobologram analysis [166], and its 
versatility is demonstrated by its wide-spread use in reported analyses of drug-drug 
interactions [163, 176].
While the results of in vitro experiments to assess the cytotoxic interactions 
between TPT and [^^^I]MIBG described in Chapters 5 & 6  are valuable, it is desirable to 
examine TPT/[^^^I]MIBG combination therapy in vivo, before progressing to clinical 
evaluation. This will be the topic of Chapter 7.
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Chapter 7
Analysis of the cytotoxic interaction between 
topotecan and in vivo
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7.1 Introduction
7.1.1 Anti-tumour effects o f  topotecan and I]MIBG
The results of in vitro experiments to assess the cytotoxicity of TPT and 
as single agents and in combination, previously described in Chapters 4-6 provide valuable 
information about the interaction between these drugs. However, it is desirable to examine 
the efficacy and optimal order of delivery of TPT/[^^’I]MIBG combination therapy in vivo, 
before progressing to clinical evaluation. This was accomplished using SK-N-BE(2c) and 
UVW/NAT nude mice tumour xenograft models, previously described [177, 178].
7.1.2 Effect o f  TPT and on marrow toxicity
The dose limiting tissue in neuroblastoma patients treated with [^^^IJMIBG is bone 
marrow and toxicity is manifest by prolonged thrombocytopenia [179]. Furthermore, 
topotecan is also myelotoxic [126].
It was therefore important to investigate the effects of combinations of these agents 
on platelet production and proliferative capacity of haemopoietic stem cells in 
experimental animals. See Figure 7-1.
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Figure 7-1: Haemopoiesis
CFU-A cells are progenitors of the myeloid lineage, and are one division removed from 
the pluripotent stem cells. These are more abundant than the pluripotent stem cell and 
are radiosensitive.
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7.2 Materials & methods
7.2.1 Experimental animals.
Six-week-old male and female, congenitally athymic nude mice of strain M Fl 
nu/nu were obtained from Harlan Olac, Bicester, UK. In vivo experiments were carried out 
in accordance with the UK Coordinating Committee for Cancer Research guidelines on 
experimental neoplasia in animals [180].
7.2.2 Xenografts.
Two tumour models were employed. SK-N-BE(2c) xenografts, initiated by 
subcutaneous insertion of tumour fragments, were appropriate for the evaluation of 
experimental therapy of large tumours whereas UVW/NAT xenografts, established by the 
injection of a single cell suspension, were used for investigation of combination treatment 
of smaller tumours.
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7.2.3 SK-N-BE(2c)
Tumour growth was established by intrasplenic injection of 3 x 10  ^ exponentially 
growing SK-N-BE(2c) cells as previously described [177], Following the growth of 
tumours in the spleen and liver, animals were euthanized and tumour fragments 2-3mm in 
diameter were then implanted subcutaneously in the subcostal flanks of other nude mice. 
Mice were used for experimental therapy 17 days after tumour implantation when the 
subcutaneous tumours had reached approximately 10mm diameter (SOOmm^).
7.2.4 UVW/NAT
Xenografts were established in nude mice by subcutaneous (s.c.) injection of 3 x 
10  ^UVW/NAT cells, freshly harvested at 60 to 70% confluence to ensure that their growth 
was in the logarithmic phase. [‘^ T]MIBG therapy experiments were initiated nine days 
later, at which time tumour volume was approximately 60mm^. To monitor potential 
toxicity, body weight was measured daily and experimental animals were scored for signs 
of distress using standard guidelines [178].
7.2.5 Ejfect o f topotecan pretreatment on the biodistribution o f  [^^fjM IBG
Twenty four hours before administration of ['^^I]MIBG, the mice received, by 
intraperitoneal (i.p.) injection, 1.75 mg/kg of topotecan or the equivalent volume of saline. 
At least one hour before [^^^I]MIBG injection, tumour-bearing mice were weighed and 
injected i.p. with 1  ml of a 0 . 1 % potassium iodide solution to diminish thyroid uptake of 
radioiodine. The animals then received, by i.p. injection, 2MBq of [’^ ^I]MIBG. The 
precise activity administered to each mouse was measured using a Curiemonitor-2
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ionization chamber (Radiation Components, Bracknell, UK). After 24 hours mice were 
euthanized. Samples of femur contents, tumour, heart, lung, adrenal glands, muscle, 
kidney, thyroid and liver were excised and weighed and the associated radioactivity was 
measured in an automated gamma counter (Packard Biosciences Ltd, Berkshire, UK). 
Comparison of tissue activity levels was performed by Student’s t-test.
7.2.6 Therapy experiments.
Groups of twelve mice with SK-N-BE(2c) or UVW/NAT tumours were used for 
each treatment regimen. The mice were randomized into six treatment groups which 
received, by i.p. injection, saline (control), 18 MBq of [^^TjMIBG alone (SK-N-BE(2c) 
tumours) or 10 MBq of [^^^IjMIBG alone (UVW/NAT tumours), 1.75 mg/kg of topotecan 
alone or combinations of the two agents.
As with the in vitro analysis of the interactions between TPT and [^^^IJMIBG 
(Chapters 5 & 6 ), three treatment schedules were assessed: topotecan administered 24h 
before [i], after [ii] or simultaneously with [iii] [^^^I]MIBG. The dose of [^^^I]MIBG 
administered to the mice was previously shown to induce significant delay of the growth, 
but incomplete sterilisation of SK-N-BE(2c) [181] or UVW/NAT xenografts [182]. The 
injected dose of topotecan was equivalent to 8 8 % of the maximal tolerated dose contained 
in one administration of a fractionated dose [183].
Subcutaneous tumours were measured with callipers immediately prior to treatment 
and every two or three days thereafter. On the assumption of ellipsoidal geometry, 
diameter measurements were converted to an approximate volume by multiplying half the 
longest diameter by the square of the mean of the two shorter diameters. Mice whose 
xenograft volume reached 1900mm^ were euthanized. The tumour volumes, against time,
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were plotted for each animal. In the growth/regrowth phase, these profiles were log-linear. 
Separate log-linear regressions were fitted to each animal’s data.
For each treatment group, the mean time taken to reach two times (SK-N-BE(2c) 
xenografts) or ten times (UVW/NAT xenografts) the tumour volume at the initiation of 
treatment was calculated to allow comparison among treatment groups. Cure was defined 
as the failure of tumours to increase in size over a period of 30 days. The comparison of 
antitumour efficacies of the various treatment combinations was performed by the Mann- 
Whitney U-test. p  < 0.05 was considered statistically significant. All statistical tests used 
GraphPad Prism software, version 3.0, 1999 (CA).
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7^2/7 Assessment o f marrow toxicity
Separate groups of six mice were used for the determination of possible adverse 
effects on bone marrow of the various combinations of and topotecan. One,
two, three and six weeks following treatment, mice were killed and samples of blood 
(0.5ml) were collected using 1.5mg/ml dipotassium EDTA as anticoagulant. The numbers 
of thrombocytes per ml were determined by an automated analyser (STK-S Coulter, 
Miami, FI, USA).
As a further indicator of myelotoxicity, the clonogenic potential of CFU-A cells in 
the same groups of mice was determined. These are transiently engrafting haemopoietic 
stem/progenitor cells whose proliferative capacity is indicative of the status of the 
haemopoietic stem cell compartment in general [184] (Figure 7-1). After separating 
surrounding muscle and epiphyses from femurs under sterile conditions, marrow was 
obtained by flushing out femur contents with PBS using a 25-guage syringe. Clonogenic 
haemopoietic stem/progenitor cells were numerically assessed using the in vitro CFU-A 
assay as described previously [185].
Briefly, a feeder layer consisting of 0.6% agar in -MEM with 25% donor horse 
serum was prepared. Prior to plating, and after equilibrating to 37°C, growth factors (R & 
D Systems, Abingdon, UK) were added to the feeder layer. Specifically, murine GM-CSF 
was added to 0.2ng/ml; recombinant human CSF-1 to 6 ng/ml and recombinant murine CSF 
to 12 ng/ml. One milliliter of this feeder layer mixture was plated out per standard 3cm 
tissue culture dish and allowed to set.
The upper agar layer consisted of 0.3% agar in -MEM and 25% donor horse 
serum to which normal murine bone marrow cells were added to a concentration of 5 x 10  ^
per ml. One milliliter of this upper layer agar mix was then placed on top of the feeder
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layer and allowed to set. The plates were incubated at 37°C in an atmosphere of 10% COj 
and 5% O2 . The assays were allowed to develop for 11 days and the CFU-A colonies, 
defined as having a diameter greater than 2mm, were scored. Platelet and CFU-A colony 
counts of the various treatment groups were compared by Student’s t-test.
7.3 Results
7.3.1 Ejfect o f topotecan on the biodistribution o f [^^fjM lBG.
The influence of prior administration of topotecan on the distribution of [^^^IjMIBG 
in tumour-bearing nude mice was determined by measurement of radioactivity in excised 
tissues (Figure 7-2). Concentration of [^^^I]MIBG in SK-N-BE(2c) or UVW/NAT tumours 
was second only to that in adrenals. Previous exposure to topotecan had no effect on 
l^^TjMIBG accumulation by UVW/NAT tumours but induced a modest though 
insignificant increase in uptake by SK-N-BE(2c) tumours. Similarly, while topotecan 
treatment induced greater accumulation of [^^^IJMIBG in adrenals and heart in both groups 
of tumour-bearing mice, these increases were not significant.
In contrast, the concentration of [^^TjMIBG was low in muscle, kidney, lung, thyroid 
and marrow. In none of these non-sympathetically innervated tissues was there a significant 
difference in radiopharmaceutical uptake after topotecan administration. Topotecan had no 
effect on the concentration of activity in bone marrow.
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Figure 7-2: The effect of topotecan 
pretreatment on [^^ I^JMIBG biodistribution
Nude mice bearing (A) SK-N-BE(2c) or (B) UVW/NAT 
xenografts were treated with saline or topotecan 24h before 
1’3‘IIMIBG.
Means and standard deviations of 6  determinations. 
Topotecan pretreatment had no significant effect on tissue 
uptake of [* ‘^I|MIBG
T - tumour 
M - muscle 
Li - liver 
H - heart 
Ki - kidney 
Thy - thyroid 
Lu - lung  
Bm - bone marrow 
A - adrenal
□  + Saline
□  + Topotecan
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7.3.2 In vivo ejfects of I]MIBG and topotecan alone or combined
None of the animals in this study suffered weight loss. Figure 7-3 shows the effect 
on the growth of SK-N-BE(2c) tumour xenografts of the administration of topotecan or 
[^^^IjMIBG either alone or in combination. Figure 7-4 shows the effects of these same 
treatment regimens on UVW/NAT tumours. Tumour cure rates are presented in Table 7-1.
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Figure 7-3: Effect of and TPT
alone and in combination on the growth of 
SK-N-BE(2c) tumours in nude mice
Treatment was administered 17 days after s.c. 
implantation of 2-3mm tumour fragments. Each 
treatment group consisted of 12 animals. Results are 
mean ± s.d.
no-carrier-added I'^'IjM IBG concentration was 
18MBq,TPT concentration was 1.75mg/kg
▲ saline control
♦ TPT only
■ I]MIBG on ly
X Schedule [i]
X Schedule [ii]
* Schedule [iii]
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Figure 7-4: Effect of [i3iI]MIBG and TPT 
alone and in combination on the growth of 
UVW/NAT tumours in nude mice
Treatment was administered 9 days after s.c. injection of 1 
xlO^ UVW/NAT cells. Each treatment group consisted of 
12 animals. Results are mean ± s.d.
no-carrier-added concentration was lOMBq,
TPT concentration was 1.75mg/kg
À saline control
♦ TPT only
■ on ly
X Schedule [i]
X Schedule [ii]
* Schedule [iii]
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7.3.3 SK-N-BE(2c) tumours
The tumours of mice which received i.p. injection of saline (controls) had a volume 
doubling time (Tj) of 10.4 ± 2.0 days (mean ± s.d.). Single treatments with topotecan or 
[’^ ^IJMIBG significantly increased the Tj to 19.7 ± 6 . 6  days (p < 0.001) or 22.8 ± 10,1 days 
(p < 0.001) respectively. No complete tumour regression resulted from either single agent 
therapy.
Combination schedule [i] produced a greater tumour growth delay (Tj = 26.3 ± 10.3 
days) than either drug alone but the difference was not statistically significant. 
Administration of the two agents by combination schedule [ii] produced a greater Tj (34.3 ±
8.3 days) than schedule [i] and sterilised 8 % of tumours. This schedule was significantly 
more effective than either topotecan (p < 0 .0 0 1 ) or [^^4lMlBG (p < 0 .0 1 ) given alone.
The most effective tumour control was obtained when the two agents were given 
simultaneously (combination schedule [iii]). The resulting T^ (53.2 ± 7.5 days) was 
significantly greater than those of the other two combination treatments (p < 0 .0 0 1 ). 
Schedule [iii] treatment also cured 42% of tumours.
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SK-N-BE(2c) UVW/NAT
T2 cure rate Tio(days)
cure rateTreatment (days) (%) (%)
saline
control
10.4 ± 2.0 0 18.6 ± 4.2 0
TPT
alone
19.7 ± 6 .6 0 25.3 ± 6.1 17
[13ii]MIBG
alone
2 2 .8  ± 10.1 0 31.9 ± 7.4 50
Schedule
[i]
26.3 ± 10.3 0 37.1 ± 12.8 50
Schedule
[ii]
34.3 ± 8.3 8 49.7 ± 12.0 67
Schedule
[iii]
53.2 ± 7.5 42 71 100
Table 7-1: Tumour cure and delayed tumour growth resulting from 
the administration of topotecan or [^^ I^]MIBG alone or in combination
Cure rates are expressed as percentages of animals in each treatment group.
SK-N -BE(2c): T2  values are the mean number of days ± s.d. required for a doubling of 
volume of SK-N-BE(2c) tumours.
UVW /NAT: T jq values are the mean number of days ± s.d. required for a ten-fold 
increase in volume of UVW/NAT tumours. All tumours treated simultaneously with 
topotecan and [^^TjMIBG failed to regrow. These were assigned a T^q value > 71 
corresponding to the day of termination of the experiment.
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7.3.4 UVW/NAT tumours
In the saline-treated group of mice, tumours reached a ten-fold increase in volume 
(Tio) in 18.6 ± 4.2 days (mean ± s.d.). None of the tumours in this control group 
spontaneously regressed.
Tumours treated with topotecan alone had significantly greater Tio values than the 
saline group; 25.3 ± 6 .1  days, and two tumours were cured (17%). In mice which received 
[^^4]MIBG alone, a Tjo of 31.9 ± 7.4 days, and a cure rate of 50% was achieved. Both 
single agent treatments were significantly more effective than saline (topotecan p  < 0 .0 1 , 
[*'4]MIBGp< 0.001).
The T,o value (37.1 ± 12.8 days) corresponding to the delivery of [’^ 4]MIBG 24h 
after injection of topotecan (combination schedule [i]) was greater than those of the groups 
which received either drug as a single agent, and the cure rate was 50%. However, this 
improvement was not statistically significant.
When topotecan was administered 24h after [’^ OjMIBG (combination schedule [ii]), 
rather than in the reverse order (schedule [i]), an increased Tjo (49.7 ± 12.0 days) was 
observed, and 67% of tumours were cured. This represented a significant improvement in 
efficacy relative to topotecan alone (p < 0.001), but not relative to [’^ 0]MIBG alone or 
relative to schedule [i].
A more dramatic effect was noted when the two agents were given simultaneously 
(combination schedule [iii]). Unlike combination schedules [i] and [ii], concurrent delivery 
of [^^4]MIBG and topotecan cured all UVW/NAT tumours.
This constituted a significant improvement in efficacy relative to combination 
schedule [i] as well as both single agent treatments (p < 0.014) although not relative to 
schedule [ii].
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7.3.5 Assessment o f marrow toxicity o f alone, and combinations o f topotecan
and [^^fjM lBG
Table 7-2 depicts the bone marrow toxicity associated with combined [^ ’^l]MIBG 
and topotecan treatment in mice hosting SK-N-BE(2c) tumours. Table 7-3 presents the 
responses of similarly treated UVW/NAT xenografts.
In SK-N-BE(2c) treated with 18MBq of [^^4]MIBG, there was a significant decline 
in colony-forming units and thrombocytes at one week after [^^4]MIBG treatment with or 
without topotecan (p < 0.01). No difference in bone marrow toxicity was observed 
between topotecan and non-topotecan-treated animals. Recovery to normal values was 
observed at two weeks.
In mice bearing UVW/NAT tumours and treated with lOMBq of [^^0]MIBG, no 
evidence of thrombocytopenia was observed up to 6  weeks after treatment with any of the 
3 combination schedules (Table 7-3). There was no significant difference in platelet count 
between any of the treatment groups. Likewise, the clonogenic potential of pluripotent 
stem cells was not adversely affected by any of the treatment regimes. While CFU-A 
colony counts were, in most saline-treated animals, higher than those of the combination 
treatment groups, these differences did not reach statistical significance.
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Saline
control
[131I]MIBG
alone
Schedule
[i]
Schedule
[ii]
Schedule
[iii]
Week 1 7.7 ± 1.7
9 7 6 ± 186
3.2 ± 0.9^
438 ± 107^
2.4 ± 0.6*
503 ± 134^
2.2 ± 0.7*
475 ± 1 1 9 ^
2.4 ± 0.7*
524 ±172^'
Week 2 9.1 ± 2.2
1107 ± 262
8.1 ± 2.5
848 ± 288
6.8 ± 1.6
971 ± 218
7.0 ± 1.9
922 ± 204
6.4 ± 2.0
9 0 7 ± 293
Week 3 8.8 ± 2.1
1133 ± 304
7.3 ± 2.6
922 ± 154
7.7 ± 2.0
8 5 7 ± 202
6.8 ± 1.6
9 0 0 ± 139
6.6 ± 1.8
824 ± 173
Week 6 7.6 ± 2.5
1150 ± 2 4 9
8.3 ± 2.3
1004 ± 167
7.8 ± 1.9
103 6 ± 167
8.9 ± 2.7
902 ± 213
6.9 ± 1.9
8 5 5 ± 197
Table 7-2: CFU-A colony formation and platelet production in SK- 
N-BE(2c) tumours in nude mice
The effect of combined [^^TjMIBG and TPT administration on CFU-A progenitor cells 
was examined by colony forming assays and were expressed as colonies / 5 x 10  ^ cells. 
Platelet counts were taken from blood collected by heart puncture, and were expressed 
as counts x 1 0 ® /I.
Results of CFU-A colony forming assays are stated in bo ld  type. Platelet counts are 
stated in italics. All results were analysed by Student’s t-test, and are means ± s.d. of 6  
determinations. All were not significant except *, where p  < 0.01.
no-carrier-added l^^4]MIBG concentration was 18MBq,TPT concentration was 
1.75mg/kg.
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Saline
control
[13ii]MIBG
alone
Schedule
[i]
Schedule
[ii]
Schedule
[iii]
Week 1 8.8 ± 3.0
1044 ± 349
9.3 ± 2.5
1108 ± 1 8 5
7.9 ± 2.6 
7242 ± 577*
8.2 ± 2.8
1139 ± 3 2 0
6.8 ± 1.8
1087 ± 3 1 8
Week 2 10.0 ± 4.0
1255± 291
8.3 ± 2.0
1 0 6 0 ± 235
9.4 ± 2.9
1238 ± 303
6.5 ± 2.2
951 ± 226
8.2 ± 1.9
9 6 6 ± 193
Week 3 9.7 ± 3.3
984 ± 240
9.0 ± 2.8
1010 ± 1 9 5
7.1 ± 1.8
943 ±211
5.9 ± 2.6
986 ± 1 6 5
7.6 ± 2.2
942 ± 189
Week 6 8.5 ± 2.7
1127 ± 212
7.7 ± 1.9
976 ± 1 7 8
6.8 ± 1.6
995 ± 283
7.6 ± 2.4
9 3 7 ± 208
8.2 ± 2.5
1220 ± 256
Table 7-3: CFU-A colony formation and platelet production in 
UVW/NAT tumours in nude mice
The effect of combined [^^TjMIBG and TPT administration on CFU-A progenitor cells 
was examined by colony forming assays and were expressed as colonies / 5 x 1(F cells. 
Platelet counts were taken from blood collected by heart puncture, and were expressed 
as counts x 1 0 ® /I.
Results of CFU-A colony forming assays are stated in bo ld  type. Platelet counts are 
stated in italics. All results were analysed by Student’s t-test, and are means ± s.d. of 6  
determinations. All were not significant.
no-carrier-added [^^TjMIBG concentration was 10MBq, TPT concentration was 
1.75mg/kg.
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7.4 Summary of results
In this study, topotecan induced radiosensitisation, resulting in enhanced 
effectiveness of [^^4]MIBG in SK-N-BE(2c) and UVW/NAT xenograft models. However, 
as with the investigations of combined treatments in vitro (Chapters 5 & 6 ), the 
effectiveness of combinations of TPT and [^^4]MIBG was dependent on scheduling. 
Schedule [iii] was most effective, while schedule [i] was the least effective scheduled 
combination.
The dose limiting tissue in neuroblastoma patients treated with ['^'ijM IBG is bone 
marrow and toxicity is manifest by prolonged thrombocytopenia [179]. Furthermore, 
topotecan is also myelotoxic [126]. In this study, combinations of topotecan and 
[^^4]MIBG induced a reduction of platelet numbers and a decrease in the clonogenic 
capacity of CFU-A stem cells in SK-N-BE(2c) tumour-bearing mice at one week after 
treatment. However, these indices of marrow integrity returned to normal levels two 
weeks after treatment. This suggests that, while SK-N-BE(2c) tumour-bearing mice were 
adversely affected by combination treatments, this effect was transient, and the animals did 
not exhibit long-term damage to marrow integrity.
These results indicate that it may be possible to increase the efficacy of ['^^I]MIBG 
by concomitant or subsequent administration of TPT, without increased toxicity to the 
bone marrow.
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Chapter 8
The effects of topotecan and [^^T]MIBG 
on cellular mechanisms
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8.1 Introduction
8.1.1 The ejfect o f  topotecan and on cell cycle distribution
The established model of TPT action predominantly involves collision of the 
replication fork with TPT-stabilized Topo I -  DNA complexes, resulting in irreversible 
dsDNA breaks [83, 85]. This suggests that the effectiveness of this drug will be most 
evident in cells undergoing S-phase [83, 85].
It has previously been reported that cells in late Gj, G^ and M are more sensitive to 
ionising radiation than cells in early Gj and S-phase, possibly due to cell cycle checkpoints 
leading to repair or apoptosis [186]. However the effect of [^^^I]MIBG on the cell cycle 
distribution of NAT expressing cells remains unresolved.
Likewise, the effects of combinations of TPT and [^^*I]MIBG have not been 
investigated. A role for Topo I has been postulated in cellular pathways involved in the 
response to DNA damage, and several studies have suggested Topo I involvement in DNA 
damage repair [170-175]. This would suggest that administration of DNA damaging 
agents in conjunction with TPT may induce effects beyond the traditional transcription- 
and S-phase-related models previously reported, and these additional effects may be 
reflected in the distribution of cells at different stages of the cell cycle.
In this study, the effects of TPT and [’^ 4]MIBG, either alone or in combination, on 
the cell cycle distribution of treated cells was assessed using fluorescence-activated cell 
sorting, or FACS analysis.
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8J.2  The effect oftopotecan and [^^f]MIBG on topoisomerase I-induced unwinding
Topo I activity during replication prevents torsional stress to the DNA molecule 
[82, 83]. During transcription, transient unwinding of the DNA helix prevents RNA 
polymerase generating supercoiled tension in template DNA [187]. Furthermore, a role for 
Topo I has been postulated in cellular pathways involved in the response to DNA damage. 
Several studies have suggested Topo I involvement in DNA damage repair and have 
reported a decrease in Topo I - mediated unwinding of supercoiled DNA following 
irradiation [161, 170-175, 188]. However, the effect of [^^^IjMIBG on Topo I activity is 
unresolved. Likewise, the effects of [^^^IJMIBG in combination with TFT on the efficiency 
of Topo I-induced unwinding is, to date, unknown. In this study, the effects of TPT and 
[131j]]vjiBg  ^ either alone or in combination, on topoisomerase I activity was assessed by 
Topo I relaxation assay (see Section 4.2.1).
8.2 Materials & methods
8.2.1 Cell Lines
SK-N-BE(2c) and UVW/NAT cells were seeded at a density of 4 x 10  ^ cells/cm^ in 
75cm^ flasks (Iwaki® products, Bibby Sterilin Ltd. Staffordshire, UK) and grown in RPMI 
1640 medium containing 200mM L-glutamine, 25mM HEPES and 10% PCS at 37°C and 
5% CO 2 . All media and supplements were obtained from Invitrogen (Paisley, UK). After 
48h, fresh media was added to the cells, containing either topotecan, [‘^ T]MIBG or a 
scheduled combination of both agents. Following treatment, cells were analysed by flow 
cytometry and Topo I relaxation assay.
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8.2.2 Concentrations and incubation times o f  TPT and
The doses of TPT and [^^T]MIBG employed in studies of DNA damage and repair 
were the doses of each agent required to reduce clonogenic survival to 50% of control 
cultures, as determined by clonogenic assay (see Chapter 4). For the treatment of SK-N- ] 
BE(2c) cells, [^^T]MIBG concentration was 4 MBq/ml, and topotecan concentration was 
2ng/ml. For UVW/NAT cells, [^^4]MIBG concentration was 4.1 MBq/ml and TPT 
concentration was 4.2ng/ml.
The incubation times of TPT and [*^^I]MIBG used in this study were the same as 
those used for investigations of in vitro cytotoxicity, as described in Section 4.2.2. Briefly, 
[13ii]mibG incubation time was 2h, after which uptake is maximal [154J, followed by a 
further 24h in fresh media to allow for the accumulation of damage due to the radiological 
bystander effect [17].
TPT incubation time was 24h, which has previously produced optimal supra-
additive killing of cells treated with TPT and external beam irradiation 1139].
il
8.2.3 Scheduled combinations o f TPT and I]MIBG
As with investigations of the toxic effects of these agents (see Chapters 5, 6  &7), 
three treatment modalities were investigated. In schedule [i] topotecan was administered 
24 hours before ['^^I]MIBG treatment. In schedule [ii] topotecan was administered 24 
hours after [^^T]MIBG treatment. In schedule [iii] topotecan and [^^^I]MIBG were 
administered simultaneously. See Figure 5-3.
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8.2.4 FACS analysis
Following treatment, cells were trypsinised and counted. Cells were washed twice 
with PBS (centrifugation was 4mins at 1500RPM) and resuspended in PBS at a 
concentration of 1 x 10® cells/ml. Cells were fixed by addition of 100% ethanol at 4°C 
(3ml per 1 x 10® cells), so that the final concentration of ethanol was 75%. Cells were 
incubated for Ih at 4°C.
Fixed cells were centrifuged at 1750RPM for 7mins, and washed twice with PBS. 
Cell pellets were resuspended in 1ml PBS containing 50ug/ml Propidium Iodide (Sigma 
chemicals, Dorset UK). RNase A (Qiagen Ltd. W. Sussex, UK) was added to a final 
concentration of 5ug/ml, and cells were stained for 3h at 4”C before analysis by flow 
cytometry. Analysis was carried out using a BD FACS can analyser (Becton Dickinson 
Systems, Cowley, UK), and results were analysed using BD CellQuest™ Pro software, 
version 5.1.1.
8.2.5 Topoisomerase I  relaxation assays
Following treatment, topoisomerase I was extracted from SK-N-BE(2c) and UVW/NAT 
cells, and Topo I activity was determined using the Topoisomerase I Assay Kit (Topogen 
Inc, Columbus, Ohio, USA) as described in Section 4,2.1.
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8.3 Results
8.3.1 Cell cycle distribution o f SK-N-BE(2c) and UVW/NAT cells
The proportions of SK-N-BE(2c) and UVW/NAT cells in different phases of the 
cell cycle, assessed by flow cytometry are shown in Figure 8-1. Of the two cell lines, a 
higher percentage of SK-N-BE(2c) than UVW/NAT cells were in Gj (75.13 ± 0.29%, 
compared to 62.56 ± 0.53% of UVW/NAT cells). Conversely, a higher proportion of 
UVW/NAT cells were undergoing DNA replication and mitosis. 10.47 ± 0.25% of SK-N- 
BE(2c) cells were in S-phase, compared to 12.26 ± 0.24% of UVW/NAT cells. 11.79 ± 
0.45% of SK-N-BE(2c) cells were in G^/M, compared to 21.22 ± 0.64% of UVW/NAT 
cells.
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Figure 8-1 : The cell cycle distribution of SK-N-BE(2c) and 
UVW/NAT cells
The proportions of (A) SK-N-BE(2c) and (B) UVW/NAT cells in different phases of 
the cell cycle, assessed by flow cytometry. Each determination was carried out in 
triplicate. Results are mean ± sd of 15000 cells and are presented as the percentage of 
total cells counted. Proportions are shown as GpSiGj/M :
(A) 75.13 ± 0.29 : 10.47 ± 0.25 : 11.79 ± 0.45
(B) 62.56 ± 0.53 : 12.26 ± 0.24 : 21.22 ± 0.64
O f the two cell lines, a higher percentage of SK-N-BE(2c) cells were in G ,, whereas a 
higher proportion of UVW/NAT cells were undergoing cell division and mitosis.
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8 3 .2  The effects on cell cycle distribution oftopotecan and [ ' IJMIBG as single agents
83.2-1 SK-N-BE(2c)
The effects of TPT and [^^^I]MIBG as single agents on the cell cycle distribution of 
SK-N-BE(2c) cells are shown in Figure 8-2. Treatment by TPT alone induced a reduction 
in the percentage of cells in G,, from 75.13 ± 0.29% to 43.65 ± 2.15%. A 
contemporaneous increase in the percentage of cells in S-phase was observed following 
TPT treatment, from 10.47 ± 0.25% to 19.92 ± 0.46%, as was an increase in the proportion 
of cells in G^/M, from 11.79 ± 0.45% to 33.27 ± 1.46%.
Administration of [^  ^ I]MIBG alone also reduced the percentage of cells in G^, from 
75.13 ± 0.29% to 56.07 ± 0.38%. Therefore, [^^T]MIBG was less effective than TPT at 
reducing the distribution of cells in Gj. Similarly, while administration of [|^'I]MIBG 
alone induced an increase in the proportion of cells in both S-phase (from 10.47 ± 0.25 to 
17.45 ± 0.43%), and G^/M (from 11.79 ± 0.45% to 22.69 ± 0.27%), this was less effective 
than TPT alone.
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Figure 8-2: The effect of TPT and I]MIBG administration on 
the cell cycle distribution of SK-N-BE(2c) cells
This figure shows the cell cycle distribution of untreated SK-N-BE(2c) cells (U) 
and the effect on the distribution of treatment with TPT or [’^ ^jMIBG (+ ).
In the above figures, the percentage of cells in G,, S and G 2 /M are shown in (A), (B) 
and (C) respectively.
Treatment by either agent alone induced a reduction in the percentage of cells in G,, 
and an increase in the percentage in S-phase and in G 2 /M. TPT reduced a higher 
percentage of cells in G, than [*^*I|MIBG,and increased the proportion of cells in 
both S-phase and G 2 /M:
Topotecan treated cells (G,:S:G 2 /M) - 43.65 ± 2.15 : 19.92 ± 0.46 : 33.27 ± 1.46) 
|*31I|MIBG treated cells (G,:S:G 2 /M) - 56.07 ± 0.38 : 17.45 ± 0.43 : 22.69 ± 0.27)
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8J.2-2  UVW/NAT
The effects of TPT and [^^^I]MIBG as single agents on the cell cycle distribution of 
UVW/NAT cells are shown in Figure 8-3. Results obtained following administration of 
TPT or [^^^I]MIBG as single agents were similar to those observed in SK-N-BE(2c) cells. 
Treatment by TPT reduced the proportion of UVW/NAT cells in G^-phase from 62.56 ± 
0.53% to 24.15 ± 0.50%, and increased the percentage of cells in S-phase and G^/M from 
12.26 ± 0.24% and 21.22 ± 0.64% to 16.32 ± 0.12% and 57.86 ± 0.25% respectively.
Furthermore, while administration of [^^*I]MIBG alone also reduced the percentage 
of cells in Gj (from 62.56 ± 0.53% to 50.65 ± 0.16), and increased the proportions in S- 
phase (from 12.26 ± 0.24% to 15.06 ± 0.49%) and G^/M (from 21.22 ± 0.64% to 31.81 ± 
0.53%), the changes induced by administration of ['^^IJMIBG were not as pronounced as 
the cell cycle distribution changes induced by TPT.
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Figure 8-3: The effect of TPT and administration on
the cell cycle distribution of UVW/NAT cells
This figure shows the cell cycle distribution of untreated UVW/NAT cells (U) and 
the effect on the distribution of treatment with TPT or |'^T|MIBG (+ ).
As in Figure 8-2, in the above figures, the percentage of cells in G ,, S and G 2 /M are 
shown in (A), (B) and (C) respectively.
Results were similar to those observed in SK-N-BE(2c) cells. Treatment by either 
agent alone induced a reduction in the percentage of cells in G,, and an increase in 
the percentage in S-phase and in G 2 /M. Again, in UVW/NAT cells, TPT reduced a 
higher percentage of cells in G; than |'^0|MIBG,and increased the proportion of 
cells in both S-phase and G 2 /M:
Topotecan treated cells (G,:S:G 2 /M) - 24.15 ± 0.50 : 16.32 ± 0.12 : 57.86 ± 0.25) 
I'^'IIMIBG treated cells (G,:S:G 2 /M) - 50.65 ± 0.16 : 15.06 ± 0.49 : 31.81 ± 0.53)
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8 3 .3  The ejfect o f  combinations o f  TPT and f  I]MIBG on cell cycle distribution 
8 3 3 -1  SK-N-BE(2c)
The effects of combinations of TPT and on the cell cycle distribution of
SK-N-BE(2c) cells are shown in Figure 8-4. As with the effects of either agent alone, 
administration of all three combination schedules induced a similar reduction in the 
percentage of cells in G^, and an increase in the percentage in both S-phase and in G 2 /M. 
Schedule [i] induced a greater accumulation of cells in S-phase than either agent alone, or 
schedules [ii] or [iii].
No combination schedule was as effective as TPT as a single agent at increasing 
accumulation of cells in G 2 /M. However, all three combination schedules were more 
effective than [^^T]MIBG alone at increasing accumulation of cells in Gg/M. Interestingly, 
while administration of combination schedules [ii] and [iii] induced identical changes in S- 
and Gg/M-phase distribution, schedule [i] administration was more effective at inducing S- 
phase arrest, and less effective at increasing Gg/M accumulation.
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Figure 8-4: The effect of combinations of TPT 
and on the cell cycle distribution of
SK-N-BE(2c) cells
This figure shows the results from Figure 8-2, along with the 
results obtained by the three scheduled combinations of TPT 
and l'3'IIMIBG.
Again, the percentage of cells in G ,, S and G 2 /M are shown in 
(A), (B) and (C) respectively.
As with the effects of either agent alone, administration of all 
three combination schedules induced a reduction in the 
percentage of cells in Gj, and an increase in the percentage in 
both S-phase and in G 2 /M. Schedule |i| induced a greater 
accumulation of cells in S-phase than either agent alone, or 
schedules |ii| or |iii|. However, no combination schedule was 
as effective as TPT as a single agent at increasing 
accumulation of cells in G 2 /M.
Interestingly, while administration of schedules [ii] and |iiil 
resulted in similar alterations in cell cycle distribution, 
schedule |i| administration did not alter the percentage of cells 
in each phase in the same way, suggesting that cells may be 
responding to schedule li| treatment differently.
▲ Untreated cells
♦ TPT only
■ [i^4]mIBG on ly
X Schedule [i]
X Schedule [ii]
* Schedule [iii]
Schedule |i| (G^:S:G2 /M )- 47.75 ± 0.80 : 21.64 ± 0.58 : 24.17 ± 0.38 
Schedule [iii (G^:S:G2 /M) - 47.62 ± 0.33 : 19.06 ± 0.70 : 29.20 ± 0.51 
Schedule [iii] (G,:S:G2 /M) - 47.99 ± 0.23 : 18.42 ± 0.48 : 30.06 ± 0.65
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8J.3-2  UVW/NAT
The effects of combinations of TPT and [^^^IJMIBG on the cell cycle distribution of 
UVW/NAT cells are shown in Figure 8-5. Again, administration of all three combination 
schedules induced a reduction in the percentage of cells in Gj, and an increased cell 
distribution in S-phase and in Gg/M. Unlike SK-N-BE(2c) cells, in UVW/NAT cells, all 
three combination schedules induced a greater accumulation of cells in S-phase than either 
agent alone. Again, no combination schedule was as effective as TPT as a single agent at 
increasing accumulation of cells in G 2 /M. However, all three combination schedules were 
more effective than [^^^I]MIBG alone at increasing the proportion of cells in the G^/M 
compartment.
Administration of combination schedules [ii] and [iii] induced identical changes in 
S-phase and Gj/M distribution in UVW/NAT cells, whereas schedule [ij administration 
was more effective than schedules [ii] and [iii] at inducing S-phase accumulation, and less 
effective at inducing G^/M accumulation.
8.3.4 The ejfects o f TPT and f  on topoisomerase I  activity
Topo I extracted from SK-N-BE(2c) and UVW/NAT cells treated with of TFT or 
[^^^I]MIBG as single agents, exhibited a reduced ability to induce relaxation of the 
supercoiled pHOT-1 plasmid. Likewise, Topo I isolated from cells treated with all three 
combination schedules had a reduced unwinding efficiency (Table 8-1).
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Figure 8-5: The effect of combinations of TPT and 
[131i ]m i b G on the cell cycle distribution of 
UVW/NAT cells
This figure shows the results from Figure 8-3, along with the 
results obtained by the three scheduled combinations of TPT and
1‘3i i i m i b g .
Again, the percentage of cells in G,, S and G2 /M are shown in 
(A), (B) and (C) respectively.
Administration of all three combination schedules induced a 
reduction in the percentage of cells in G,, and an increase in 
the percentage in both S-phase and in G 2 /M. Again, schedule |i| 
induced a greater accumulation of cells in S-phase than either 
agent alone, or schedules I iii or liiif However, unlike SK-N- 
BE(2c) cells, in UVW/NAT cells, schedules liil and liiil were 
also more effective than TPT alone at increasing accumulation in 
S-phase. Again, no combination schedule was as effective as 
TPT as a single agent at increasing accumulation of cells in 
G 2 /M.
Also, as with SK-N-BE(2c) cells, administration of schedule li] 
altered cell cycle distribution of UVW/NAT cells in a different 
way to schedules liil and |iiil, suggesting that cells treated by 
schedules liil and liiil may be responding differently to cells 
treated by schedule lif
▲ Untreated cells
♦ TPT only
■ [^ 31i ]MIBG  only
X Schedule [i]
X Schedule [ii]
* Schedule [iii]
Schedule\ \ \ (G,:S:G 2 /M) - 39.35 ± 0.36 : 18.49 ± 0.05 : 37.05 ± 0.27 
Schedule liil (G,:S:G 2 /M ) - 30.06 ± 0 .5 9 :  17.61 ± 0.49 : 49.78 ± 1.01 
Schedule liiil (G,:S;G 2 /M) - 29.72 ± 0.35 : 17.25 ± 0.40 : 50.97 ± 0.47
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SK-N-BE(2c) UVW/NAT
Untreated control 1.01 1.99
TPT only 0.56 1.11
[i3iI]MIBG only 0.49 1.21
Schedule [i] 0.46 1.55
Schedule [ii] 0.63 1.86
Schedule [iii] 0.48 1.64
Table 8-1: Effect of TPT and [i^iIJMIBG on 
topoisomerase I levels in SK-N-BE(2c) and UVW/NAT 
cells
This table shows the effects ot TPT and [^^T]MIBG on Topo I levels in 
SK-N-BE(2c) and UVW/NAT cells, found by Topo I relaxation assay.
TPT and [^^TjMIBG, either alone or in combination, induced a reduction 
in the ability of Topo I isolated from treated SK-N-BE(2c) and 
UVW/NAT cells to unwind supercoiled DNA.
I
' 1
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8.4 Summary of results
Of the two cell lines, a higher percentage of SK-N-BE(2c) than UVW/NAT cells 
were in (75.13 ± 0.29%, compared to 62.56 ± 0.53%), while a higher proportion of 
UVW/NAT cells were undergoing DNA replication and mitosis (for SK-N-BE(2c) cells, 
S-phase and G^/M proportions were 10.47 ± 0.25% and 11.79 ± 0.45% respectively; for 
UVW/NAT S-phase and G^/M proportions were 12.26 ± 0.24% and 21.22 ± 0.64% 
respectively).
In both cell lines, administration of TPT as a single agent resulted in a reduction in 
the proportion of cells in G^, and a concurrent increase in accumulation of cells in S- and 
Gg/M-phases. The effects of TPT are consistent with reduced progression through S- 
phase, and Gg arrest that has previously been reported following administration of 
topisomerase I inhibitors [189-191].
To date, there has been no investigation into the effects of [^^T]MIBG on ceil cycle 
distribution. This study confirmed that [^^^IjMIBG also reduced the percentage of cells in 
G ^-phase and increased the proportion of cells in the remaining cell cycle compartments. 
The ability of [^  ^ I]MIBG to induce reduction in the proportion of cells in G,, and increase 
accumulation in G^/M observed in SK-N-BE(2c) and UVW/NAT cells is consistent with 
previously reported effects of ionising radiation, which is most effective against cells in 
late Gi“, G2 - and M-phase [186].
Following administration of schedule [ii], the percentage of SK-N-BE(2c) cells in 
different cell cycle compartments (G|-, S- and G^/M-phases) were 47.62 ± 0.33%, 19.06 ± 
0.70% and 29.20 ± 0.51% respectively. A similar distribution was observed following 
schedule [iii] treatment (Gj-, S- and G 2 /M-phase proportions were 47.99 ± 0.23%, 18.42 ± 
0.48%, and 30.06 ± 0.65% respectively). However, schedule [i] administration did not
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alter the percentage of SK-N-BE(2c) cells in each phase in the same way (Gp, S~ and 
G 2 /M-phase proportions were 47.75 ± 0.80%, 21.64 ± 0.58% and 24.17 ± 0.38% 
respectively). This suggests that there may be a qualitative difference between the cellular 
response to schedule [i] treatment and the response to administration of schedules [iij and 
[iii].
Similar results were obtained from the treatment of UVW/NAT cells. Administration of 
schedule [ii] and schedule [iii] induced comparable alterations in the percentages of cells in 
different cell cycle compartments (schedule [ii] ratios were 30.06 ± 0.59%, 17.61 ± 0.49% 
and 49.78 ± 1.01% for Gj-, S- and Gz/M-phases respectively, and schedule [iii] ratios were 
29.72 ± 0.35%, 17.25 ± 0.40% and 50.97 ± 0.47% respectively). However, as with SK-N- 
BE(2c) cells, schedule [i] administration did not alter the percentage of UVW/NAT cells in 
each phase in the same way (G p, S- and Gj/M-phase proportions were 39.35 ± 0.36%, 
18.49 ± 0.05% and 37.05 ± 0.27% respectively), again suggesting a qualitative difference 
to the effects caused by schedule [i] administration.
Administration of TPT and [^^T]MIBG, either as single agents, or in any scheduled 
combination, induced a reduction in Topo I-mediated unwinding of supercoiled DNA. 
TPT-induced reduction in unwinding efficiency is in agreement with previously reported 
effects of camptothecin analogues, and it is hypothesised that this is caused by stabilisation 
of the Topo I - DNA cleavable complex, which keeps Topo I molecules irreversibly bound 
to DNA [85]. This reduces the amount of free Topo I in these cells, and therefore the 
amount of free enzyme in nuclear extracts used to assess Topo I activity.
[^^^I]MIBG also caused a reduction in Topo I-induced relaxation. This is in 
agreement with previously reported effects of ionising radiation, which induced a down- 
regulation in Topo I catalytic activity in cells attempting DNA repair [161, 188].
164
Chapter 9
The effects of topotecan and ['^T]MIBG on DNA
damage and repair
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9.1 Introduction
9.1.1 The ejfect oftopotecan on DNA damage
Previous studies have reported synergistic cell killing in vitro by ionising radiation 
and Topo I inhibitors [85, 137-141], associated with increases in topoisomerase I binding 
to DNA, and formation of double strand breaks (DSBs) [85, 136, 170-172]. To date, no 
attempt has been made to study whether topotecan can affect the number of DNA lesions 
caused by targeted radionuclide therapy using [’^ ^I]MIBG.
To assess the effect of topotecan on |^^T]MIBG-induced DNA strand breaks, two 
NAT expressing cell lines, the neuroblastoma cell line SK-N-BE(2c) and the NAT gene- 
transfected glioblastoma cell line UVW/NAT, were dosed with [^^^I]MIBG and/or TPT to 
cause DNA damage. Cells were then assayed for DNA strand breaks either immediately 
after treatment, or following a 24h incubation, to allow for DNA repair.
9.7.2 Single cell gel electrophoresis (SCGE) assay
Cells were assayed for DNA strand breaks using the single cell gel electrophoresis 
(SCGE), or the comet assay. In this method, individual damaged cells are embedded in 
agarose on a microscope slide. The cells are lysed and the cellular contents removed, with 
the exception of nuclear material, which is subjected to mild alkaline conditions. This 
causes partial DNA unwinding from DNA strand break points.
The cells are then electrophoresed. The electrical current causes DNA to migrate 
towards the anode. Therefore cells with increased DNA damage display increased DNA 
migration, leading to the distinctive "comet tail" which gives the assay its name [192] (see 
Figure 9-1).
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AB
Figure 9-1 : Single cell gel electrophoresis assay (comet assay)
This figure shows examples of cells that have been subjected to single cell gel 
electrophoresis, also known as the comet assay.
In this method, individual damaged cells are embedded in agarose on microscope slides. 
After lysis and DNA unwinding, cells are electrophoresed, causing DNA to migrate towards 
the anode.
Cells with larger amounts of DNA damage display increased DNA migration, leading to the 
distinctive "comet tail" which gives the assay its name.
In the examples below, (A) shows a cell with minimal DNA damage, while (B) shows a cell 
with extensive DNA damage.
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9.2 Materials & methods
9.2.7 Cell lines
SK-N“BE(2c) and UVW/NAT cells were seeded at a density of 1 x 10  ^ cells/cm^ in 
25cm^ flasks (Nunclon Plastics, Denmark) and grown in RPMI 1640 medium containing 
200mM L-glutamine, 25mM HEPES and 10% PCS at 37°C and 5% CO^. All media and 
supplements were obtained from Invitrogen (Paisley, UK). After 48 hours, fresh media 
was added to the cells, containing either topotecan, [^ 0^ ]MIBG or a scheduled combination 
of both agents.
9.2.2 Concentrations and incubation times o f  TPT and [^^f]MIBG
The doses of TPT and [^ ’^l]MIBG employed in studies of DNA damage and repair 
were the doses of each agent required to reduce clonogenic survival to 50% of control 
cultures, as determined by clonogenic assay (see Chapter 4). For the treatment of SK-N- 
BE(2c) cells, [’^ TjMIBG concentration was 4 MBq/ml, and topotecan concentration was 
2ng/ml. For UVW/NAT cells, [^^^IJMIBG concentration was 4.1 MBq/ml and TPT 
concentration was 4.2ng/ml.
The incubation time was 2h for [^^^I]MIBG, after which uptake is maximal [154]. 
For TPT, incubation time was 24h, which has previously produced optimal supra-additive 
killing of cells treated with TPT and external beam irradiation [139]. Adopting a similar 
drug exposure procedure allowed comparison of published data with the results of 
combined TPT and [^^^I]MIBG-induced cytotoxicity reported in Chapters 5 & 6 .
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9.2.3 Scheduling oftopotecan and treatments
As previously discussed, although synergistic cell killing in vitro and in vivo by 
ionising radiation and Topo I inhibitors have been widely reported, there is no consensus 
with respect to the order of delivery of these therapeutic agents (see Table 5-1).
Therefore, the three combination treatment schedules utilised in in vitro and in vivo 
analyses of the cytotoxic interaction between topotecan and [^^^I]MIBG were assessed for 
their potential to induce DNA framentation and inhibit DNA damage repair. Again, in 
schedule [i] topotecan was administered 24 hours before [^^^I]MIBG treatment. In 
schedule [ii] topotecan was administered 24 hours after [^^^IjMIBG treatment. In schedule 
[iii] topotecan and [^ ’^IjMIBG were administered simultaneously. See Figure 5-3.
Following treatment, cells were either assayed by single cell electrophoresis 
immediately, or incubated in fresh medium for a further 24h to allow for possible repair of 
DNA damage before assaying.
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9.2.4 SCGE assay
SCGE assays were carried out using the Trevigen CometAssay™ Single Cell 
Electrophoresis Assay kit (Trevigen Inc. Gaithersburg, Maryland, USA), according to the 
manufacturer's instructions. Briefly, cells at a concentration of 5 x 10  ^ cells/ml were 
combined at a ratio of 1:10 with low melting point agarose (LM Agar ose). 75//1 of this 
LMAgarose/cell mixture was pipetted onto a Trevigen Cometslide™, and stored at 4°C to 
set. Slides were immersed in lysis solution (2.5M Na Cl, lOOmM EDTA pH 10, lOmM 
Tris base, 1% sodium lauryl sarcosinate, 1% Triton X-lOO), then immersed in alkaline 
solution (300mM Na OH, ImM  EDTA) followed by electrophoresis in 1 x TBE buffer 
(0.089M Tris base 0.089M Boric acid, 0.02M EDTA, pH 8.0) for 10 mins at 1 volt/cm.
Slides were stained wih 1 x SYBR® Green solution (Trevigen Inc) and examined by 
fluorescence microscopy (435-500nm) using a Zeiss Axiovert inverted microscope (Carl 
Zeiss Ltd, Welwyn Garden City, Hertfordshire UK). Images were captured by a Zeiss MC 
100 SPOT camera, and saved by Axiovision 3.0.6.1 software. Comets were measured by 
NIH Image 1.57 software, using the methodology described previously by Geller et al. 
[193].
Statistical analyses of results were carried out using software freely available online 
at the SIS A (Simple Interactive Statistical Analysis) website [194], and the VassarStats: 
Statistical computation website [195]. The mean number of comets analysed in each 
treatment group was 120 and 110 for SK-N-BE(2c) and UVW/NAT cells respectively.
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9.3 Results
9.3 A Analysis o f DNA fragmentation
The amount of cellular DNA damage present in each comet was measured by tail 
moment (originally defined as the median distance migrated by the DNA multiplied by the 
fraction of DNA in the comet tail), as described by Olive, et al. [196, 197].
The results of combination treatments of SK-N-BE(2c) and UVW/NAT cells are 
shown in Figures 9-2 and 9-3 respectively. Each spike represents an individual comet 
moment, expressed as arbitrary units (au), where lau equals one percent of the median tail 
moment in untreated controls.
The mean number of SK-N-BE(2c) comets analysed per treatment group was 120. 
The mean number of UVW/NAT comets analysed per treatment group was 110.
A wide variation in tail moment values was observed for both cell lines. For 
example, untreated SK-N-BE(2c) cells tested at Oh exhibited tail moments ranging from 
2.985au to 450.03au. Untreated UVW/NAT cells tested at Oh exhibited tail moments 
ranging from 4.68au to 1737.58au.
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Figure 9-2: Total DNA fragmentation in SK-N-BE(2c) cells
DNA damage in treated SK-N-BE(2c) cells as measured by SCGE assay. Cells were 
treated with topotecan alone, [^^T]MIBG alone, or with one of the scheduled combinations 
shown in Figure 5-3.
Results were calculated using the tail moment method devised by Olive et al [196,197]. 
Tail moment is defined as the average distance migrated by the DNA multiplied by the 
fraction of DNA in the comet tail. Measurements were plotted as arbitrary units, where 
lau  was equal to 1 percent of the median tail moment in untreated conti'ols. Mean number 
of comets analysed per treatment group was 1 2 0 .
A) The size of each individual comet moment observed when SK-N-BE(2c) cells are 
assayed immediately following treatment.
B) The size of each comet moment 24h after tieatment.
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Figure 9-3: Total DNA fragmentation in UVW/NAT cells
DNA damage in treated UVW/NAT cells as measured by SCGE assay. As with SK-N- 
BE(2c), cells were treated with topotecan alone, [^^^IJMIBG alone, or with one of the 
scheduled combinations shown in Figure 5-3.
Again, results were calculated using the tail moment method and measurements were 
plotted as arbitrary units. Mean number, of comets analysed per treatment group was 110.
A) The size of each individual comet moment when UVW/NAT cells were assayed 
immediately following tr eatment.
B) The size of each comet moment 24h after tr eatment.
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93 .2  Distribution o f results
The comet moments obtained immediately after treatment (ie. Fig 9-2A and Fig 9- 
3A) were plotted as histograms to show the distribution of the data (Figure 9-4 for SK-N- 
BE(2c) results; Figure 9-5 for UVW/NAT results). The results for each cell line were 
evaluated for conformity to a normal distibution.
In a normal distribution, the mean and the median are identical, and the skew value 
is 0. For data that is significantly skewed, the mean and median are distinctly different, 
and the z-value, (which is the skew value divided by the standard error of skewness), is 
significantly high [198]. The equations used to calculate the skew value, the standard error 
of skewness (SES) and the z-value are shown in Figure 9-6. Statistical significance can be 
established by using the z-p  calculator found on the VassarStats website [195].
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Figure 9-4: Distribution of results in SK-N-BE(2c) ceils
Distribution of comet measurements. This figure shows the distribution of comet sizes (see 
Figure 9-2A), for untreated SK-N-BE(2c) cells and SK-N-BE(2c) cells treated with TPT and 
[ *^ ‘1 |M1BG, either alone or in combination.
Analysis of skewness of tail moments data is presented in Table 9-1.
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Figure 9-5: Distribution of results in UVW/NAT cells
Distribution of comet measurements. This figure shows the distribution of comet sizes (see 
Figure 9-3A), for untreated UVW/NAT cells and UVW/NAT cells treated with TPT and 
1 jMIBG, either alone or in combination.
Analysis of skewness of tail moments data is presented in Table 9-2.
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For univariate data .........F^,
the formula for skewness is:
A s =
( N  - l y
B
C
SE S J  N
S- 0
SE S
where
Skewness value 
F is the mean 
s is the standard deviation 
N  is the number of data points 
SES - standard error of skewness
Figure 9-6: Statistical analysis of skewness
This figure shows the equations used to test whether data derive from a normal 
distribution.
A) The equation used to test data for skew. Skewness was calculated using ExceF^ 
statistical software.
B) The equation used to calculate the standard error of skewness (Tabachnick & Fidell 
[198]).
C) The equation used to calculate the z-value, which describes deviation from the mean 
in a disti'ibution. lunit of z is equal to one standaid deviation. This equation is 
described by Tabachnick & Fidell [198].
From the z-value, the p-value of statistical significance was calculated using the z-p 
calculator freely available online [195].
177
93.2-1 SK-N-BE(2c):
Tail moments data derived from untreated controls, and from cells treated with TPT 
and [^^h]MlBG, exhibited a significant level of positive skewness, suggesting that these 
results are not normally distributed. See Table 9-1.
93.2-2 UVW/NAT:
As with SK-N-BE(2c), tail moments derived from untreated controls, and from 
cells treated with TFT and [^^hjMIBG, were significantly skewed. Again, this suggests 
that these results are not normally distributed. See Table 9-2.
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control TPT
only
[i3iI]M IBG
only
Schedule
[i]
Schedule
[ii]
Schedule
[iii]
M ean 122.16 297.04 193.17 266.66 272.33 365.46
M edian 1 0 0 . 0 0 227.64 172.56 232.30 255.46 218.79
Skew 0.952 1.677 1.251 2.170 1.581 1.923
S.E.S 0.225 0.225 0.208 0 . 2 2 0 0 . 2 1 0 0.215
z value 4.224 7.468 6 . 0 2 1 9.864 7.528 8.952
p  value <0.005 <0.005 <0.005 <0.005 <0.005 <0.005
Table 9-1: Analysis of skewness of tail moment data derived from 
SK-N-BE(2c) cells treated with TPT and [
This data is derived from the histograms displayed in Figure 9-4
For every treatment group, there was a distinct difference between the mean and the 
median. Significance of skewness was calculated using the method of Tabachnick & 
Fidell [198]. Briefly, z-values were calculated by dividing the Skew score by the S.E.S 
(standard error of skewness), from tins, the appropriate p-value was assigned.
In SK-N-BE(2c) cells, all of the data curves displayed a significant positive skew.
This suggests that the comet size of SK-N-BE(2c) cells are not normally distributed, 
necessitating the use of a non-parametiic analysis.
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control TPT
only
[i3iI]MIBG
only
Schedule
[i]
Schedule
[ii]
Schedule
[iii]
Mean 211.48 502.19 414.59 511.51 530.12 679.02
Median 1 0 0 . 0 0 367.01 323.20 395.50 461.96 542.68
Skew 3.158 1.079 1.380 1.561 0.706 0.854
S.E.S 0.228 0.245 0.250 0.237 0.257 0.263
z value 13.824 4.404 5.522 6.592 2.750 3.252
p  value <0.005 <0.005 <0.005 <0.005 <0.005 <0.005
Table 9-2: Analysis of skewness of tail moment data derived from 
UVW/NAT cells treated with TPT and [i^iIJMIBG
This data is derived from the histograms displayed in Figure 9-5
UVW/NAT cells, like SK-N-BE(2c) cells, displayed a distinct difference between the 
mean and the median. Significance of skewness was calculated using the method of 
Tabachnick & Fidell [198].
In UVW/NAT cells, all of the data curves were significantly skewed.
As in the case of tail moments produced in SK-N-BE(2c) cells (Table 9-1), this analysis 
also suggests that the comet size data were not normally distributed, necessitating the 
use of a non-parametric analysis.
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9.3.3 Analysis o f  Results
As the results obtained from both cell lines did not conform to a normal 
distribution, it was necessary to use a non-parametric statistical test to analyse the data. 
Results were analysed using the Mann-Whitney U test (from the SISA website [194]). In 
this method, the results of two groups are combined, ranked in order of size, and a rank 
number assigned. The U test then compares of the sum of the rank values for each group 
to determine if they are similar enough to come from the same population, or significantly 
different (ie. from different populations).
9.3.4 Comparison o f  DNA Fragmentation in treated cells at Oh and 24k -  Analysis o f  DMA 
damage repair
Following treatment with TPT and [^^TjMIBG as single agents or in combination, 
SK-N-BE(2c) and UVW/NAT cells were assayed immediately after treatment. Similarly 
treated cells were assayed 24 hours after treatment. The extra incubation time allowed 
DNA repair to occur, and this was analysed by comparing the amount of DNA 
fragmentation in each treatment group at Oh to the amount of DNA fragmentation in 
similarly treated cells at 24h.
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9.3.4-1 SK-N-BE(2c)
SK-N-BE(2c) cells assayed 24h after treatment exhibited significantly lower levels 
of DNA fragmentation than similarly treated cells assayed at Oh, following administration 
of TPT or ['^*I]MIBG as single agents, or following combination schedule [i]. However, 
cells treated with combination schedule [ii] or schedule [iii] did not display significant 
reduction in DNA fragmentation after 24h compared to similarly treated cells assayed at Oh 
(Figure 9-7).
93.4-2 UVW/NAT
As with SK-N-BE(2c), treated UVW/NAT cells assayed 24h after treatment 
exhibited significantly lower levels of DNA fragmentation than similarly treated cells 
assayed at Oh, following administration of TPT or [^^h]MIBG as single agents, or 
following combination schedule [i]. However, unlike SK-N-BE(2c), where the reduction 
in DNA fragmentation observed in cells treated by combinations of TPT and [^^h]MIBG 
was dependent on scheduling, in UVW/NAT cells a significant decrease in DNA damage 
was also observed in cells treated with combination schedules [ii], and [iii] (Figure 9-8).
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Figure 9-7: Repair of DNA fragmentation in 
SK-N-BE(2c) cells
The amount of DNA fragmentation observed immediately 
after treatment was compared to similarly treated cells left in 
fresh medium for 24h to allow DNA repair. Data is presented 
as medians of data range and 95% confidence intervals,
SK-N-BE(2c) cells treated with TPT alone, IJMIBG alone, 
or with TPT scheduled before J'^^IJMIBG, (schedulejij) 
exhibited a significant reduction in DNA damage when 
assayed 24h after treatment, compared to similarly treated cells 
assayed at Oh. However, cells treated with TPT scheduled 
either after I'^TjMIBG (schedulejiij), or simultaneously with 
I'^TJMIBG (schedule! iii I), and assayed 24h after treatment 
exhibited no significant change in DNA fragmentation, 
compared to treated cells assayed at Oh.
▲ Control
♦ TPT only
■ [ ^ ^H]MIBG only
X Schedule [i]
X Schedule [ii]
* Schedule [iii]
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Figure 9-8: Repair of DNA fragmentation in 
UVW/NAT cells
Again, the amount of DNA fragmentation observed 
immediately after treatment was compared to similarly treated 
UVW/NAT cells left in fresh medium for 24h to allow DNA 
repair.
Treated UVW/NAT cells assayed at 24h displayed a 
significant decrease in DNA fragmentation, compared to 
similarly treated cells assayed at Oh. Unlike SK-N-BE(2c) 
cells, in UVW/NAT cells, reduction of DNA damage was not 
affected by the order of administration.
[ii] [iii]
A Control
♦ TPT only
■ ['^iJlMIBG only
X Schedule [i]
X Schedule [ii]
* Schedule [iii]
184
9.3.5 DNA fragmentation in treated compared to untreated cells at Oh and 24h - Analysis 
o f the duration o f  DNA damage
DNA fragmentation in treated and untreated SK-N-BE(2c) and UVW/NAT was 
assessed at Oh and 24h to examine the amount and duration of DNA damage caused by 
single agent and combination regimens.
Compared to untreated controls, SK-N-BE(2c) and UVW/NAT cells dosed with 
topotecan and either alone or in combination and assayed immediately after
treatment displayed statistically significant levels of DNA fragmentation (Table 9-3). 
When assayed 24h after treatment, cells treated with either agent alone or with 
combination schedule [i], no longer exhibited significant amounts of DNA damage, 
compared to untreated controls, suggesting that efficient DNA repair has occurred.
However, SK-N-BE(2c) and UVW/NAT cells treated with combination schedule 
[ii] and schedule [iii] and assayed at 24h continued to exhibit significant levels of DNA 
fragmentation, suggesting that cells treated with either of these regimens are not as 
efficient at DNA damage repair than cells treated by schedule [i], or by either agent alone.
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control TPTonly
[1311] MIBG 
only
Schedule
[i]
Schedule
[ii]
Schedule
[iii]
1
Oh NS /)<0.05 p  < 0.05 p  < 0.05 p < 0.05 p  <0.05
24h NS NS NS NS p  < 0.05 p < 0.05
H< Oh NS p  < 0.05 p  <0.05 p  < 0.05 p  < 0.05 p < 0.05
5 24h NS NS NS NS p  < 0.05 p  < 0.05
Table 9-3: Significance of cellular DNA damage caused by TPT and 
[13ii]m i b G treatment
All of tlie treatment regimens (ie. administration of each agent either alone, or in 
combination) resulted in significant levels of DNA fragmentation in cells assayed 
immediately, compared to untreated controls.
However, in cells left for 24h to allow for DNA damage repair there was no significant 
difference between untreated conti'ols, and cells treated with either agent alone, or when 
TPT was scheduled before [^^T]MIBG in combination therapy. DNA fragmentation 
remained significantly high only when TPT was scheduled simultaneously with, or after 
[i^T]MIBG.
This suggests that administration of topotecan concurrently with, or following 
[î31j ]m i b G results in a reduced ability to efficiently repair DNA damage in SK-N- 
BE(2c) and UVW/NAT cells. However, administration of topotecan prior to I^^^HMIBG 
has no effect on DNA damage repair pathways.
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9.4 Summary of results
The treatment of SK-N-BE(2c) and UVW/NAT cells with topotecan or [^ ^^ i j m IBG, 
either as single agents, or in combination resulted in significant levels of DNA 
fragmentation immediately after administration. This effect was independent of the 
scheduling of the two agents.
NAT expressing cells treated with a combination of topotecan and 
displayed a reduced capacity for DNA repair compared to cells treated with either agent 
alone. However this effect was dependent on the order of delivery of the two agents. Only 
when topotecan was administered following ['^^IMIBG (schedule [iij), or concurrently 
with 1^ 3‘I]]viIBG (schedule [iii]) was DNA damage repair significantly impaired.
This corresponds to the order of effectiveness of different combination schedules to 
induce clonogenic cell kill and delay of tumour growth (Chapters 5, 6 &7). However, 
while less effective than schedules [ii] and [iii], administration of combination schedule [ij 
produced supra-additive levels of cytotoxicity in vitro (Chapters 5 & 6), and increased the 
growth delay of experimental tumours in vivo (Chapter 7). This suggests that the time 
points examined in this study of DNA fragmentation and repair were not sufficient to 
adequately correlate long-term disruption of DNA repair, and TPT/MIBG-induced toxicity. 
These issues will be discussed further in Chapter 10.
The effects of TPT administration on [^^TjMIBG-induced DNA damage described 
in this chapter could be due to inhibition of DNA repair mechanisms [170-172], or TPT- 
induced Topo I cleavage activity [161]. These theories will be discussed in greater detail 
in Chapter 11.
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Chapter 10
Discussion
I:
The results of this study, 
and proposals for future work
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10.1 Development of a real-time RT-PCR assay for prediction of the uptake of 
[131j]Mibg  by neuroblastoma tumours
10.] J  Clinical diagnosis o f neuroblastoma
Chapter 2 described the development of a rapid and specific assay for NAT 
expression in biopsy samples obtained from neuroblastoma patients. The assay, based on 
real-time PCR analysis, showed substantial power to predict MIBG uptake capacity and 
has the potential to select patients for [^ ^^ i j m iBG therapy.
The clinical diagnosis of neuroblastoma currently involves histological 
examination of biopsy specimens and diagnostic MIBG scintigraphy [21], which involves 
the administration of a tracer dose of radioiodinated MIBG. In addition to providing an 
indication of the suitability of patients for ['^TjMIBG therapy, scintigraphy allows the 
localisation of metastatic deposits and (if supplemented by information allowing the 
estimation of tumour size) also enables dosimetric calculation. The assay detailed in this 
report could support the data obtained by MIBG scintigraphy by identifying those patients 
most suitable for [^ ^^ i j m IBG  therapy as a front line treatment.
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10.1.2 Comparison ofTaqMan RT-PCR to existing methodologies
TaqMan RT-PCR analysis of NAT expression was superior, in terms of speed and 
reproducibility, to previously published methods of NAT mRNA quantitation [62]. The 
real-time PCR technique allowed the simultaneous evaluation of a large number of 
individual samples as well as internal controls. This assay involves the use of industry- 
standardised reagents and requires less manipulation of sample than traditional PCR 
techniques, resulting in increased reliability and accuracy.
10.1.3 Limitations ofTaqM an RT-PCR
Of the 54 patients’ samples with evaluable MIBG scans, 48 (89%) showed MIBG 
uptake into the primary tumour, while 43 (80%) of the tumour samples were positive for 
the expression of NAT mRNA. This is equivalent to 90% concordance with respect to 
positive outcome of the two tests. All 6 tumours (11%) that failed to accumulate MIBG 
had undetectable NAT mRNA expression. However, biopsies from 5 patients (10.4%) 
with positive MIBG scans did not express detectable NAT mRNA.
Therefore, while a positive PCR test always predicted tumour uptake of MIBG, a 
negative PCR test failed to correctly determine MIBG uptake capacity with a frequency of 
45%.
This suggests that PCR-based assessment of NAT gene expression cannot be 
regarded as fully predictive of MIBG uptake.
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10.1 A Heterogeneity of uptake
There are plausible explanations for the occasional coincidence of a negative PCR 
test with a positive MIBG scan. It is possible that heterogeneous uptake of radioidinated 
MIBG is occurring. In this scenario, while one area of a tumour mass is expressing the 
NAT gene and can be imaged successfully, another area of the same tumour mass may not 
express the NAT gene and will not take up radiolabelled MIBG. A biopsy taken from the 
NAT-negative area would therefore give a negative PCR result. However, radioiodinated 
MIBG would still accumulate in the NAT-positive area of the tumour mass, leading to a 
positive MIBG scan.
10.1.5 Quality o f  biopsy material
It is also possible that the quality of biopsy material used for analysis was not 
optimal. In the present study, specimens were subjectively assessed for neuroblastoma 
content and those with less than 20% neuroblastic component were rejected. It would be 
preferable to establish an objective assessment of the proportion of malignant cells in 
biopsy material.
10.1.6 Alternative internal references
To predict tumour cell concentration of MIBG more accurately, it may be 
necessary to use alternative internal standards with specificity for neuroblastoma cells. 
Possibilities include the transcript of the tyrosine hydroxylase gene [199], which is 
expressed only in catecholamine-synthesising cells, or mRNA specific for neural crest cell 
proteins such as PGP9.5 [200] or GDj synthase [201].
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10.1.7 Involvement o f an alternative MIBG uptake pathway?
Monoamine transporters other than NAT may be partly responsible for the 
accumulation of MIBG by tumour cells. Although the principal mechanism of cellular 
uptake of MIBG involves the NAT, the possibility of tumour concentration via vesicular or 
cell-membrane-associated monoamine transporters cannot be discounted [202, 203]. 
Alternatively, mutant forms of NAT could be involved. These may be undetectable by the 
PCR primers employed in this study.
It may be necessary to design a new primer / probe set, which hybridises to another 
region of the NAT cDNA sequence. If uptake is entirely due to transcription
of a single version of NAT mRNA, then identical results should be obtained by analysis of 
the copy numbers of different regions of the NAT mRNA sequence. However, any 
differences in the starting copy numbers detected by primers which anneal to different 
regions of the published NAT cDNA sequence would suggest the presence of alternative 
versions of NAT mRNA.
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10.2 Future work arising from the development of a real-time RT-PCR assay
10.2.1 Tumour heterogeneity and sensitivity o f scintigraphy and RT-PCR
A  major obstacle to the application of molecular tests on real tumours rather than 
cultured cells is tumour heterogeneity with respect to expression of specific markers. In 
order to assess the sensitivity of the RT-PCR assay in vivo, it is necessary to compare 
MIBG concentration with real-time PCR data derived from tumours which contain known 
percentages of NAT-positive cells.
10.2.2 The use o f multicellular mosaic spheroids
This can be achieved by the use of a tumour model, which incorporates cell 
population heterogeneity. Multicellular mosaic spheroids are composed of variable 
percentages of two cell populations with different characteristics [204]. This model would 
address the limitation to detectability imposed by heterogeneity of NAT expression.
In this case, one of the cell populations would display no expression of the NAT 
gene, while the other would be positive for NAT gene expression. In order to assess the 
sensitivity of the assay, mosaic xenografts composed of a range of proportions of NAT- 
expressing cells would be established. Scintigraphic analyses of these xenografts would be 
compared to the results of analyses of NAT gene expression by TaqMan RT-PCR to assess 
the respective sensitivities of the two procedures. See Figure 10-1
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Percentage of NAT expressing cells:
0% 10% 25% 50% 75% 100%
Cell with no NAT gene expression Cell expressing NAT gene
Figure 10-1: Multicellular mosaic spheroids
Multicellular mosaic spheroids are composed of variable percentages of two cell 
populations with different characteristics. In this case, one of the cell populations display no 
expression of the NAT gene, while the other is positive for NAT gene expression.
Establishing mosaic spheroids with a range of proportions of NAT-expressing cells would 
allow determination of sensitivity of scintigraphic analyses of these xenografts compared to 
the results of analyses of NAT gene expression by TaqMan RT-PCR.
Furthermore, a mosaic spheroid model would allow estimation of minimum requirement for 
NAT gene transfection to allow sterilisation by combinations of targeted radiotherapy and 
radiopotentiators.
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10.3 The effect of topotecan pre-treatment on intracellular uptake of [ IJMIBG
103.1 TPT-induced enhancement o f  [’^ 3]MIBG uptake in vitro
SK-N-BE(2c) and SHSY5Y cells tested immediately after removal of 
unincorporated TPT displayed a small, but insignificant increase in uptake of [^^^ijmIBG. 
Significant enhancement of [^^^ijmIBG uptake was observed 24h after removal of the drug 
(approximately 2-2.5 times the level observed in untreated controls), after which the 
increased accumulation of the radiopharmaceutical fell, and had returned to the levels 
observed in untreated cells 72h after removal of TPT (Chapter 3). However enhanced 
uptake did not correspond with an increase in hNAT gene expression in vitro.
Interestingly, increased uptake of [^^iijmibG was also observed in vitro in TPT 
pretreated UVW/NAT cells, which contain an expression vector incorporating the bNAT 
gene under the control of a viral (RSV) promoter. Untreated and TPT treated UVW/NAT 
cells displayed negligible expression of the hNAT gene, and no increase in bNAT mRNA 
levels. This suggests that the enhancement of f’^ TjMIBG uptake observed in this cell line 
was not due to an increased activation of either the endogenous hNAT gene promoter, or 
an alteration in RSV promoter-driven bNAT gene expression.
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10.3.2 Drug-induced enhancement o f IJMIBG uptake in vivo
The in vitro results, reported in the previous section, suggested that, as pre-treatment 
with TPT enhanced intracellular concentration of this regimen would induce an
increase in [^3i%]]\/XIBG-induced toxicity. However, while previous studies reported that a 
wide range of DNA-interacting drugs cause increases in uptake of radio-labelled MIBG, 
these increases were not found to be tumour specific. For example, following cisplatin pre­
treatment, greater concentration of radio-labelled MIBG has been reported in a variety of 
normal organs [71, 158], suggesting that some non-target tissues may be adversely affected 
by combination therapy involving administration of chemotherapeutic drugs followed by 
[^''I]MIBG.
10.3.3 The effect o f  topotecan on the biodistribution o f [^^3JMIBG
The concentration of [^ ^^ i j m IBG in SK-N-BE(2c) or UVW/NAT tumours was second only 
to that in adrenals. The influence of prior administration of topotecan on the 
biodistribution of [^^^xjMIBG in tumour-bearing nude mice was examined. Pretreatment 
with topotecan had no effect on ['^'IjMIBG accumulation by UVW/NAT tumours but 
induced a modest though insignificant increase in uptake by SK-N-BE(2c) tumours. 
Likewise, topotecan treatment induced greater accumulation of ['3fi]MIBG in adrenals and 
heart in both groups of tumour-bearing mice. However, these increases were not 
significant.
The concentration of [^^^xjMIBG was low in muscle, kidney, lung, thyroid and 
marrow, and in none of these non sympathetically innervated tissues was there a significant 
difference in radiopharmaceutical uptake after topotecan administration.
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10.3.4 Assessment o f marrow toxicity
The bone marrow is the dose limiting tissue in neuroblastoma patients treated with 
[^3'I]MIBG, and toxicity is manifest by prolonged thrombocytopenia [179]. Furthermore, 
topotecan is also myelotoxic [126]. Encouragingly, TPT did not increase the concentration 
of activity in the bone marrow of experimental animals. Furthermore, while 
therapeutically effective combinations of topotecan and [^3B]MIBG induced a reduction of 
platelet numbers and a decrease in the clonogenic capacity of CFU-A transiently- 
engrafting stem cells in SK-N-BE(2c) tumour-bearing mice, these indices of marrow 
integrity returned to normal levels two weeks after treatment.
This suggests that combined therapy involving these agents will not increase 
adverse reactions in a therapeutic setting.
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10.4 The effect of topotecan on expression of the noradrenaline transporter gene
The effects on NAT gene expression of other DNA interacting agents, as shown in 
Table 3-1, have been previously reported. Each has been shown to cause an upregulation 
of mRNA signal by semi-quantitative RT-PCR [154, 157] and by Northern blotting [158]. 
In this study, real time RT-PCR showed that there was no significant upregulation of NAT 
gene expression in SK-N-BE(2c) and UVW/NAT cells following treatment with TPT.
It is possible that alternatively spliced, or mutant forms, of NAT mRNA could be 
involved, which allow production of functional NAT protein, but are undetectable by the 
PCR primers employed in this study.
Alternatively, factors other than increased NAT gene expression may be 
responsible for increased [^^hjMIBG uptake. Expression of the NAT gene product may be 
partially controlled at the post-transcriptional or post-translational stages by an as yet 
undiscovered pathway. This would lead to alterations in the cellular concentration of 
functional NAT protein, without affecting gene transcription. Development of assay for 
NAT protein concentration (eg. Western blot) would help to resolve this issue.
Furthermore, monoamine transporters other than NAT may be partly responsible 
for the accumulation of [^ ^^ i j m IBG by tumour cells. Although the principal mechanism of 
cellular uptake of [^ i^ j j m ib G involves the NAT protein, the possibility of tumour 
concentration via vesicular or cell membrane-associated monoamine transporters cannot be 
discounted [202, 203].
It should also be noted that previous analyses of NAT gene product were based on 
densitometric quantitation of band intensities, whereas real time RT-PCR relies on 
standards of known concentration, allowing an exact quantitation of starting number of 
copies of the target sequence. It is possible, therefore, that previously reported increases in
198
band intensity in NAT positive samples, may reflect the limitations of the technology, 
rather than a genuine increase in NAT gene expression.
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10.5 The effects of combinations of topotecan and [ T]MIBG in vitro and in vivo
10.5.1 Supra-additive cytotoxicity in SK-N-BE(2c) and UVW/NAT cells in vitro
In many previous studies, synergistic cell killing in vitro by ionising radiation and 
Topo I inhibitors was reported in a wide range of human and animal cell lines, [85, 136- 
141]. Also, in vivo radiopotentiation by Topo I inhibitors has been demonstrated in 
xenografts of murine fibrosarcoma and MCa-4 mammary carcinoma [140, 142] and 
rhabdomyosarcoma [143].
Whi]e TFT and [^^^I]MIBG have been combined in pilot studies being undertaken 
in the Netherlands, no preclinical studies have attempted to combine topotecan and 
[^^4]MIBG therapy. Therefore, the potential of TFT to potentiate this form of targeted 
radiotherapy was unresolved.
In vitro investigations of the interaction between topotecan and [*^^I]MIBG in SK- 
N-BE(2c) and UVW/NAT cells by both isobologram and median-effect / combination- 
index analyses indicated that supra-additive toxicity in NAT expressing cells was achieved 
by combinations of these two agents. Radiopotentiation in SK-N-BE(2c) was observed at 
low toxicity levels following all three scheduled combinations. However, at higher 
toxicity levels (ie. > IC 5 0 ) combination treatment was less effective. UVW/NAT cells also 
exhibited supra-additive responses. However in this cell line radiopotentiation was 
observed at higher toxicity levels (ie. > IC 5 0 ), but were not as affected by doses lower doses 
of combination treatment (ie. < IC 3 0 ).
The contradictory effectiveness of varying doses of combinations of TFT and 
[131i ]m i b G to these two cell lines may reflect an underlying difference in their respective 
response to each agent. SK-N-BE(2c) cells were highly sensitive to low doses of TFT 
(90% survival at Ing/ml; 10% survival at 5ng/ml (Figure 4-3). Thereafter a plateau, with
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respect to clonogenic survival, was observed (ie. concentrations of TFT greater than 
5ng/ml did not result in greater levels of toxicity). UVW/NAT were not as sensitive to low 
doses of the drug (90% survival at Ing/ml; 45% survival at 5ng/ml), however a greater 
proportion of UVW/NAT were susceptible to treatment (ie. the plateau observed in 
UVW/NAT cells was approximately 2%, compared to %10% in SK-N-BE(2c) cells).
This plateau is in agreement, with previously reported effects of TFT [132] and of 
other Topo I inhibitors [137, 162], and is attributed to the S-phase specificity of topotecan- 
induced toxicity. In any population of cells, different sub-populations will be at different 
stages of the cell cycle. Cells in Gj during treatment will be unaffected by topotecan 
exposure.
The results of cell cycle analysis reported in Chapter 8  confirmed that a higher 
percentage of SK-N-BE(2c) than UVW/NAT cells were in G  ^ (75.13 ± 0.29%, compared 
to 62.56 ± 0.53%), while a higher proportion of UVW/NAT cells were undergoing DNA 
replication and mitosis (for SK-N-BE(2c) cells, S-phase and G^/M proportions were 10.47 
± 0,25% and 11.79 ± 0.45% respectively; for UVW/NAT S-phase and Gg/M proportions 
were 12.26 ± 0.24% and 21.22 ± 0.64% respectively).
This suggests that, while SK-N-BE(2c) cells are more sensitive to topotecan- 
induced toxicity, a higher proportion of the cell population is in Gj. Consequently, a 
higher percentage of cells will be resistant to the drug. UVW/NAT cells are more resistant 
to topotecan-induced toxicity. However, more UVW/NAT cells are in S-phase, and a 
lower percentage are in G  ^ during treatment. Therefore, a higher percentage of these cells 
will be affected by topotecan treatment.
Both SK-N-BE(2c) and UVW/NAT cells were sensitive to [^^^IjMIBG. However 
the results of SCGE assays suggest that UVW/NAT cells exhibit more efficient DNA 
damage repair than SK-N-BE(2c) cells (Chapter 9).
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These observations may explain the differing responses of UVW/NAT and SK-N- 
BE(2c) cells to topotecan/[^^T]MIBG combination therapy. Combining these agents 
resulted in supra-additive toxicity in SK-N-BE(2c) cells at low levels of toxicity, due to 
sensitivity to both agents and less efficient DNA repair. However, at higher toxicity levels 
the apparent infra-additive interaction may be due to the greater proportion of SK-N- 
BE(2c) cells in Gj (~ 10%), which are not affected by topotecan treatment.
Combining topotecan and [^^*I]M1BG in UVW/NAT cells resulted in an infra­
additive interaction at low levels of toxicity, possibly due to higher resistance to TPT 
combined with more efficient DNA repair. However, higher doses of the two drugs (ie. > 
IC5 0 ) resulted in supra-additive levels of kill, possibly due to an inability of DNA repair 
mechanisms to adequately deal with greater levels of damage, combined with a higher 
proportion of UVW/NAT cells treatable by higher doses of TPT (ie. ~ 98% compared to ~ 
90% for SK-N-BE(2c) cells).
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10.5.2 The effect on toxicity in vitro and in vivo o f alternative scheduling o f topotecan and
The results of this study indicated that supra-additive levels of cytotoxicity were 
achieved in vitro in NAT expressing cells treated with combinations of TPT and 
[^^^I]MIBG. Furthermore, TPT potentiated the therapeutic index of [^^TjMIBG targeted 
radiotherapy in NAT-expressing tumours in vivo.
Combination-index analyses suggested that administration of TPT prior to 
[131i ]m i b G (schedule [i]) was less effective than administration of TPT following or 
concurrently with f/^T]MIBG (schedule [ii] and schedule [iii] respectively). Furthermore, 
with respect to growth delay or cure of experimental tumours, exposure to TPT 24h before 
[^^4]MIBG (schedule [i] was less effective than administration of topotecan 24h after 
[^ ’^I]MIBG (schedule [ii]), which was not as effective than simultaneous treatment with 
[*^T]MIBG and topotecan (schedule [iii]).
10.5.3 Cytotoxicity and TPTdnduced enhancement o f  [^^^IJMIBG uptake
SK-N-BE(2c) and UVW/NAT cells and xenografts treated with TPT subsequently 
exhibited an enhanced uptake of [^^T]MIBG (see Chapter 3). However, the efficacy of TPT 
administration of NAT expressing cells prior to [^^^I]MIBG was less than TPT 
administration either following, or concurrently with [^^^I]MIBG (Chapters 5, 6  & 7). This 
suggests that increased uptake of the radiopharmaceutical due to prior administration of 
TPT (and, presumably, increased [‘^ TjMIBG-induced toxicity) was not as important a 
factor for overall survival as increased disruption of DNA repair, observed in cells treated 
by combination schedules [ii] and [iii], as reported in Chapter 9.
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10.6 The effects of topotecan and [ T]MIBG on cellular mechanisms
10.6.1 The effect o f  scheduling o f  topotecan and on cell cycle distribution
The results of cell cycle analyse reported in Chapter 8  demonstrated that 
administration of the less effective combination schedule (schedule [i]) resulted in a 
different cell cycle distribution than administration of schedules [iij or [iii]. While 
previous studies were unable to find a clear link between cell cycle distribution and 
cytotoxicity [189, 190], it is tempting to theorise a possible link between these phenomena.
Administration of TPT as a single agent increased the percentages of cells in S- 
phase and G2 /M. If this was followed by [^^^I]MIBG therapy, as in schedule [ij, then, 
while the increased proportion of cells in Gj/M would be radiosensitive, the increased 
proportion of cells in S-phase would be more radioresistant than would be found in 
untreated cells, where the majority of cells are in Gj, While some of these cells will be in 
early Gj, and therefore exhibit radioresistance, others are will be in late G,, and therefore 
exhibit radiosensitivity [186].
Administration of [^^^IJMIBG before TPT, as in schedule [ii], will increase the 
proportion of cells in S-phase, and G^/M. Cells in S-phase will be more sensitive to 
subsequent TPT treatment, through formation of double strand breaks by the fork collision 
model [85], and cells in G% have previously been reported to attempt repair of DNA double 
strand breaks (DSBs) [205, 206]. As a role for Topo I has been postulated in DNA damage 
repair [170-175], increased Topo I activity during Gj-associated DSB repair would 
increase sensitivity to TPT during this phase of the cell cycle.
Likewise, simultaneous administration of TPT and [^^TjMIBG, as in schedule [iii] 
will increase the proportion of cells in S-phase, which will increase TPT sensitivity but 
induce radioresistance. However, simultaneous scheduling will also increase the
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proportion of cells in G^/M, which will induce radiosensitivity and also possible TPT 
sensitivity through disruption of DNA repair.
} 0.6.2 The effect o f  scheduling o f  topotecan and [^ ‘^l]MIBG on DNA damage and repair
Treatment by either drug as a single agent, or by the less effective schedule resulted 
in a different response to DNA damage in cells assayed by single cell gel electrophoresis 
(SCGE), than treatment by schedules [ii] and [iii] (see Chapter 9). While administration of 
the two agents alone, or in any of the scheduled combinations resulted in significant 
amounts of DNA fragmentation in cells assayed immediately after treatment, cells assayed 
24h after treatment exhibited levels of DNA fragmentation which were indistinguishable 
from those of untreated controls, following administration of TPT or [’^ T]MIBG as single 
agents. Similar time dependency (ie extensive damage compared to untreated controls 
immediately after treatment and insignificant damage 24h later) also resulted from 
combination schedule [i].
However, administration of combination schedule [ii] or schedule [iii], resulted in 
significant levels of DNA fragmentation compared to untreated controls immediately after 
treatment, and significant DNA damage was also observed after 24h. This suggests that 
DNA repair pathways are not as efficient and greater long-term effects were achieved in 
cells treated by either schedules [ii], or schedule [iii]. Administration of combination 
schedule [i] was not as effective at disrupting DNA repair than either of the other two 
combination schedules.
These effects could be due to inhibition of DNA repair mechanisms [170-172], or 
TPT-induced Topo I cleavage activity [154]. These theories will be discussed in greater 
detail in Chapter 11.
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10.7 Future work arising from the investigations of combinations of topotecan and
10.7,1 Multiple administration o f  TPT to enhance supra-additivity o f  cell kill
Prior administration of TPT enhanced uptake. Subsequent (or
concurrent) administration of TPT resulted in reduced DNA repair. It is possible that 
multiple administrations of TPT could be used to combine these effects, resulting in 
greater levels of toxicity in vitro and in vivo. In this schedule, TPT would be administered 
prior to [^^T]MIBG to enhance cellular uptake, while a second administration of TPT 
concurrently with, or following the radiopharmaceutical would disrupt DNA damage 
repair.
10.7.2 Future work arising from  investigations o f the effects o f  topotecan and 
on cellular mechanisms
The results of this study provide a useful insight into the effects of combinations of 
TPT and [^^^I]MIBG on cellular mechanisms. However, further investigations will be 
required. For example, while less effective than schedules [ii] and [iii], administration of 
combination schedule [i] was capable of producing supra-additive levels of cytotoxicity in 
vitro, and caused effective growth delay of experimental tumours in vivo. This suggests 
that the time points examined in the study of DNA fragmentation and repair reported in 
Chapter 9 were not sufficient to adequately correlate long-term disruption of DNA repair, 
and either in vitro reduction in clongenicity or in vivo delay in xenograft tumour growth. 
Examination of DNA fragmentation at time points between Oh and 24h will be necessary
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to discover the relative DNA repair efficiency in cells treated with either agent alone, and 
in cells treated by combination schedule [i].
Furthermore, the studies of cell cycle distribution and topoisomerase I activity 
described in Chapter 8 only investigated the effects of TPT and immediately
after treatment (ie. Oh), while the effects of combination therapy on DNA damage and 
repair described in Chapter 9 described the effects of the two agents at two time points; Oh 
and 24h after treatment. Therefore, just as examination of DNA fragmentation at time 
points between Oh and 24h will be necessary to investigate DNA repair efficiency, 
investigations into the longevity of altered cell cycle distribution due to administration of 
different schedules, and the extent of reduced Topo I catalytic activity following 
administration of TPT and/or [^^TjMIBG, at different time points after removal of the two 
drugs (Oh to 24h), may help to elucidate the underlying mechanism of DNA damage repair 
inhibition.
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Chapter 11
Discussion
II:
The role of topoisomerase I in the 
response to DNA damage
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11.1 Introduction
Topoisomerase I activity is utilised during replication to prevent extreme stress to 
parent DNA, allowing the replication fork to proceed down the DNA strand, and 
preventing newly synthesised DNA becoming tangled in parent DNA [82, 83]. During 
transcription, transient unwinding of the DNA helix prevents RNA polymerase generating 
supercoiled tensions in template DNA [187]. Furthermore, a role for Topo I has been 
postulated in cellular pathways involved in the response to DNA damage. Several studies 
have suggested Topo I involvement in DNA damage repair [170-175].
This chapter describes the current understanding of cellular factors which affect 
topoisomerase 1 activity, how this can lead to an altered role for Topo I following DNA 
damage, and suggest possible approaches to the resolution of the underlying mechanism of 
TPT-induced radiopotentiation.
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11.2 Factors which affect topoisomerase I activity: PARP-1 and p53
Poly(ADP-ribose) polymerase (PARP-1), is an enzyme involved in DNA repair 
[207, 208]. PARP-1 binds strongly to the sites of DNA damage, and activates DNA ligase 
III and DNA polymerase |3 by an indirect mechanism which involves binding to the base 
excision repair (BER) scaffold protein XRCC-1 (X-Ray Cross-Complementing-1) [161, 
208-210]. PARP-1 also binds directly to Topo I, and induces increased formation of Topo 
I -  DNA complexes [211].
PARP-1 is also responsible for the modification of the activity of a variety of 
proteins, including p53 and itself, by addition of poly(ADP-ribose) units [188, 209, 210], 
which alters the activity of the target protein [212]. PARP-1 is irreversibly degraded in 
cells undergoing apoptosis [213].
Boothman et al first reported a decrease in Topo I - mediated unwinding of 
supercoiled DNA following irradiation. They also reported that addition of PARP-1 
inhibitors prevented this down-regulation of Topo I [161]. Down-regulation of Topo I 
enzymatic activity by PARP-1 was confirmed by Smith et al, who also reported that Topo I 
could form a complex with p53 which caused enhancement of Topo I - mediated 
unwinding [188].
11.3 Topoisomerase I activity and DNA damage
Following the formation of a number of different types of DNA lesions, (eg. single 
strand breaks, creation of apurinic sites, base-pair mismatches, etc) there is a down- 
regulation in Topo I catalytic activity in cells attempting DNA repair. This effect appears 
to be due to PARP-1-induced ADP-ribosylation, which occurs in the presence of the 
substrate Nicotinamide adenine dinucleotide (NAD+) [161, 188]. Therefore, PARP-1
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ADP-ribosylates p53, preventing p53 enhancement of Topo I catalytic function [161], and 
also down-regulates Topo I catalytic activity by the same method.
However, PARP-1 is not only responsible for down-regulation in catalytic function, 
and can also induce increased formation of Topo I -  DNA complexes. Therefore, with 
nicked DNA acting as a substrate for Topo I, there is a rapid sequestration of Topo I onto 
the sites of DNA lesions [170-172, 174, 211].
There is some evidence to suggest that a variety of DNA lesions, if located near a 
Topo I scissile site, can stimulate a Topo I-mediated cleavage reaction, either on the 
scissile strand, or on the opposite strand [214]. This would exacerbate the effects of the 
original lesion by causing the formation of additional single strand breaks (SSBs), 
irrepairable double strand breaks, (and also deleterious recombination events and covalent 
protein-DNA crosslinks).
Following DNA damage, if cells were undergoing repair, down-regulation of 
topoisomerase I catalytic activity by ADP-ribosylation, would help to prevent potentially 
hazardous Topo I-induced strand breaks on the scissile and non-scissile strand [161]. 
Therefore, any involvement that Topo I has in the repair of DNA damage would not 
involve its DNA cleavage / resealing activity. It may be that inactive Topo I may be 
helping to stabilise the site of damage until the DNA repair pathway becomes involved 
[174, 214].
Alternatively, it is possible that the creation of a complex between inactive Topo I 
and DNA at the site of damage may act as a marker for DNA repair enzymes [174, 175, 
214]. See Figure 11-1.
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Figure 11-1: Hypothesised role of 
topoisomerase I in DNA repair
This figure demonstrates the theory that 
Topo I has a role in DNA repair, following 
DNA damage :
Minimal DNA damage occurs. CellsA)
attempt DNA repair.
B) DNA strand breaks have occurred. 
There is a rapid sequestration of 
Topoisomerase I onto DNA lesions. Topo 
I catalytic activity is down-regulated by 
PARP-1 in the presence of NAD+. p53 
enhancement is prevented. This prevents 
potentially lethal Topo I-initiated cleavage 
reactions. PARP-1 binding induces 
increased Topo I - DNA complex 
formation.
C) Topo 1 - DNA complex may stabilise 
the site of the lesion until the engagement 
of DNA repair enzymes. Alternatively, 
Topo 1 may act as a marker of the site of 
DNA damage.
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11.4 Involvement of the camptothecins following DNA damage
The underlying mechanism of TPT radiopotentiation of cell death, is, at present, 
unknown. Most theories rely on the assumption that TPT-induced cell death follows the 
fork collision model [85]. Camptothecin analogues (such as TPT) stabilise the Topo I - 
DNA cleavable complex, preventing the religation step, and keeping Topo I irreversibly 
bound to DNA. During the next round of DNA replication, collision of the stabilised Topo 
I - DNA complex with the replication fork results in an irreversible double strand break, 
leading to cell cycle arrest and cell death. See Figure 11-2.
However, a more controversial theory suggests that the effect of TPT on Topo I 
may be more extreme. Boothman et al suggested that the radiopotentiation seen in cells 
treated with camptothecin analogues may be due to enhanced Topo I activity [161].
Due to their ability to initiate DNA strand breakage and ligation events, Topo I - 
DNA complexes are potentially dangerous to the cell. In normal circumstances, the 
interacellular levels of Topo I are kept relatively constant, and the levels and duration of 
Topo I - DNA complexes are strictly controlled [175, 215, 216]. In the alternative theory, 
topotecan, by increasing the longeivity of the Topo I - DNA complex increases the 
probability of unintended Topo I- mediated cleavage reactions [161, 175]. Topo I could 
then cleave the intact strand opposite the initial lesion, converting the radiation-induced 
SSB into a potentially lethal DSB [161, 214]. See Figure 11-2.
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Figure 11-2: Hypothesised 
Interaction between I]MIBG
and topotecan
This figure demonstrates the theory behind 
the assumption that therapy in
combination with topotecan will lead to 
increased DNA damage and therefore 
increased cell death:
A) 1‘^ TlMIBG damages cellular DNA due 
to radioactive decay of isotopes.
B) DNA strand breaks have occurred. 
Topoisomerase I binds to DNA, possibly 
during DNA repair pathway .
C) Topotecan binding to topoisomerase I 
molecule stabilises the Topo I - DNA 
complex, which may inhibit DNA repair 
enzymes.
D) During the next round of DNA 
replication, collision of the replication fork 
with the TPT - Topo I - DNA complex 
leads to an irreversible double strand break. 
Also, TPT may convert Topo I into a DNA 
toxin. Topo I could then cleave the intact 
strand opposite the initial lesion, causing an 
irreversible double strand break
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11.5 Future work which may resolve the role of the camptothecins following DNA 
damage
An experimental study could be undertaken to resolve the underlying mechanism of 
TPT-induced radiopotentiation. Cells at different stages of the cell cycle, treated with 
combinations of TPT and radiation, would be tested by neutral comet assay, which only 
detects double strand breaks. If the classic theory is correct, DSBs should only be 
detectable in cells that have undergone S-phase.
However, if DSBs are inducible at other stages of the cell cycle, this would suggest 
that the alternative theory is correct. Optimisation of the timing of TPT administration 
would induce the maximum effect in the shortest time, in order to prevent cells going 
through the whole cell cycle before evaluation.
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Chapter 12
Discussion
III:
Further avenues of research arising from 
this study, and final conclusions
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12.1 Possible enhancement of supra-additive cytotoxicity caused by combinations of 
topotecan and I]MIBG
The results of this study indicate that supra-additive levels of killing may be 
achieved in NAT expressing cells and xenografts treated with a combination of TPT and 
This chapter will describe the possibility of enhancing the effectiveness of 
this combination by introducing other drugs with the potential to induce synergy with TPT 
and/or [^^4]MIBG. The potential of radiosensitising agents other than TPT to enhance 
[^^4]MIBG therapy will also be discussed, as will the use of alternatives to '^4 as the 
choice of radionuclide in some therapeutic situations.
12.L I  Potential o f  targeting cellular pathways to enhance topotecan-induced toxicity
In normal circumstances, the levels and duration of Topo I - DNA complexes are 
strictly controlled by several pathways [175, 215, 216]. Tyrosyl DNA phosphodiesterase 
(Tdp 1) catalyses the removal of the Topo I linked to 3’-DNA terminus by hydrolysing the 
covalent bond between the Topo 1 tyrosyl residue and the 3’-DNA phosphate [215J. 
Furthermore, TPT-stabilised Topo I -  DNA complexes can be removed by Topo I 
ubiquitination, which flags the molecule for degradation by the 26S proteosome [216].
Therefore, it may be possible to enhance TPT-induced toxicity by disrupting these 
cellular pathways. Gene silencing of Tdp 1, by for example, the utilisation of RNAi 
technology, would prevent removal of the Topo I polypeptide by Tdp 1-induced 
hydrolysis. Likewise, a treatment regime incorporating the 26S proteosome inhibitor 
MG132 [217], would block the ubiquitin-induced degradation of Topo I.
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12.2 Improving on I]MIBG-derived regimens: Alternative radiosensitising agents
Optimisation of radiation damage induced in target cells can be obtained by 
rational combination of this treatment with radiosensitising agents. While the results of 
this study confirm radiopotentiation of [^ ’^iJMIBG-induced toxicity by the topoisomerase I 
inhibitor topotecan, other agents with the potential to induce radiosensitisation could prove 
to be more beneficial.
1 2 2 2 . PJ34
PJ34 is an inhibitor of PARP-1. It has previously been shown to be especially 
effective in enhancing cytotoxicity of low dose irradiation [222]. Therefore, PJ34 could 
also be an effective radiosensitiser of [^^4]MIBG-induced toxicity.
Furthermore, as PARP-1 is responsible for both down-regulation in Topo I catalytic 
activity in cells attempting DNA repair [161], and increased formation of Topo I -  DNA 
complexes [211], investigations of treatment regimens including both PJ34 and TPT could
122.1 Disulfiram (DS)
DS enhances cytotoxicity to cytotoxic drugs in cancer cells [218]. It counteracts 
the activity of the anti-apoptotic transcription factor NF-kB [219] NF-kB is activated by 
radiation, and tumour cells with increased NF-kB activity are resistant to chemo- and 
radiotherapy [220, 221]. However, the effectiveness of DS as a radiosensitiser of
[i3ij]MjgG targeted radiotherapy is unresolved.
■/
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help to resolve the contributions of these activities to TPT-induced radiopotentiation.
. i
12.3 Choice of radionuclide: Alternatives to as a conjugate for MIBG
Agents other than topotecan have the potential to prove effective as 
radiosensitisers. Likewise, radionuclides other than may prove to be more effective in 
some situations. The goal of targeted radiotherapy is delivery of radiation to tumour cells 
with the sparing of normal tissue. However, in order to maximise the effectiveness of the 
therapeutic agent, and minimise normal tissue toxicity, the choice of radionuclide is 
important. Factors such as subcellular localisation of the targeting agent, size of the 
tumour mass, path length of radioisotope decay and linear energy transfer (LET - the 
measure of energy transferred per unit length of track) [223] should be taken into account.
While the focus of this study has been the (3-emitter [^^4]MIBG, '^4 has a long 
path length and relatively low LET. Therefore, as tumour size decreases, the amount of 
energy absorbed by the tumour becomes progressively smaller, and more of the energy is 
deposited outside the target [224].
For this reason, ’^ 4 may not be the optimal choice of radionuclide in all therapeutic 
situations. For NAT-expressing tumours, which have the potential to be treated by 
radiolabelled MIBG, establishing the most appropriate radionuclides whose decay 
particles vary with respect to LET and path length could improve the therapeutic efficacy 
of this targeting molecule (Table 12-1, Figure 12-1).
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Radionuclide Decay particle Particle range Half life Current use
131j b 0.8mm 8 days therapy
2iiAt a 0.05mm 7 hours therapy
123J Auger electron 1-lOnm 13.2 hours imaging
1251 Auger electron 1-lOnm 60.1 days imaging
Table 12-1: Alternatives to as a conjugate for MIBG
Different radionuclides have different properties which may be more beneficial than 
in certain circumstances. See Figure 12-1.
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125J
0 tumour cell • successfully targeted cell
0 untargeted cell: sub-lethally • untargeted cell: irreparablydamaged by radiological bystander damaged by radiological
effect bystander effect
Figure 12-1: Relationship between particle range, radiological 
bystander effect and linear energy transfer
A) Large tumour masses: As has a longer particle length than 2" At, '23i or '25;^  the 
radiological bystander effect will cause damage to a greater number of cells.
B) Micometastases: In smaller tumours, will be less effective as the majority of the 
energy will be deposited outside the tumour mass. 2" At has a far greater LET, therefore, 
damage caused by 2 *'At to adjacent cells is more likely to be irreparable, leading to far 
greater toxicity in micometastases.
C) Circulating tumour cells: '231 and '2^ 1 have a very short range, but a very high LET, and 
are therefore only toxic to individual cells. They will be most effective against circulating 
tumour cells. The longer path lengths of *^ ‘I and 2 "At are more likely to
cause damage to normal tissue.
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12.3.1 /"At]MABG
^“ At, an «-emitting isotope of Astatine (At), is a radiohalogen that has potential as
an alternative to radio-iodine in the treatment of neuroblastoma by noradrenaline analogues 
[20].
Astatine is found underneath iodine in group 7A of the periodic table, and has 
similar chemical properties [225]. Naturally occurring astatine is incredibly rare (less than 
29 grams are present in the earth's crust), but synthetic At can be generated in a cyclotron 
by bombarding bismuth with a-particles [225].
2 *‘At has a shorter particle range than (SOpim for “^ At, compared to SOOptm for 
‘^ ‘l). This means that p"At]M A BG therapy will affect fewer untargeted cells by the 
radiological bystander effect than [‘^ ‘l]MIBG therapy.
However, ^"At has a very high LET compared to [226], therefore the damage 
caused by [ ‘^‘At]MABG-induced radiological bystander effect is more likely to be lethal 
than damage caused by [‘^ ‘l]MIBG therapy, resulting in a greater probability of irreparable 
damage, and, therefore, far superior toxicity in micometastases [20, 226] (Table 12-1; 
Figure 12-1).
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123.2 and
It has previously been assumed that the effectiveness of Auger electron emitters 
such as ‘2^ 1 and would be confined to molecules within reach of the nucleus [227, 2281. 
These atoms decay by electron capture and internal conversion, which results in the 
emission of extremely densely ionising radiation of very short range (1-lOnm). Therefore, 
targeting agents which remain cytoplasmic, or membrane bound, would not be as effective 
if conjugated to Auger electron emitters than if conjugated to radionuclides with longer 
path lengths, such as ^-em itters [227, 228 j.
However, it has previously been reported that [‘^ ^IJMIBG and [‘^ ^IjMIBG were 
more toxic to neuroblastoma cells than would be expected by cytoplasmic MIBG 
localisation [2 0 ], suggesting that these short range emitters would be well suited to the 
treatment of circulating tumour cells (Table 12-1; Figure 12-1). The effectiveness of ‘^ I^ 
and ‘2 ^ 1  labelled MIBG may be explained by the recent identification of radiation-induced 
biological bystander effects [229-236], and it is possible that targeting molecules 
conjugated to short-range Auger emitters may be of greater therapeutic benefit than was 
previously believed.
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12.4 Radiation-induced biological bystander effects (RIBBEs)
While the contribution to kill of neighbouring non-targeted cells by radioactive 
decay particles emanating from targeted cells is relatively well characterised [237, 238], 
the significance of radiation-induced biological bystander effects (RIBBEs) has only 
recently been perceived [229]. RIBBEs involve the cellular processing of the radiation 
insult into toxic metabolites. Therefore, translation of the physical radiation insult into 
biological signals or toxins, means that cytotoxicity is elicited by both direct DNA damage 
and also from RIBBEs. RIBBEs have been reported utilising high and low LET radiation 
delivered by focused microbeams and by transfer of media from irradiated to unirradiated 
cells [230-236] (Figure 12-2).
RIBBEs are a significant contributor to the total effects elicited in cells exposed to 
low dose and dose rate irradiation [239]. As this is a feature of targeted radionuclide 
therapy [240], the magnitude of RIBBEs may be pertinent to the success of this mode of 
treatment. The mechanisms and potency of these bystander effects, particularly those 
induced by radiopharmaceuticals, are, as yet, unresolved.
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▲ Rad iolabeled agent O Untargeted tumour cell
o damaged by radiologicalTumour cell bystander effectO Untargeted tumour cell# Successfully  targeted tumour 
cell
damaged by release of adverse 
signals from neighbouring  
cells
Figure 12-2: Radiation-induced biological bystander effect (RIBBE)
RIBBE involves the cellular processing of the radiation insult into toxic metabolites;
A) Tumour cells are targeted by a radiolabelled agent
B) Only a fraction of the tumour is successfully targeted. The majority remain 
unaffected.
C) Energy released by decay of the radioisotope emanates from the targeted portions 
of the tumour in three dimensions, causing damage to neighbouring cells that have not 
been successfully targeted.
D) Damaged cells release biological signals which in turn cause damage to 
neighbouring cells.
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12.5 NAT gene therapy
12.5 J  Targeted radionuclide therapy fo r  tumours with no radiotargetable feature
Most tumours do not possess a radiotargetable feature. However, the UVW/NAT 
cell line used in this study is derived from the human glioblastoma cell line UVW which 
was transfected with a pREP9 episomal expression vector containing a copy of the bovine 
NAT cDNA. This demonstrates that introduction of NAT transgenes into tumours with no 
radiotargetable feature can endow them with the capacity for uptake of radioiodinated 
MIBG.
Generally, mammalian transcriptional control elements are unsatisfactory for 
cancer gene therapy, due to low expression capacity and limited tumour specificity. A 
promising alternative means of restricting transgene expression to malignant cells is the 
exploitation of the telomerase activity of tumour cells [241-244], or the utilisation of 
radiation-inducible control elements [245, 246].
226
12.5.2 Tumour specific gene expression: Telomerase promoter elements
Telomeres are necessary for chromosome stability. In normal cells, there is a 
gradual loss of telomeric sequences during successive cell divisions, and in the absence of 
mechanisms to prevent telomere shortening, cells have a limited proliferative life span 
before entering senescence [247]. In immortal cells, including cancer cells, telomere length 
is maintained through the actions of a specialized reverse transcriptase, called telomerase. 
Telomerase activity is thought to be essential for immortalization of human cells in vitro 
and of cancer cells in vivo, and it is detectable in 85% of malignant tumors [248].
Telomerase activity depends upon the presence of both the RNA subunit (hTR) and 
the catalytic protein subunit (hTERT) [249]. It has previously been demonstrated that both 
hTR and hTERT promoters can induce high levels of NAT transgene transcription, 
enabling [^^T]MIBG- and p^^At]MABG-mediated host cell kill in a variety of tumour cell 
lines [237, 250-252].
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12.5.3 Radiation-inducible control elements
Selective transgene expression may also be achieved by radiation-inducible control 
elements, such as the promoter [245, 246]. The tumour growth suppressor
is a potent inhibitor of cyclin-dependent kinases, and enhanced protein levels 
are found in cells undergoing either p53-associated Gi arrest or apoptosis following DNA 
damage [253]. It has been demonstrated that activation of the promoter
occurs following external beam irradiation and hypoxia in tumour xenografts, regardless of 
their p53 status. Furthermore the promoter has low levels of activity in the
absence of these stimuli in tumours, but not normal cells, suggesting a tumour specific 
mode of activation [246].
It should therefore be possible to utilise the p 2 t^^ -^ /^cip-i pj-Q^oter to drive 
expression of NAT in tumours following activation by radiopharmaceutical s. In 
neuroblastoma cells, following introduction of a vector incorporating the NAT gene under 
the control of the promoter, a priming dose of [^^TjMIBG is administered.
This is accumulated specifically in the neuroblastoma cells, and results in stimulation of 
the promoter, leading to enhanced NAT expression. Subsequent
administration of high doses of [^^T]MIBG would therefore be more therapeutically 
effective.
For the treatment of other tumour types, without endogenous NAT gene expression, 
a priming dose of conformai external beam irradiation could be used to induce activation 
of the promoter. However, while triggering the promoter by
external beam irradiation shows promise for treatment of discernable tumour masses, it is 
inappropriate for management of covert disease.
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12.6 NAT gene therapy: Gene delivery
Selective NAT gene expression in malignant tissues, through the use of tumour 
specific, or radiation-inducible promoter elements suggests that these strategies could be of 
therapeutic benefit. However, in many cases, the efficacy of gene therapy has been 
hampered by inefficient gene delivery.
12.6.1 Viral vectors
Of the clinical trials of gene therapy carried out to date, 6 6 % have concerned the 
treatment of cancer, and 70% have utilised viral vectors [254]. During infection of a cell, 
viruses use specific entry mechanisms to gain entry. This makes viruses attractive as 
vectors for gene therapy [10, 254]. However, the challenge of developing viral vectors lies 
in harnessing their targeting efficiency while abrogating their ability to cause infection and 
cell death. Recently, mutant viruses have been shown to be capable of delivering 
transgenes, allowing high levels of gene expression and selective replication in tumour 
cells [255].
Retroviruses were the first vectors used in gene therapy, and remain the most 
commonly used (28% of all trials). However, retroviruses have a relatively limited 
capacity to carry therapeutic genes, and the risk of insertional mutagenesis by retroviral 
integration into the chromosomes of target cells further limits the effectiveness of these 
vectors [254].
Adenoviruses are the second most commonly utilised viral vector (26% of all 
trials), while, to date, clinical trials involving herpes simplex viral (HSV) vectors have 
been limited (2.8% of all trials) [254]. Adenoviruses are attractive candidates for gene 
delivery due to their capacity for carrying large DNA loads and their high efficiency of
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transduction, and recombinant HSV vectors have recently demonstrated efficient delivery 
and expression of transgenes [2551. Construction of recombinant adenoviral or HSV 
vectors could allow delivery of telomerase promoter- or promoter-NAT
transgene constructs.
12.6.2 Immunoliposomes
Non-viral delivery vehicles (cationic lipid/DNA complexes) have been utilised in 
9.3% of gene therapy trials [254]. The tumour targeting of CCLs can be improved by 
coupling a monoclonal antibody (mAb) or its Fab fragment, directed to tumour-specific 
antigens, to their external surface.
This strategy has been described using mAbs directed against the neuroblastoma- 
and melanoma-specific antigen GDj [256-259]. Conjugation of CCLs to other tumour 
targeting mAbs would allow successful gene delivery specifically to malignant tissue [260- 
265]. See Table 12-2.
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Antibody Cell Target References
81C6
(Anti- tenacin)
Extracellular mati’ix glvcoprotein 
tenacin
- Expressed in >95% brain malignancies
[260, 261]
Anti-GDj Disialoganglioside
- Expressed on surface of neuroblastoma 
and melanoma tissue
- Low expression in normal tissue [262,263]
Anti-CEA GPI-anchored cell surface membrane protein CEA
- Expressed in a wide variety of tumours
- Antigen not present in normal cells
[264,265]
Table 12-2: mABs or Fab fragments which may be coupled to CCLs
Tumour targeting of Coated Cationic liposomes (CCLs) can be improved by coupling 
a monoclonal antibody (mAb) or its Fab fragment, directed to tumour-specific antigens, 
to their external surface.
This would allow successful gene delivery specifically to malignant tissue.
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12.7 The use of multicellular mosaic spheroids to determine transfection efficiencies
As described in Section 10.2.2, mosaic spheroids with a range of proportions of 
NAT-expressing cells would allow determination of sensitivity of scintigraphic analyses to 
the results of analyses of NAT gene expression. This model would also allow an 
estimation of minimum requirement for NAT gene transfection to allow tumour 
sterilisation by the administration of combinations of targeted radiotherapy (ie. [^^T]MIBG 
as used in this study, or ['^^IJMIBG [^^IJMIBG or [ ‘^‘At]MABG as described in section 
12.3), and radiosensitising agents (ie. TFT as used in this study, or DS or PJ34 as described 
in section 12.2) following NAT gene therapy (Figure 10-1).
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12.8 Conclusions
12.8.1 Development o f a real-time RT-PCR assay for prediction o f the uptake o f
Assays based on real-time PCR methodology may also facilitate the development 
of novel therapies designed to alter cellular function at the transcriptional level [71]. For 
example, several studies have indicated that a wide range of DNA-interacting agents cause 
an increase in the ability of neuroblastoma cells to actively uptake radio-labelled MIBG 
[154, 157-159], and, likewise, TPT induces increased accumulation of this
radiopharmaceutical (see Chapter 3). Whilst TPT-induced enhancement of uptake did not 
correlate with an increase of NAT gene product, the molecular mechanisms involved have 
yet to be elucidated, and the assay described in Chapter 2 has the potential to allow 
quantitative analysis of the effects of these agents on NAT expression and enable the 
design of improved therapeutic schedules.
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12.8.2 Cytotoxic interaction between topotecan and
The results of this study indicate that supra-additive levels of killing may be 
achieved in NAT expressing cells and xenografts treated with a combination of TPT and 
[^^TJMIBG. Furthermore, combination treatment was well tolerated by experimental 
animals and caused negligible myelotoxicity.
However, the effectiveness of combinations of topotecan and [*^T]MIBG was 
dependent on the order of administration. Maximal TPT-induced radiosensitisation was 
induced by the administration of the drug concurrently with, or following [^^TjMIBG. 
Furthermore, while radiopotentiation may be linked to disruption of DNA repair, the exact 
mechanisms were outside the scope of this study, and remain unresolved. Nevertheless, the 
results of this study suggest that combinations of topotecan and [^^4]MIBG, produce 
encouraging results in vitro and in vivo.
If the synergy demonstrated in model systems between topotecan and [*^T]MIBG in 
the present study can be replicated in patients with neuroblastoma, there is potential for 
real therapeutic gain. Clinical studies of topotecan given simultaneously with, and 
subsequently to, [^^T]MIBG have commenced in the United Kingdom, and in Europe.
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